

AUTHOR INDEX VOLUME 37

- Abdalla, Salah, 138
Abe, Shigeru, 2228
Acharya, Gopal, 2418
Adam, D., 1620
Adkinson, N. Franklin, Jr., 1463
Agacfidan, Ali, 1746
Aggarwal, Sunil K., 818
Agrawal, Krishna C., 818
Aguado, J. M., 2490
Aguirre, Tania, 580
AIDS Clinical Trials Group
 Virology Committee
 Resistance Working Group, 1095
Ajiki, Yoko, 1749
Akahane, Kazumi, 1764
Akalin, H. E., 1637
Akalin, H. Erdal, 1831
Akao, Mitsutaro, 1313
Akashi, Akira, 287, 1826
Akova, M., 1637
Akova, Murat, 1831
Aksnes, Arne, 2024
Alam, N. H., 1572
Alcouloumre, Marcia S., 2628
Alder, Jeffrey, 864, 1329
Aldridge, Kenneth E., 1986
Aliu, Yusuf O., 1050
Allard, J. P., 2239
Allegra, Carmen J., 1227
Allen, S. D., 1696
Allen, Stanley D., 2716
Allouch, P., 737
Alos, Ignacio, 2059
Alpert, Nathaniel M., 1270, 2144
Alteri, Enrica, 2087
Althaus, Irene W., 1127
Amicosante, Gianfranco, 1324
Amirault, Pascal, 1790
Amsterdam, Daniel, 896
Anaissie, Elias J., 51
Anderson, Kevin P., 1945
Andreumont, A., 1432
Andrews, Charla, 178
Aoki, Hiroyuki, 2173
Aoki, Yuhko, 2656, 2662
Appelbaum, P. C., 1649
Arai, Sumio, 287, 1826
Arakawa, Yoshichika, 984
Arduino, Jean-Marie, 1095
Argenson, Jean Noel, 1214
Arika, Tadashi, 363, 785
Arisawa, Mikio, 2656, 2662
Arison, Byron, 1737
Aristoff, Paul A., 1127
Arlet, Guillaume, 2020
Armstrong, Donald, 398, 2323
Aronovitz, Gerson H., 159
Artaza, M. A., 1587
Arthur, Michel, 78, 1563
Arts, Eric J., 1305
Ashdown, Leslie R., 905
Ashtekar, Dilip R., 803
Ashton, Sarah H., 393
Ateshkadi, Arash, 2650
Atzori, Chiara, 1492
Averett, Devron R., 441
Awan, Aftab R., 2478
Aymard, M., 2239
Azad, Raana F., 1945
Babich, John, 2144
Babst, Anna F., 1552
Bacheler, Lee T., 2606
Back, Arthur F., 1552
Bader, John P., 754
Baginski, Rainer, 750
Bajaksouzian, Saralee, 1799
Bakken, Johan S., 1171
Balfour, Henry H., Jr., 357, 835
Ballet, Jean-Jacques, 889
Ballow, Charles H., 1065, 1073
Baltian, Manik, 1614
Balzarini, J., 332
Balzarini, Jan, 2540
Bamberger, David M., 203
Bando, Kaori, 957
Baqr, Shahida, 2688
Baquero, F., 1982
Baquero, Fernando, 2059, 2427
Baquero, Maria-Rosario, 2059
Barbadora, Karen, 1238
Barbhaiya, R. H., 1180
Barbour, Alan G., 1115, 1704
Bargiggia, Stefano, 2212
Barker, Patrick J., 84
Barko, Nir, 2483
Barluzzi, Roberta, 2422
Barmada, S., 2678
Barone, Joseph A., 778
Barrios, Alcira Angelo, 859
Barrow, William W., 652
Barry, A. L., 893
Barry, Arthur L., 14
Barry, Beatrix, 1599
Bartizal, Ken F., 39
Bartlett, John A., 2449
Bartlett, Marilyn S., 39, 1543, 2166
Bartos, Linda, 512
Barza, Michael, 931
Barzen, Georg, 1367
Basco, Leonardo K., 924
Bastone, Elisa B., 914
Batra, Kumar K., 1025
Bauchet, J., 633
Bauer, Friedrich Eckhard, 2153
Bauer, Gerhard, 115
Bayer, Arnold S., 546, 2030
Bazmi, Hengameh Z., 875
Beam, Thomas R., Jr., 896
Beauchamp, Denis, 2727
Beaudouin, Robert, 1264
Beck, Francis, 1873
Becker, S. A. W. E., 2638
Beckett, Laurel A., 1095
Beijnen, Jos H., 1426
Bell, Constance A., 2668
Beller, Jean-Paul, 1873
Bellido, J. L. Muñoz, 911
Benchimol, Marlene, 2722
Bender, Rudolf, 1659
Bengtsson, Stellan, 2200
Bennett, Diane, 613
Bennett, L. Lee, Jr., 1004
Bennett, Peter M., 153
Bennett, Sam, 825
Bennett, W. M., 347
Benson, Constance A., 1444
Benson, John M., 1343
Bentorcha, Fairouze, 2593
Berger, L. C., 1713
Bergeron, Michel G., 2727
Bergeron, Yves, 2727
Berggren, Terriel, 2033
Berkowitz, Barry A., 393
Berlutti, F., 2618
Bernan, Valerie, 1624
Bernard, E., 921
Bernard, Edward M., 398, 2323
Bertasso, A., 559
Berti, Marisa, 741
Bertrand, Kevin P., 1624
Bethell, Richard C., 1473
Bethune, Linda, 746
Betriu, Carmen, 1717
Beumer, Henriette, 885
Beveridge, Terry J., 715
Beyer, Jörg, 1367
Bhatt, Arun D., 183
Bhattacharya, M. K., 1197
Bhattacharya, Prabhat Kumar, 2459
Bhattacharya, S. K., 1197
Bienen, E. Jay, 1082
Bierman, Robert H., 778
Bilello, John A., 115
Billard, Lynne, 825
Billhardt, Uta-Maria, 1659
Binczewski, Brian, 1238
Bindra, Rani R., 1360
Birmingham, Mary C., 1065, 1073
Biron, Karen K., 19
Bischofberger, Norbert, 2247
Bistoni, Francesco, 2422
Bjørneklett, Arvid, 2443
Black, Paul L., 71
Black, Roberta J., 1095
Blahy, Olga M., 1576
Blais, Johanne, 1701, 2571
Blanchet, Françoise, 1790
Blasi, Elisabetta, 2422
Blatter, Marianne, 1971
Blazquez, J., 1982
Blazquez, Jesus, 2059
Blom, Jens, 2550
Blum, Hubert E., 1539
Bodeau, Amy L., 2710
Bodey, Gerald P., 51, 2504
Bodey, G. P., 729
Bodmer, Thomas, 2054
Body, Barbara A., 39
Bogaki, Mayumi, 839
Bohm, Rudolf, 1370
Boivin, Guy, 357
Bolan, Gail A., 1670
Bold, Guido, 2087
Bollen, A., 142
Bombardelli, Ezio, 1492
Bond, Lynne, 474
Bongaerts, G. P. A., 2017
Bonnay, M., 1432
Bonnem, Eric, 512
Bonner, Daniel P., 213, 1289
Bonnesen, Shari Powers, 1614
Bonnet, M., 1015
Bordon, Florence, 1247
Borin, Marie, 1137
Borin, Marie T., 2650
Borner, Klaus, 1835
Boroto-Esoda, Katyna, 1720
Borsch, Carina M., 128
Bosso, John A., 1414
Bostian, Keith A., 377
Bouchard, Céline, 1373
Boucher, Charles, 1390
Boucher, Charles A. B., 1525, 2231
Boudinot, F. Douglas, 1343
Boudjema, Karim, 1873
Boulerice, François, 1305
Bourget, Philippe, 54
Bourneix, C., 1432
Bouvet, Olivier, 464
Bouza, Emilio, 1200
Bova, Carol A., 178
Bowden, Raleigh A., 1360
Bowdon, Bonnie J., 1004
Boyce, Steven T., 1890
Boyd, Malcolm R., 642
Boyd, Michael R., 754, 1037
Bradford, Patricia A., 251, 1989, 2578
Bradley, Suzanne F., 2003
Brake, W. B., 1713
Brandicourt, Olivier, 970
Brasseur, Philippe, 889
Bray, Patrick G., 1318
Brazeau, Gayle A., 246
Binczewski, Brian, 1238
Bressolle, Françoise, 464
Bril-Bazuin, C., 2318
Brion, N., 737, 2674
Broccoli, Gianpietro, 2212
Brockmeyer, N. H., 1010
Broder, Samuel, 810
Brogard, J. M., 1488
Brook, I., 1882
Brook, Itzhak, 997, 1452, 1531
Brookshire, Kenneth W., 213
Brouwer, J. T., 595
Brown, Barbara A., 1850
Brown, Prince, 613
Brown, Richard B., 1
Brown, Sheldon T., 398, 2323
Bruch, Suzanne, 2449
Bruggeman, Cathrin A., 218
Brumfitt, W., 1558
Bruneton, Jean, 859
Brunnemann, Sherry R., 93
Bruno, Antonella, 1492
Bryskier, André, 1560
Bubp, Jeff, 1137
Buckheit, Robert W., Jr., 754
Burger, David M., 1426
Burstein, Esther, 2483
Busch, Janice, 775
Bush, Karen, 851, 1989
Busso, Mariano, 1127
Butler, T., 1572
Butler, Thomas, 2418
Buu-Hoi, A., 2159
Byrnes, Vera W., 947, 1576
Cacalano, Grace, 667
Cahill-Feehan, Carol, 1693

- Cal, Stanley X., 1869
 Caliendo, Angela M., 1480
 Callahan, Ronald J., 1270
 Callaway, James E., 1614
 Calvat, Sylvie, 281
 Cambau, Emmanuelle, 1247
 Cameron, Janet, 1390
 Cameron, Janet M., 2231
 Cameron, Miriam L., 2449
 Cammack, Nick, 1390, 2231
 Cammarata, Catherine, 1986
 Campbell, D. A., 1180
 Campbell, Lee Ann, 8
 Canfield, Craig, 1417
 Cannon, Deborah L., 875
 Cantin, Line, 1993
 Canton, Rafael, 2059
 Cantoni, Lavinia, 2527
 Carbon, Claude, 1790, 2466
 Carelli, Maria, 2527
 Carey, Patrick M., 2650
 Carias, Lenore L., 610, 1061, 2760
 Carret, G., 1685
 Cars, Otto, 2200
 Carsenti-Eselle, H., 921
 Carter, Stephen G., 144
 Cartwright, Frank D., 1726
 Casadevall, Arturo, 1383
 Casetta, A., 2159
 Cassileth, Peter A., 474
 Cataldo-Caputal, Lucille, 1556
 Cavaliere, Stephen J., 1171
 Cavé, André, 859
 Cekleniak, Natalie, 1624
 Cercenado, E., 1604
 Cercenado, Emilia, 1200
 Cesana, M., 2545
 Cesana, Marina, 2298
 Chachaty, E., 1432
 Chamberland, Suzanne, 1701, 1993, 2571
 Chambers, Henry F., 1144
 Chan, Chor-Bun, 2007
 Chan, C. Y., 1001
 Chan, Marion Man-Ying, 1909
 Chandrasekar, P. H., 1927
 Chapelsky, Martha, 775
 Chaplain, C., 737
 Chastre, Jean, 281
 Chavalitshewinkoon, Porntip, 403
 Cheeseman, Sarah H., 178
 Chen, Ming, 2550
 Cheng, A. F. B., 1001
 Cheng, Yung-chi, 1420
 Chichino, Guido, 1492
 Chimata, Minoru, 229
 Chimirri, A., 1497
 Chin, Nai-Xun, 566
 Chio, Li-Chun, 1914
 Chiodini, Rodrick J., 1645
 Chopra, Ian, 153
 Chow, Andrew T., 1468
 Chow, Joseph W., 134, 1187, 2474
 Chow, Yung-Kang, 1480
 Christensen, Søren Brøgger, 2550
 Chu, Chung K., 875
 Chuah, See Kean, 1711
 Chuard, Christian, 625
 Citron, Diane M., 1150
 Clanton, David J., 754
 Clark, Nancye C., 2311
 Clarkson, Allen B., Jr., 1082
 Clavier, Françoise, 970
 Clecner, Bya, 1373
 Cleeland, Roy, 2144
 Clement, Jacob, 864, 1329
 Clemons, Karl V., 1177, 2224
 Clewell, Don B., 134, 2474
 Coates, Jonathan A. V., 1473
 Cochereau-Massin, I., 633
 Coen, Donald M., 19
 Coene, Marie-Claire, 2101
 Coffey, Tracey J., 1938
 Cohen, Louise G., 2187
 Cohen, Michael A., 2563
 Cohen, Myron S., 950
 Cohen, Yves, 692
 Colaizzi, John L., 778
 Cole, Stewart T., 414
 Coleman, Ruth A., 2027
 Colina, F., 2490
 Coll, Ramon, 868
 Collatz, Ekkehard, 1247
 Collins, Linda, 2009
 Collins, Linda A., 598, 1364
 Colturani, F., 2545
 Comodi-Ballanti, M. R., 2618
 Condra, Jon H., 947, 1576
 Conejo, Carmen, 187
 Conly, J. M., 574
 Connelly, Michele C., 2247
 Connor, Edward, 532
 Connor, James, 532
 Conway, Anthony J., 2033
 Cook, James A., 393
 Cooke, N. J., 804
 Cooksey, Robert C., 1348, 2311
 Cookson, Barry, 681
 Cooley, Timothy P., 1480
 Cools, Willy, 2101
 Cooper, Brian W., 234
 Cooper, Chester R., Jr., 2407
 Cooreman, M. P., 1506
 Corbett, Anita H., 2599
 Corey, Lawrence, 975
 Correa-Coronas, Rafael, 474
 Correia, John A., 1270, 2144
 Cory, Michael, 2668
 Cosgrove, Yvonne T., 8
 Costa, Yannick, 1896
 Costa-Perira, Rabi, 183
 Costerton, J. W., 2000
 Coudron, Philip E., 1447
 Courvalin, Patrice, 78, 1456, 1563, 1896, 2093, 2119
 Cowser, Lex M., 171
 Cox, H., 1924
 Cozens, Robert, 2087
 Craig, William A., 2650
 Crane, Deborah D., 357
 Crawford, Jack T., 1348
 Cretton, Erika M., 1816
 Crooke, Rosanne M., 1945
 Crucey, Antonio, 1717
 Crumpacker, Clyde S., 1095
 Cui, X., 2496
 Cunningham, Francesca E., 1343
 Curfs, Jo H. A. J., 276
 Currens, Michael J., 1037
 Curvale, Georges, 1214
 Cynamon, M. H., 2344
 Daffe, Mamadou, 1536
 Dal Bo, Lorenzo, 2212
 Dale, Glenn E., 1400
 Dal Pizzol, Virginia, 2693
 Dalton, Harry, 2193
 Damiani, Aldo, 106
 Dan, M., 293
 Dandekar, Kishor A., 1160
 D'Aquila, Richard T., 1095, 1480
 Davidson, Ross J., 1154
 Davies, Julian, 2379
 Davis, Michelle, 19
 Day, C. A., 2506
 Day, D. F., 2506
 Dayer, P., 2132
 Dazer, Maureen E., 2563
 de Anta, Teresa Jimenez, 138
 de Aquino Almeida, João Carlos, 2722
 de Beco, Virginie, 281
 Debyser, Zeger, 2540
 de Cespédès, Gilda, 2593
 Decker, William D., 754
 De Clercq, E., 332
 de Clercq, Erik, 218, 2540
 de Graaff, J., 1184
 de Jonge, Boudewijn L. M., 342
 de la Coussaye, Jean-Emmanuel, 464
 de Lalla, Fausto, 2693
 Delbos, Françoise, 2593
 del C. Ceinos, Maria, 1728
 Delehanty, John, 975
 Dellamonica, P., 921
 Delouis, Christine, 54
 Del Valle, O., 1587
 Demain, Arnold L., 84
 DeMuria, Deborah, 2187
 Denaro, Maurizio, 741
 Denny, William, 403, 991
 De Rosa, Franco, 1679
 Derouin, Francis, 2371
 De Sarro, A., 1497
 De Sarro, G. B., 1497
 Desmyter, Jan, 2540
 De Souza, Wanderley, 580, 2722
 DeStefano, M. S., 2344
 Dever, Lisa L., 1115, 1704
 DeVore, Kimberly M., 1480
 Dhindsa, Harinder S., 2754
 Diasio, Christoph R., 1771
 Díaz, M. Dolores, 1200
 Dieck, Harold A., 1082
 Digranes, Asbjørn, 2024
 Dijkstra, Jan, 2293
 Dionne, Gervais, 130
 DiPiro, Joseph T., 1343, 1463
 Doherty, Catherine, 123
 Doherty, Patrick, 1737
 Domagala, John M., 2563
 Dombret, Marie-Christine, 281
 Donabedian, Susan, 134
 Donabedian, Susan M., 2474
 Donowitz, G. R., 2261
 Donta, I., 308
 Doury, Jean-Claude, 924
 Downey, Kathleen M., 1127
 Downs, Mary Beth, 71
 Drancourt, Michel, 1214
 Dreyer, Geoffrey B., 71
 Driver, Vickie B., 1945
 Drusano, George L., 115, 483
 Drusano, G. L., 2496
 DuBois, J., 574
 Dubois, Jacques, 1373
 Ducharme, Murray P., 2706
 Duchateau, V., 1860
 Dudley, Michael N., 1723, 1756
 Dueweke, Thomas J., 1127
 Dullenkopf, Klaus, 1367
 Dumas, J. C., 1232
 Duncanson, F. P., 1580
 Dunn, David L., 357
 Dunne, W. Michael, Jr., 2522
 Dupeyron, Jean-Pierre, 501
 Dupont, Marie-Ange, 1536
 Duport, Catherine, 962
 Durack, David T., 903
 Durant, J., 921
 Dutko, Frank J., 297
 Dutta, P., 1197
 Duval, Jean, 78, 789, 1896, 2119, 2466
 Dworkin, R., 2678
 Dykstra, C. C., 1713
 Dykstra, Christine C., 2668
 Dylewski, Joseph, 1373
 Earnhardt, K. I., 2261
 Echols, Roger, 1670, 2193
 Edelstein, Martha A. C., 908
 Edelstein, Paul H., 908
 Edlund, Charlotta, 1665
 Edmunds, Kay, 1799
 Edmunds, Michael, 1238
 Edwards, Barbara A., 2754
 Edwards, David J., 2706
 Edwards, Fitzroy F., 398, 2323
 Edwards, John E., Jr., 546, 2628
 Egan, William, 1420
 Ehrett, Stuart, 1630
 Eledjam, Jean-Jacques, 464
 Eling, Wynand M. C., 276
 Eliopoulos, C. T., 366
 Eliopoulos, George M., 507, 598, 1364, 2009
 Eliopoulos, G. M., 366, 1604
 Elliott, T. B., 1882
 Ellner, Jerrold J., 1799, 1807
 Elsea, Sarah H., 2179
 El Solh, N., 2159
 Emge, Thomas J., 1909
 Emini, Emilio A., 947, 1576
 Emori, Masako, 722
 Engel, Lee S., 1856
 Enoxacin Prophylaxis Study Group, 474
 Entenza, J., 921
 Entenza, José, 1971
 Erice, Alejo, 357, 835
 Erickson, John, 810
 Eron, Joseph J., 1480
 Espinel-Ingroff, Ana, 39
 Esteve, Montserrat, 868
 Etter, L., 2432
 Etter, Laura, 1061
 Fabre, David, 464

- Fadat, G., 1955
 Faessler, Alex, 2087
 Fagon, Jean-Yves, 281
 Fairley, Terri A., 2668
 Faleschini, E., 2545
 Falkenstein-Paul, Hildegard, 696
 Fallani, Stefania, 2693
 Fantin, Bruno, 2466
 Farinotti, Robert, 281
 Farmer, Susan W., 453
 Farzadegan, H., 360
 Farzadegan, Homayoon, 429
 Fass, Robert J., 2080, 2348
 Faurisson, F., 633
 Feibusch, Evan L., 106
 Ferencz, Nicholas, 818
 Fernandez, Hervé, 54
 Ferraro, Mary Jane, 598, 1364
 Ferraro, M. J., 366
 Fey, P. D., 2432
 Fich, Karen, 2550
 Fichtl, Richard E., 1504
 Field, Hugh J., 2478
 Fields, Marc T., 203
 Fier, Joshua, 2293
 Figgitt, David, 403, 991
 Filadaro, Francesco, 1958
 Finegold, S. M., 2638
 Finegold, Sydney M., 2509
 Fischman, Alan J., 1270, 2144
 Fishman, Jay A., 1543
 Flaherty, John, 1137
 Flandrois, J. P., 1685
 Flexner, C., 360
 Flor, Soledad C., 1468
 Fluckiger, Ursula, 1971
 Foca, Alfredo, 393
 Focht, Josef, 2298
 Folen, Barbara D., 301
 Fong, Dunne, 1909
 Foo, Hsin-Hsin, 2500
 Foor, Forrest, 84
 Ford, Harry, Jr., 810
 Ford, Jeanne, 2193
 Forrest, Alan, 1065, 1073, 2187
 Fothergill, Annette W., 2307
 Fouda, Hassan G., 314
 Fournet, Alain, 859
 Fournier, Genevieve, 2020
 Foweraker, J. E., 804
 Fox, Maureen C., 171
 Foy, Jilanna, 1436
 Frachet, B., 2674
 Frainow, Henry S., 2736
 Francioli, Patrick, 1971
 Francioli, Patrick B., 207
 Franzblau, Scott G., 1997
 Franzini, P., 2545
 Freifeld, Alison, 495
 French, Pamela, 2736
 Fresnadillo, M. J., 911
 Frey, Carrie, 39
 Frick, Lloyd W., 2285
 Fridland, Arnold, 2247
 Friedland, Ian R., 1630
 Froelich-Ammon, Stacie J., 646
 Fromtling, Robert A., 39
 Frost, R. Wayne, 2106
 Fu, K. P., 301
 Fuchs, P. C., 893
 Fuchs, Peter C., 14
 Fujii, K., 67
 Fujisawa, Chiho, 2173
 Fujita, Y., 1043
 Fukasawa, Masatomo, 2743
 Fukatsu, Hiroshi, 2756
 Fukuoka, Takashi, 322
 Fukuoka, Yoshikazu, 384
 Fukutomi, Yasuo, 2265
 Fulton, David R., 1655
 Fung-Tomc, Joan, 213, 1289
 Furfine, Eric S., 2285
 Furman, Phillip A., 1720, 2285
 Furudera, Takenori, 1826
 Furuya, Nobuhiko, 675
 Gadgil, Shrikant D., 314
 Gaffar, Maria C., 778
 Galgiani, John N., 39, 2126, 2517
 Galimand, Marc, 1456, 1896, 2093, 2119
 Gallati, Harald, 2418
 Galtier, Marc, 464
 Gálvez, Antonio, 148
 Gamage, Swarna, 403, 991
 Gambertoglio, John, 1137
 Gangness, David, 1171
 Gao, Qing, 130, 1390
 Garber, Sena, 2606
 García, I., 2490
 García, Isabel, 187
 García, Jesus, 868
 García, M. M., 2638
 García-Rodríguez, J. A., 911
 Gardner, Mark J., 314
 Gargallo-Viola, Domingo, 868
 Garneau, Valérie, 1701
 Garon, Claude F., 46
 Gaspar, Erzebet, 2593
 Gasser, I., 1587
 Gastañares, Maria-Jose, 2427
 Gatti, Giorgio, 1137
 Gaudebout, Claude, 970
 Gaudreau, Christiane, 1174
 Geggel, Robert L., 1655
 Gehanno, Pierre, 1599
 Geisel, Janet, 393
 Gelezinas, Romas, 1305
 Gelfusa, Vincenzo, 1190
 George, Robert C., 681
 George, William J., 818
 Georgii, Aletta, 2064
 Georgopapadakou, N. H., 559, 2045
 Gerard, Geoffrey C., 1334
 Gerbaud, Guy, 1456, 2093
 Gerlach, E. H., 1696
 Gerok, Wolfgang, 1539
 Ghaleh, Bijan, 1777
 Ghanoum, Mahmoud A., 546, 2628
 Ghezzi, Maria Cristina, 1958
 Ghezzi, Pietro, 2527
 Ghione, Mario, 1492
 Ghosh, Dilip Kumar, 2459
 Giamarellou, Helen, 308
 Gibert, Claude, 281
 Gikas, Achilleas, 51
 Gilbert, James, 32
 Gilbert, D., 2678
 Gilbert, Deborah, 1723
 Gilbert, Deborah H., 1756
 Gilbert, D. N., 347
 Gilja, Odd Helge, 2024
 Gillespie, S. H., 2493
 Gilliland, Susan S., 436, 1377
 Gillum, J. Gregory, 2193
 Gilman, Thomas M., 93
 Gilmore, James D., 1452
 Giroux, M., 1232
 Glauser, Michel P., 207, 1971
 Gleaves, Curt A., 1360
 Goering, R. V., 2432
 Goetz, Matthew B., 1334
 Goh, Khye Seng, 652, 1560
 Gohara, Yukiko, 287, 1826
 Gold, H. S., 1604
 Goldman, Hy, 1305
 Goldman, Mark E., 947
 Goldstein, Beth P., 741
 Goldstein, Ellie J. C., 1150
 Goldstein, Neil H., 297
 Gollapudi, Sastry V., 1711
 Golub, Lorne M., 592
 Gomez, Maria, 1717
 Gomez, R., 2490
 Gómez-Jiménez, J., 1587
 Gomez-Lus, Rafael, 138
 Gonçalves, Noémia Rodrigues, 2722
 Gong, Yi-Fei, 2247
 Gooch, W. Manford, III, 159
 Gooding, Beth Briggs, 349
 Goody, Roger, 2612
 Goos, M., 1010
 Gootz, Thomas D., 646, 2179
 Gordillo, Manuel E., 1203
 Gorrens, Jos, 2101
 Gorzynski, Eugene A., 896
 Goss, Thomas F., 1073
 Gotlib, Leah, 1576
 Goto, Sachiko, 60
 Govan, John, 123
 Grady, Robert W., 1082
 Graham, Donald J., 1576
 Grasso, S., 1497
 Green, Michael, 1238
 Grewal, Jaswinder, 2645
 Griffith, Jeffrey K., 1253
 Griggs, D. J., 662
 Grill, Susan, 1420
 Groothuis, Jessie R., 1655
 Grosset, Jacques, 407, 692, 1690
 Gu, Ligang, 2265
 Gu, Zhengxian, 130, 1390
 Guay, David R. P., 436
 Guay, Gordon G., 191
 Gueret, Dominique, 970
 Guerillot, F., 1685
 Guerra, Isabel, 148
 Guerry, Philippe, 2599
 Guinea, Jesus, 868
 Gulakowski, Robert J., 754
 Gulnik, Sergei, 810
 Gunther, Michael R., 950
 Gupta, Pramod, 864, 1329
 Gupta, Rachna, 882
 Gur, D., 1637
 Gür, Deniz, 1831
 Gutmann, L., 1406
 Gutmann, Laurent, 1247, 1387
 Haag, Jo Jean, 1670
 Hackbarth, Corinne J., 1144
 Hakusui, Hideo, 2173
 Halinen, Sirkka, 592
 Hall, Geraldine, 39
 Hall, J. E., 1713
 Hall, Joseph, 592
 Hall, L. M. C., 1637
 Hall, M. C., 662
 Halstensen, Alfred, 2024
 Halushka, Perry V., 393
 Hamer, Davidson H., 931
 Hamilton, H., 1620
 Hamilton, Robert G., 1463
 Hamilton-Miller, J. M. T., 1558
 Hamzeh, Faye M., 602
 Hancock, Robert E. W., 453
 Hand, Debra L., 2557
 Hand, W. Lee, 2557
 Hansen, Lori M., 2699
 Hansen, Sharon L., 1334
 Hanson, Linda H., 1177, 2224
 Hanssen, Brenda R., 265
 Hara, Kohei, 2762
 Hardie, J. M., 2493
 Harding, G. K. M., 574
 Hare, Roberta S., 2074
 Hare, R. S., 708
 Hariprasad, June, 1504
 Harrington, Joan A., 918
 Harrison, Barbara, 1444
 Harvey, Kevin, 2193
 Harvey, Tracey, 1711
 Hase, Toyoji, 363
 Hasegawa, Takaaki, 1781
 Hasegawa, Takashi, 2217
 Haselbeck, Bob, 1614
 Hashimoto, Nobuo, 901
 Hashizume, Terutaka, 2756
 Hattori, Hiroaki, 839
 Hattox, Susan E., 178
 Häusler, Alex, 84
 Havenith, Mick, 218
 Hawkey, P. M., 804
 Hayakawa, Isao, 2112
 Hayashi, Hideya, 810
 Hayashi, Ryogo, 100
 Hayden, Frederick G., 297
 Hayes, Michael M., 2500
 Hayman, Alan C., 246
 Hayran, Murat, 1831
 Healy, Niamh, 1473
 Heifets, Leonid, 111, 1380, 2364
 Heijntink, R. A., 595
 Heikkilä, Elina, 1297
 Heisig, Peter, 696
 Heller, Allen H., 2193
 Hemming, Val G., 1655
 Hendrix, Craig W., 429
 Hengels, K. J., 1506
 Hengge, U. R., 1010
 Henry, N. K., 554
 Herndon, Betty L., 203
 Herrero, J. A., 2490
 Hesse, Werner H., 2622
 Heudes, Didier, 1790
 Hewitt, Ross G., 512
 Heykants, Jos, 2224
 Hickey, Sheila, 1630
 Hidaka, T., 67
 Hidaka, Takayoshi, 722
 Hikida, Munee, 199
 Hill, Bertha C., 2311

- Hill, Craig L., 1707
Hill, Edgar, 975
Hill, James M., 1856
Hille, Heidemarie, 2153
Hillgoss, Donald M., 314
Hintermann, Gilberto, 84
Hiraga, Y., 1043
Hirakata, Yoichi, 675
Hiramatsu, Keiichi, 1219, 2278
Hirata, Michimasa, 2534
Hirata, Takahiro, 2656
Hirsch, Martin S., 1480
Hirsh, Dwight C., 2699
Hiscott, John, 130
Hiscox, Steven A., 1473
Hitchcock, C. A., 1962
Hitchcock, Michael J. M., 1816
Hizi, Amnon, 1037
Hjelm, Ulrika, 1285
Ho, Chi-Tang, 1909
Ho, Dah Hsi, 2504
Ho, May, 2418
Hoban, Daryl J., 1154
Hobden, Jeffery A., 1856
Hocquemiller, Reynald, 859
Hoepelman, Andy I. M., 885
Hoffman, Jacob M., 947
Hoffner, Sven E., 1285
Høiby, E. Arne, 2024
Holder, Ian A., 1890
Holy, A., 332
Holy, Antonin, 2540
Honore, Nadine, 414
Hoogkamer, Johannes F. W., 2622
Hoogkamp-Korstanje, J. A. A., 2017
Hook, Edward W., III, 1670
Hooper, David C., 2588
Hoosen, Anwar A., 2733
Hopkins, Sam, 1720
Horaus, Thea, 2593
Hori, Satoshi, 2278
Hori, Toshinobu, 984
Horiuchi, Sankichi, 2486
Hoshino, Kazuki, 2112
Hostettler, John S., 2224
Houck, Herbert J., 613
Hougen, Thomas, 1655
Howell, John M., 2754
Howells, R. E., 2337
Howells, Robert E., 1318
Huang, Hua-Bin, 566
Huang, Jun-Li, 1370
Huang, Wei Mun, 457
Huart, Alain, 1777
Huband, Michael D., 2563
Hughes, George S., 2650
Hughes, Stephen H., 1037
Hughes, Walter T., 1417
Huhn, Dieter, 1367
Huls, Christine E., 1414
Huovinen, Pentti, 1158, 1297
Husson, M., 1860
- Ibrahim, Ashraf S., 546, 2628
Ichijima, Satoshi, 984
Iijima, Masako, 322
Iizawa, Yuji, 100
Ikeda, Yasushi, 384
Ilksoy, Nurcan, 875
- Imada, Akira, 100
Imagawa, Yatsuka, 2486
Imbimbo, B. P., 2545
Imbimbo, Bruno P., 637, 2212
Imboden, Paul, 2054
Imhoff, Tracy, 2030
Immendoerfer, Ulrike, 2612
Imtiaz, Uzma, 2438
Inagaki, Yoshio, 2486
Inamatsu, T., 1043
Inciardi, John F., 1025
Ingman, Tuula, 592
Inomata, Norikazu, 199
Inoue, Eiko, 1547
Inukai, Masatoshi, 980
Ioannides-Demos, Lisa L., 914
Irvin, James D., 835
Isaacson, David M., 301
Ishida, Hiroko, 2112
Ishida, Mariko, 2327
Islam, A., 1572
Isono, Fujio, 980
Israel, Debra, 2139, 2193
Ito, Hideaki, 839
Itoh, Tomoo, 2327
Iwagaki, Akitaka, 164
Iwahi, Tomoyuki, 100, 769
Iwasaki, Shigeo, 1313
Iwatani, Wakao, 785
- Jackson, M. Keven, 2716
Jackson, W. E., 1882
Jacobberger, Bernadette, 1873
Jacobs, Michael R., 1799, 1807
Jacobs, M. R., 1649
Jacobs, William R., Jr., 1348
Jacobus, David P., 1417
Jacobus, Nilda V., 2270
Jacoby, George A., 2760
Jansen, Robert W., 441
Janssen, David A., 2003
Jantos, Christian, 846
Japour, Anthony J., 1095
Järvinen, Helinä, 1158
Jarvis, Ken, 1329
Jarvis, Kenneth, 864
Jayanetra, P., 2000
Jeanfavre, Deborah Durham, 1693
Jefson, Martin R., 646
Jehl, F., 1488
Jehl, Francois, 501
Ji, Baohong, 407
Jin, Y. F., 662
Jindrich, J., 332
Jindrich, Jindrich, 2540
John, Joseph F., 1334
Johnson, C. C., 2069
Johnson, Curtis A., 2650
Johnson, David E., 483
Johnson, Elma, 1264
Johnson, E. M., 1962
Johnson, James R., 2033
Johnson, Lance C., 441
Johnson, Victoria A., 1095
Jones, R. N., 1696
Jones, Robert B., 1670
Jones, Ronald N., 349, 2747
Jones, S. K., 1713
Jorgensen, James H., 1115, 1704
- Kaatz, Glenn W., 128, 1086
Kabir, I., 1572
Kadurugamuwa, Jagath L., 715
Kageyama, Seiji, 810
Kaiser, Allen B., 702
Kaku, Mitsuo, 2762
Kakuta, Sachiko, 229
Källenius, Gunilla, 1285
Kalvakuntla, Laxman, 729
Kam, Kai-Man, 2007
Kanchonwongpaisan, Sumalee, 1108
Kamide, Ryoichi, 2217
Kamiyama, Tsutomu, 2656
Kamwan, Chantana, 2407
Kaplan, Edward L., 159
Kaplan, Joan C., 1480
Kaplan, Sheldon L., 2401, 2522
Kar, Kalipada, 2459
Kar, Sujata, 2459
Karayiannakos, P., 308
Karlowsky, James A., 1154
Karp, Judith E., 1847
Kato, Haru, 957
Kato, Katsuyoshi, 1781
Kato, Michiyuki, 1764
Kato, Naoki, 957
Kato, Nobuo, 984, 1781
Katsuta, Mitsuo, 322
Kauffman, Carol A., 2003
Kaufhold, Achim, 2740
Kaul, Sanjeev, 1160, 1816
Kawada, Harumi, 1749
Kazanjan, Powel H., 2187
Keirns, James J., 178
Kellam, Paul, 1525
Kenny, George E., 1726
Kessnle, Douglas S., 702
Kessler, Joseph A., 144
Keusch, Gerald, 1056
Keyhani, Afsaneh, 246, 2584
Kharazmi, Arsalan, 2550
Khardori, Nancy, 729, 882
Kharsany, Ayesha B. M., 2733
Kibbler, C. C., 2493
Kidd, Lauren B., 1816
Kiehn, Timothy E., 2323
Kierszenbaum, Felipe, 2235
Killmar, John, 1417
Kimura, Masashi, 801
Kimura, Sadao, 2228
King, Anna, 746
Kinowski, Jean-Marie, 464
Kinsman, Oonagh S., 1243
Kinzig, M., 1860
Kishimoto, Toshio, 801
Kishore, Alugupalli R., 240
Kiso, Yoshiaki, 810
Kitzis, Marie-Dominique, 1387
Kleim, Jörg-Peter, 1659
Klemens, S. P., 2344
Klefer, G. E. M., 595
Klietmann, Wolfgang, 2298
Klimkait, Thomas, 2087
Klimm, K., 366
Klopman, Gilles, 1799, 1807
Klugman, Keith P., 1938
Knapp, C. C., 1696
Knapp, Joan S., 1552
Kobayashi, Teruaki, 2042
- Koehler, Joy M., 905
Koenig, Bernhard, 2612
Koeppel, Peter, 1835, 2153
Koffel, Jean-Claude, 1873
Koga, Hironobu, 1877, 2762
Koga, Tetsufumi, 1749
Koh, Julia G., 778
Kohlhepp, S., 2678
Kohlhepp, S. J., 347
Kohnen, P. W., 347
Kohno, Shigeru, 1877, 2762
Kojima, Tsuyoshi, 839
Koks, Cornelis H. W., 1426
Kolek, Benjamin, 213, 1289
Kolenda, Herbert, 1518
Kondoh, Masumi, 2662
Kontinen, Yrjö T., 592
Kopp, U., 224
Koranyi, Katalin I., 314
Kort, Jens J., 115
Korting, Hans C., 2064
Kotani, Hitoshi, 2500
Kotnik, V., 1786
Koup, Richard A., 178
Kovacs, Joseph A., 1227, 1674
Krahenbuhl, James L., 2265
Krausgrill, P., 1506
Kreeger, John M., 1645
Krinke, Alison J., 2454
Kristensen, Gun, 1665
Kruze, James A., 1927
Krusell, Allan R., 1132
Kubat, Tina, 1171
Kuebelbeck, Virginia, 835
Kumar, Ashir, 159
Kuo, Cho-Chou, 8
Kurata, Tadashi, 2173
Kuritzkes, Daniel R., 1095
Kurtzberg, Joanne, 144
Kusne, Shimon, 1238
Kuwahara-Arai, Kyoko, 1219
Kuwano, Koichi, 287, 1826
Kuypers, Frans, 1108
- Labia, Roger, 939, 962
LaBombardi, Vincent J., 1556
Lachance, Nathalie, 1174
Lacroix, Jean-Michel, 2037
Ladizensky, Esther, 2483
Lafredo, Stephen C., 301
Lagrange, Philippe H., 2020
Lahiri, M., 1197
Lai, Cham-Fai, 2007
Lai, Jiunui, 1614
Laizure, S. Casey, 448
Lalande, Valerie, 407
Lam, Joseph S., 715
Lam, K., 2000
Lam, Patrick Y.-S., 2606
Lambert, C., 1860
Lambert, Dennis M., 71
Lambert, Thierry, 1456, 2093
Lamer, Christian, 281
Lamothe, François, 1174
Lamp, Kenneth C., 605, 1931
Landman, David, 1904
Lane, James, 532, 1095, 1127
Laneelle, Gilbert, 1536
Lang, Marc, 2087
Lang, R., 2333
Lange, Joep M. A., 1525
Lantero, Marta, 2427

- Larder, Brendan A., 1525
 Larrick, James W., 2534
 Larsson, Alison J., 1377
 Last-Barney, Kathleen, 1693
 Lastilla, Marco Gregorio, 1679
 Lavoie, Suzanne R., 1447
 Lawlor, Michael T., 234
 Lawrence, A. Jean, 1869
 Lawrence, Theresa, 896
 Lawrence, William D., 512
 Lazard, Thierry, 692, 1690
 Lazardi, Keyla, 580
 Lazdins, Janis, 2087
 Lazzaroni, Marco, 2212
 LeBlanc, Barbara, 2504
 Le Bras, J., 1955
 Le Bras, Jacques, 924, 970
 Lebsack, M. E., 775
 Leclercq, Roland, 78, 789, 1896, 2119, 2466
 Lee, Hsi-Ming, 592
 Lee, K., 2638
 Lee, Ving J., 851, 2270
 Lee, Yun-Sang, 2007
 Leemann, T., 2132
 Leggett, J., 2678
 Le Gros, V., 737, 2674
 Lei, Shau-Ping, 1614
 Leibowitch, Jacques, 2206
 Le Jeune, Ludo, 2101
 Lemeteil, Denis, 889
 Lemmich, Else, 2550
 Lentino, Joseph R., 339
 Lépine, Guylaine, 2037
 Lepoche, H., 1410
 Lerner, Stephen A., 2438
 Lertora, Juan J. L., 818
 Leser, Ulrike, 2612
 Leske, Valeria L., 835
 Lettieri, John T., 2106
 Levin, James M., 1444
 Levison, M. E., 2069
 Levitsky, Sidney, 2106
 Levy, Stuart B., 825, 2699
 Lew, Daniel P., 625
 Lew, D. P., 2132
 Lewin, Clement, 123
 Lewis, Mark G., 71
 Li, Cong, 2030
 Li, M. S. K., 1001
 Li, Ronald C., 371, 523
 Li, Shu C., 914
 Liebman, Howard A., 1480
 Lietman, Paul S., 429, 602
 Lim, Seung T., 1264
 Lima, Viera, 1108
 Lindley, Ivan J. D., 276
 Lindquist, S., 224
 Lindstrom, Terry D., 265
 Lindy, Otso, 592
 Lins, Ulysses, 2722
 Liotta, Dennis C., 875, 1720, 2206, 2285
 Lipke, Peter N., 1264
 Littlejohn, Tim G., 761
 Liu, Tiepu, 1771
 Liu, Yu-Ying, 2144
 Livermore, David G., 1243
 Livermore, D. M., 1637
 Livni, E., 1270, 2144
 Livornese, L. L., 2069
 Lizasoain, M., 2490
 Lloyd, Robert M., Jr., 875
 Lo, Kuen-Kong, 2007
 Lo, Shyh-Ching, 2500
 Lockwood, Graham, 297
 LoCoco, John M., 301
 Lode, Hartmut, 1835
 Lombardi, F., 2545
 Loncle, V., 2159
 Long, William J., 1576
 Lonks, John R., 1742
 Lopardo, Horacio A., 1728
 Lopez-Berestein, Gabriel, 246
 Lorscheider, Fritz L., 825
 Lortholary, Olivier, 1790
 Louchahi, K., 737, 2674
 Louis, F. J., 1955
 Louis, J.-P., 1955
 Löwdin, Elisabeth, 2200
 Lu, Zhihong, 1771
 Lumberras, C., 2490
 Lupia, Raul H., 818
 Lüthy, Ruedi, 1056
 Maass, Gerhard, 2612
 Macalintal, Clarissa, 851
 Maderazo, Eufonio G., 1132
 Maeda, Akio, 1313
 Macland, Arild, 2443
 Magallanes, Marcus, 2293
 Magnuson, Terry, 1610
 Mahr, Gerhard, 1518
 Majerus, P., 142
 Majumder, Sarmila, 2235
 Malanoski, Gregory J., 598, 2009
 Maldonado, Rosa A., 1353
 Maldonado, Rosa Amelia, 580
 Malessa, R., 1010
 Maliszewski, Maureen L., 512
 Mallet, D., 1410
 Mallie, Jean-Pierre, 1510
 Mamber, Stephen W., 213
 Mamman, Mohammed, 1050
 Manavathu, Elias K., 2438, 2645
 Mancini, Carlo, 1958
 Mann, Paul A., 2074
 Mansat, V., 1232
 Mant, Tim G. K., 637
 Mao, Jinghe, 950
 Maqueda, Mercedes, 148
 Maraki, Sofia, 51
 Marceau-Day, M. L., 2506
 Marchan, Edgar, 580
 Marchbanks, C. Randall, 1723, 1756
 Marchesi, Francine, 2054
 Marco, Francesc, 138
 Marcos, Angeles, 138
 Margolick, Joseph B., 429
 Marichal, Patrick, 2101
 Mariotte, Sophie, 939
 Markham, Richard B., 429
 Markowitz, Sheldon M., 1447
 Marler, J. K., 1122
 Marlin, Steven D., 1693
 Marrakchi-Benjaafar, S., 633
 Marshall, Bonnie, 825
 Marshall, Steven A., 2747
 Marshall, Steven H., 2760
 Martel, A. Y., 574
 Martin, Andrea, 1278
 Martin, David H., 1670, 1986
 Martin, J. Louise, 1720
 Martin, Stephan, 1278
 Martinez, Anthony, 1674
 Martinez, J. L., 1982
 Martinez-Bueno, M., 148
 Martínez-Vázquez, J. M., 1587
 Martino, Piero, 1190
 Marutani, Kiyoshi, 2217
 Marx, Gerald R., 1655
 Marzella, Louis, 120
 Mason, Edward O., Jr., 2401, 2522
 Massidda, Orietta, 1324
 Masuda, Nobuhisa, 322
 Masukawa, Yoshikazu, 199
 Matera, Giovanni, 393
 Maternan, E., 1620
 Mathez, Dominique, 2206
 Matsubara, Shuzo, 1826, 2217
 Matsuda, Kouji, 2756
 Matsumoto, Fumio, 2217
 Matsumoto, Keizo, 164
 Matsumoto, Masahiko, 2217
 Mattie, H., 2318
 Matumoto, Masahiko, 1826
 Mauël, Jacques, 991
 Maurin, M., 1410, 2633
 Maxwell, Anthony, 126
 Mayers, Douglas L., 1095, 1127
 Mayhall, C. Glen, 1334
 Mazzolla, Rosanna, 2422
 McClure, Harold M., 1816
 McCracken, George H., Jr., 1630
 McEntee, M. F., 360
 McGahren, Jim, 1624
 McGlynn, Marion, 1624
 McGrath, Betty J., 1723, 1931
 McGuirk, Paul R., 646, 2179
 McKiel, Joan R., 1756
 McKoy, Judith, 1264
 McLaughlin, Margaret M., 178
 McLean, Allan J., 914
 McLinn, Samuel E., 159
 McMahon, James B., 754, 1037
 McMillan, Angela, 875
 McMurry, Laura M., 2699
 McNally, Eugene J., 1693
 McNamara, Patrick J., 2706
 McQueen, Teresa J., 2584
 McWhinney, P. H. M., 2493
 Mechlini, Witold, 778
 Medeiros, Antone A., 1742
 Meenhorst, Pieter L., 1426
 Mehl, Paul, 2470
 Mehta, Reeta T., 2584
 Meichsner, Christoph, 1659
 Meissner, H. Cody, 1655
 Mellors, John W., 875
 Menard, Robert, 78
 Menck, Sylvia, 1518
 Menninger, John R., 2027
 Merluzzi, Vincent J., 1693
 Merz, William G., 1847, 2407
 Meservey, Mark A., 2563
 Meshnick, Steven R., 1108
 Meyer, A. P., 2318
 Michel-Briand, Yvon, 962
 Mierzwa, Ronald, 2074
 Mikami, Yuzuru, 1313
 Miksits, Klaus, 1367
 Milatovic, D., 1620
 Miller, Carole B., 1847
 Miller, George H., 2074
 Miller, G. H., 708
 Miller, Jeffrey, 2139
 Millet, V., 2239
 Milocchi, Fabio, 2693
 Mimoto, Tsutomu, 810
 Minamimura, Masashi, 1547
 Mirabelli, Christopher K., 171
 Mitra, U., 1197
 Mitsuhashi, Susumu, 793, 1547
 Mitsutake, Kotaro, 2762
 Mitsuya, Hiroaki, 810
 Mitten, Michael, 1329
 Mitten, Mike, 864
 Miyasaki, Kenneth T., 2710
 Miyazaki, Haruko M., 2762
 Miyazaki, Shuichi, 60
 Miyazaki, Yoshitsugu, 2762
 Miyoshi, Akio, 2217
 Mobarakai, Neville K., 1904
 Mobashery, Shahriar, 2438
 Mochizuki, Hidenori, 2412
 Moellering, R. C., Jr., 366, 1604
 Moellering, Robert C., Jr., 507, 598, 1364, 2009
 Mogilevsky, N., 142
 Moland, Ellen S., 260
 Molina, Judith, 1353
 Molinas, Catherine, 78
 Molitoris, Eric, 2509
 Moloo, Shamsudeen K., 1163
 Moncada, Jeanne, 1746
 Mondain, V., 921
 Monteil, H., 1488
 Monteil, Henri, 501
 Montgomerie, John Z., 1334
 Moody, Julia A., 2454
 Moore, Carol, 1264
 Mor, Natan, 111, 1380, 2364
 Moreno, E., 2490
 Morgan, U. M., 328
 Morikawa, Keiko, 270, 2684
 Morikawa, Shigeru, 270, 2684
 Morisaki, Naoko, 1313
 Morris, Anne B., 1
 Morrison, Donald, 681
 Morrison, Paul J., 637
 Morrison, Susan, 532
 Morse, Gene D., 512
 Moskovitz, Bruce L., 778
 Mourtou, Tracy, 1610
 Moynihan, Melinda, 2179
 Mroczkowski, Tomasz F., 1670
 Mueller, Barbara, 2612
 Muffat-Joly, Martine, 1599
 Müller, Hans-Jochen, 1835
 Mulligan, Maury E., 1334
 Mummaw, Nancy, 89
 Munayyer, H., 708
 Muñoz, Patricia, 1200
 Muñoz, Victoria, 859
 Murakami, Kimihiro, 2412
 Murakawa, Yohko, 810
 Murphy, Noel B., 1163, 1167
 Murray, Barbara E., 1203, 1966

- Murray, Gilles, 1373
 Murray, Henry W., 1504
 Murray, P. R., 1696
 Muth, Peter, 1518
 Muthiani, Anthony M., 1167
 Myers, Dorothea E., 835
 Myers, Roy A. M., 120
 Mylvaganam, Haima, 2024
- Naas, Thierry, 939, 962
 Nabeshima, Toshitaka, 1781
 Nadai, Masayuki, 1781
 Nadelmann, Lynda, 2550
 Naesens, L., 332
 Nagamuta, Masahiro, 2217
 Nagano, Hiroyuki, 2217
 Nagase, Mitsumasa, 229
 Nagata, Kumiko, 769
 Nagatake, Tsuyoshi, 164
 Nagarajan, K., 183
 Nahata, Milap C., 314
 Naidu, A. Satyanarayan, 240
 Naidu, Smita S., 240
 Naiman, N. A., 1713
 Naiman, Noreen A., 2668
 Nakada, Naoki, 2656
 Nakae, Taiji, 2385
 Nakagawa, Susumu, 2756
 Nakamura, Mika, 839
 Nakamura, Shinichi, 839
 Nakamura, Yumiko, 2662
 Nakano, Shigeyuki, 2042
 Nakaya, Rintaro, 2486
 Nakayama, Noboru, 2662
 Namavar, F., 1184
 Narayan, O., 360
 Narayanan, Ven L., 754
 Narita, Hirokazu, 384
 Narita, Teruo, 322
 Nash, Donald R., 1850
 Nasr, Mohamed, 2166
 Nateghpour, M., 2337
 Nau, Roland, 1518
 Ndifor, Anthony M., 1318
 Ndoutamia, Guelmbaye, 1163
 Nelson, Donald J., 2285
 Nelson, Jeffrey A., 1444
 Nelson, Kenrad E., 2407
 Nerhood, Lynda, 429
 Nervetti, G., 2545
 Neu, Harold C., 566
 Neumann, Theresa, 2244
 Neumann, Theresa M., 1670
 Neyfakh, Alexander A., 128
 Ng, Eva Y., 2588
 Ngoma, Michel, 901
 Ngu, Jacob L., 1318
 Nguyen, Hieu, 729
 Nguyen, Minh-Hong, 875
 Nicastrì, Emanuele, 1190
 Nicastrò, G., 2545
 Nicolas, Marie-Helene, 939
 Nicolas, M. H., 1406
 Nicolle, L. E., 574
 Nightingale, Charles H., 234
 Nightingale, Stephen D., 1869
 Nikaido, Hiroshi, 322, 1393
 Niki, Yoshihito, 801
 Nimmo, G., 1924
 Nishikawa, Sae, 2042
 Nishikawa, T., 1043
 Nishiki, Katsuyuki, 199
 Nishimoto, Mitsunobu, 287
- Niu, Wei Wei, 667
 Nix, David E., 371, 523, 775, 1065, 1073
 Nochy, Dominique, 1790
 Nolte, Frederick B., 39
 Nomizu, Motoyoshi, 810
 Noordergraaf, J. H., 317
 Nord, Carl Erik, 1665
 Norden, C. W., 1580
 Nordlander, E., 1977
 Nordmann, P., 1406
 Nordmann, Patrice, 939, 962
 Noriega, A. R., 2490
 Norman, Allyn, 775
 Normark, S., 224
 Norwegian Yeast Study Group, 2443
 Noskin, Gary A., 2470
 Novelli, Andrea, 2693
- Öberg, Bo, 1370
 O'Brien, Julie A., 947
 O'Callaghan, Richard J., 1856
 Odds, Frank C., 39, 685
 Odenholt-Tornqvist, Inga, 2200
 Offensperger, Silke, 1539
 Offensperger, Wolf-Bernhard, 1539
 Ogawa, Nobuya, 2042
 Oguma, T., 1043
 Ohashi, Masayuki, 2412
 Ohdo, Shigehiro, 2042
 Ohmichi, M., 1043
 Ohno, Akira, 675
 Ohshima, Yumi, 2173
 Ohshita, Yoshihiro, 2278
 Ohta, Michio, 984
 Ohya, Satoshi, 322
 Oishi, Kazunori, 164
 Oizumi, Kotaro, 287
 Okamoto, Osamu, 2756
 Okamura, Noboru, 2486
 Okazaki, Osamu, 2173
 Okonogi, Kenji, 100
 Oleske, James, 532
 Oliary, J., 2674
 Ollert, Markus W., 2064
 Olsen, Kurt, 1630
 Onuki, Youichi, 2327
 Opravil, Milos, 1056
 Osada, Yasuaki, 2112
 Osborne, A. J., 2069
 Oseko, Fumimaro, 270, 2684
 Osheroff, Neil, 646, 2179, 2599
 Osmon, D. R., 554
 Ossi, Michael J., 159
 Otabe, Yohko, 2217
 Otero, J. R., 2490
 Otteni, Jean-Claude, 1873
 Otto, Michael J., 2606
 Ou, Ching-Nan, 2401
- Paccaly-Moulin, Anne, 407
 Pacheco, Nancy D., 2688
 Pachucki, Constance T., 339
 Paessens, Arno, 1659
 Pagano, Joseph S., 144
 Pahissa, A., 1587
 Painter, Barbara, 1756
 Painter, George, 1720
 Painter, George R., 2285
 Pal, Kollol, 1693
- Pangon, B., 737
 Pankuch, G. A., 1649
 Paradiso, Linda, 474
 Pares, Marta, 868
 Paris, Maria, 1630
 Park, Matthew K., 120
 Parker, Anita C., 1028, 2391
 Parker, William B., 1004
 Parniak, Michael A., 1390
 Paschalides, Panagiotis, 495
 Pascual, Alvaro, 187
 Pasculle, A. William, 1238
 Passariello, C., 2618
 Patchen, M. L., 1882
 Patel, Jayesh A., 339
 Patel, S., 2493
 Patterson, Jan Evans, 134
 Patterson, Thomas F., 2307
 Patton, Dorothy L., 8
 Patton, Melissa, 2244
 Paulfeuerborn, Wolfgang, 1835
 Paulsen, Ian T., 761
 Pav, Joseph W., 178
 Pavičić, M. J. A. M. P., 1184
 Payares, Gilberto, 580, 1353
 Pearson, Bridget A., 1473
 Pedemonte, Ronald, 754
 Pefanis, Angelos, 308, 507
 Peláez, Teresa, 1200
 Pellizzer, Giampietro, 2693
 Peng, Tao, 2126
 Penn, Charles R., 1473
 Pennell, Andrew T., 1343
 Penni, Adrio, 1190
 Perea, Evelio J., 187
 Peregrine, Andrew S., 1050, 1163, 1167
 Perfect, John R., 903, 2449
 Periti, Piero, 2693
 Perri, Mary Beth, 134, 1187, 2474
 Perronne, Christian, 692, 1690
 Perry, Caroline R., 32
 Perry, Greg, 637
 Peter, Jean-Daniel, 501
 Petersen, Peter J., 2270
 Petitjean, O., 737, 2674
 Petteway, Stephen R., Jr., 71
 Pettinger, Mary B., 1360
 Petty, Brent G., 429
 Pfaff, Eberhard, 2612
 Pfaller, M. A., 893
 Pfaller, Michael A., 14, 39
 Pfefferkorn, Elmer R., 2358
 Pflieger, Philippe, 2599
 Phan, Lienhanh, 2241
 Philippon, Alain, 2020
 Phillips, Ian, 746
 Phillips, Robert, 1373
 Picazo, Juan J., 1717
 Pichichero, Michael E., 159
 Piddock, L. J. V., 662
 Pilkiewicz, Frank G., 1869
 Piperacillin-Tazobactam Skin and Skin Structure Study Group, 1580
 Piras, Marta M., 580
 Piras, Romano, 580
 Piret, Jacqueline, 84
 Pitha, P., 360
 Pitsakis, P. G., 2069
 Pitzurra, Lucia, 2422
 Pizzo, Philip A., 495
- Pocard, Jean-Jacques, 692, 1599, 1690
 Pocard, J. J., 633
 Pohl, Jan, 2710
 Poiesz, Bernard, 512
 Polk, Ronald, 2193
 Polk, Ron E., 2139
 Pollack, Jay R., 1171
 Pollack, Matthew, 164
 Poncioni, Bernard, 2087
 Ponglertnapagorn, Preecha, 164
 Poppe, Susan M., 1127
 Porro, Gabriele Bianchi, 2212
 Portmann, R., 293, 2132
 Potgieter, Elsa, 2740
 Pottecher, Thierry, 501
 Pourtois, M., 142
 Powell, Francoise, 1227
 Powell, Marie, 1264
 Pozzi, Luann M., 19
 Pradier, C., 921
 Pramanik, A. J., 1264
 Prange, Hilmar W., 1518
 Prichard, Lynn E., 540
 Prichard, Mark N., 540
 Prince, Alice, 667
 Prince, Randall A., 1414
 Privitera, G., 2545
 Proenca, Rui, 667
 Progulske-Fox, Ann, 2037
 Prosser, Barbara L., 2144
 Pryka, Randy D., 2106
 Pudney, Mary, 2371
 Puel, J., 1232
 Pulverer, Gerhard, 750
 Pussard, Eric, 970
 Pye, G. W., 1962
- Quale, John M., 1904
 Queener, Sherry F., 1543, 1914, 2166
 Quemard, Annaik, 1536
 Quinn, John P., 1989
 Quinquis, Valérie, 54
 Quint, W. G. V., 595
 Quintero, Julio C., 1576
 Quintiliani, Richard, 234
- Rådström, Peter, 761
 Raffi, Francois, 1777
 Ragual, Rhonda J., 1334
 Rainey, Petrie M., 1842
 Ralph, Ray, 403, 991
 Ramiliarisoa, Olivao, 924
 Rand, Kenneth H., 613
 Rankin, Catherine D., 144
 Ransijn, Adriana, 991
 Raoult, D., 491, 1410, 2633
 Raoult, Didier, 1214, 1733
 Raponi, Giammarco, 1958
 Rasaily, R., 1197
 Rasmussen, Beth A., 851, 1989
 Rastogi, Nalin, 652, 1560
 Rather, Philip N., 2074
 Rather, P. N., 708
 Rathod, Pradipsinh K., 1102
 Ravens, U., 1010
 Ray, Stephen, 1270
 Rayner, Marlene M., 2606
 Reardon, John E., 918
 Reboli, Annette C., 1334
 Reichart, Cindy, 2244

- Reichelderfer, Patricia S., 1095
 Reid, Carol D., 2606
 Reig, Roser, 138
 Reilly, J., 1180
 Renard, S., 1432
 Rende-Fournier, Rosanna, 2119
 Resconi, Anna, 741
 Resnick, Lionel, 1127
 Reuhl, Kenneth R., 419
 Reusser, Fritz, 1127
 Reynoldson, J. A., 328
 Rhodes, Audrey, 1576
 Ribera, E., 1587
 Ribner, Bruce S., 1334
 Rice, Louis B., 610, 1061, 2760
 Rice, Roselyn J., 1552
 Rich, Josiah, 2187
 Richardson, Judith F., 1219
 Richman, Douglas D., 1207
 Ricketts, Anthony P., 2358
 Riess, Günther, 1659
 Rigon, Antonio, 2693
 Rimland, David, 1334
 Rinaldi, Michael G., 39, 1383, 1847, 2307
 Ringwald, Pascal, 924
 Ripamonti, Franca, 741
 Risse, Gisa, 1367
 Rittel, Werner, 183
 Robbins, Brian L., 2247
 Robert, Alexandre, 1510
 Robert, Marta, 868
 Roberts, Glenn D., 39
 Roberts, William L., 1842
 Robillard, Norman J., 1756
 Rodríguez-Créixems, Marta, 1200
 Rodvold, Keith A., 436, 2106
 Roesel, Johannes L., 2087
 Rogers, Marc B., 2391
 Rogge, Mark C., 1468
 Roilides, Emmanuel, 495
 Roland, Gregory E., 2563
 Rollwagen, Florence M., 2688
 Rolston, Kenneth, 882
 Rolston, Kenneth V., 2584
 Rolston, Kenneth V. I., 2504
 Romand, Stéphane, 2371
 Romero, Donna L., 1127
 Ronco, Esthel, 962
 Rondel, Richard K., 2298
 Rose, Lucy M., 1004
 Rosen, Mark, 483
 Rosenbaum, Beverly, 729, 882, 2584
 Rosenberg, Ivan, 2540
 Roser, Roberto, 868
 Rosner, Judah L., 2251
 Rösner, Manfred, 1659
 Roth, Elizabeth, 1576
 Roth, Richard S., 1543
 Rothstein, David M., 191, 1624
 Rotschafer, John C., 436, 1377, 2454
 Rotstein, Coleman, 896
 Rouse, M. S., 554
 Rouse, Philippa, 2231
 Rouveau, Martine, 2020
 Roy, Tapon, 178
 Rozenberg-Arska, Maja, 885
 Rubeglio, Etelvina A., 1728
 Rubin, Robert H., 619, 1270, 2144
 Rubinstein, E., 2333
 Ruble, Cheryl A., 1086
 Ruffing, Thomas L., 947
 Ruhnke, Markus, 2153
 RV-43 Study Group, The, 1095
 Ryan, D. Michael, 1473
 Rybak, Michael J., 605, 1931
 Ryzlak, Maria T., 419
 Saari, Herkko, 592
 Sacks, Steven, 637
 Safrin, Sharon, 975, 2241
 Sagiv, R., 293
 Saha, M. R., 1197
 Saissi, Gilbert, 464
 Saito, A., 1043
 Saito, H., 67, 1259
 Saito, Hajime, 722
 Saleh-Mghir, A., 633
 Saletan, Stephen L., 1869
 Samonis, George, 51
 Samuels, D. Scott, 46
 Sanada, Minoru, 2756
 Sanchez, Ana, 1717
 Sanders, Christine C., 251, 260, 1375, 2578
 Sanders, Paula L., 448
 Sanders, W. Eugene, Jr., 260
 Sands, Michael, 1
 Sandven, Per, 2443
 Sangaletti, Ornella, 2212
 Sannerud, Kim J., 835
 Sansano, Sebastiano, 2622
 Santander, Celina, 1728
 Santora, Julie, 512
 Saral, Rein, 1847
 Sardana, Vinod V., 947, 1576
 Saric, Muhamed, 1082
 Sato, K., 67, 1259
 Sato, Katsumasa, 722
 Sato, Kenichi, 2112
 Satoh, Hiroshi, 769
 Satta, Giuseppe, 1324
 Savani, Dora V., 903
 Sawada, Masashi, 2684
 Scaglia, Massimo, 1492
 Scarnati, Helen, 2606
 Scavone, Joseph M., 2187
 Schaberg, Dennis R., 2003
 Schachter, Julius, 1746
 Schacker, Tim, 975
 Schaefferbeke, Jean, 1510
 Schaefferbeke, Madeleine, 1510
 Schäfer-Korting, Monika, 2064
 Schaffner, Carl P., 419
 Schalm, S. W., 595
 Schedletzky, Holger, 696
 Schell, Wiley A., 2449
 Schentag, Jerome J., 371, 523, 1065, 1073
 Schiefer, Hans Gerd, 846
 Schinazi, Raymond F., 875, 1707, 2206
 Schindler, Jay J., 2716
 Schipper, Pauline, 1525, 2231
 Schlabach, Abner J., 1576
 Schleif, William A., 947, 1576
 Schloegel, M., 1488
 Schmidheini, Tobias, 2054
 Schmidts, Hans-Ludwig, 846
 Schneider, Christine L., 1576
 Schneider, Peter, 2087
 Schols, D., 332
 Schrenzel, J., 2132
 Schulman, Marvin, 1737
 Schultz, Robert J., 754
 Schulze, Andrea, 750
 Schuurman, Rob, 2231
 Scotti, Roberto, 741
 Sedman, Allen J., 775
 See, Darryl M., 1593
 Segal, Jack L., 93
 Segatore, Bernardetta, 1324
 Segreti, John, 1444
 Seifert, Harald, 750
 Seifert, Michael, 2153
 Seilheimer, Dan K., 1414
 Selan, L., 2618
 Selsted, Michael E., 2628
 Semmel, Marianne, 26
 Seo, Susan M., 1086
 Seta, Nathalie, 1790
 Setacci, Domenico, 1324
 Setogawa, Tomochi, 722
 Shaddix, Sue C., 1004
 Shafer, William M., 2710
 Shafran, S. D., 574
 Shaharabany, Miriam, 1037
 Shannon, William M., 1004
 Shapiro, Theresa A., 1193
 Shasha, B., 2333
 Shaw, Karen J., 2074
 Shaw, K. J., 708
 Shawar, Ribhi, 882
 Shimada, Hideyo, 2042, 2327
 Shimada, Hisao, 2656
 Shimada, J., 1043
 Shimada, K., 1043
 Shimizu, K., 1043
 Shimomura, Yuko, 2534
 Shimomura, Masahiko, 229
 Shimoyama, Takashi, 769
 Shinnick, Thomas M., 1348
 Shipkowitz, N. L., 864
 Shipman, Charles, Jr., 540
 Shirasaka, Takuma, 810
 Shlaes, David M., 610, 1061, 1238
 Shlaes, D. M., 2432
 Shlaes, J. H., 2432
 Shyu, W. C., 1180
 Siadak, Anthony, 164
 Siegert, Wolfgang, 1367
 Sijbesma, Rint, 1707
 Silve, Gaby, 1536
 Silver, Lynn L., 377
 Silverman, Edward G., 1869
 Simon, Sanford, 592
 Sinclair, Ian, 1270
 Singh, Kavindra B., 1203
 Singlas, Eric, 1777
 Sirisanthana, Thira, 2407
 Sironi, Marina, 2527
 Sjöstedt, Svante, 1665
 Sköld, Ola, 761
 Skurnik, Mikael, 1297
 Skurray, Ronald A., 761
 Slavin, Monica A., 1360
 Slocombe, Brian, 32
 Sluchak, Julia A., 1927
 Smaoui, Hatem, 1510
 Smith, Anthony M., 1938
 Smith, C. Jeffrey, 1028, 2391
 Smith, Colin, 1243
 Smith, James W., 2166
 Smith, Marilyn S., 144
 Smithuis, F. M., 1977
 Snoeck, R., 332
 Snyderman, David R., 1655
 So, Antero G., 1127
 Soejima, Rinzo, 801
 Soike, Kenneth F., 1370
 Soler, Paul, 281
 Sommadossi, Jean-Pierre, 1816
 Sonke, R. Lee, 532
 Sonoda, Fuminari, 164
 Soong, Seng-jaw, 1771
 Sörgel, F., 1860
 Sörgel, Fritz, 1518
 Sorsa, Timo, 592
 Soussy, Claude J., 2588
 Spector, Thomas, 602, 918
 Sperber, Steven J., 106
 Spicer, W. John, 914
 Spitzer, Eric D., 1383
 Spratt, Brian G., 1938
 Springer, Timothy A., 1278
 Srdanov, Gordana, 1707
 Srinivas, Ranga V., 2247
 Stair, Thomas O., 2754
 Stals, Frans S., 218
 Stanat, Sylvia C., 19
 Standiford, Harold C., 483, 1334
 Stanislawski, Lena, 26
 Stanislawski, Marc, 26
 Stark, Christina A., 1665
 Staszewski, Schlomo, 1576
 Staunton, Donald E., 1278
 Stecca, Clara, 2693
 Steckelberg, J. M., 554
 Steele, Lorraine C., 1850
 Steele, Paul, 1436
 Steib, Annick, 1873
 Steide, Jean-Alex, 1264
 Stein, Andreas, 1214
 Stein, Daniel S., 448
 Stein, Gary E., 89
 Steingrube, Vincent A., 1850
 Stephens, L. Clifton, 729
 Stevens, David A., 1177, 1334, 2224
 Stevens, Robert C., 448
 St. John, Lisa, 2285
 Stoeckel, Klaus, 2706
 Stotka, Jennifer, 2139
 St-Pierre, Claude, 1373
 Strauss, H. William, 1270, 2144
 Strle, Franc, 1444
 Strosberg, A. Donny, 26
 Stüber, Dietrich, 1400
 Sugar, Alan M., 39
 Sugiyama, Takashi, 2042
 Sullivan, John L., 178
 Sullivan, Maureen C., 234
 Sullivan, Veronica, 19
 Sum, Phaik-Eng, 2270
 Sumita, Yoshihiro, 2743
 Summanen, P., 2638
 Summers, Anne O., 825

- Sun, He, 1132
 Sundström, Lars, 761, 1297
 Suomalainen, Kimmo, 592
 Supp, Andrew P., 1899
 Supparatpinyo, Khuanchai, 2407
 Sutton, David, 642
 Sutton, Lorraine, 2760
 Suzuki, Eiko, 1219
 Suzuki, Yasuyuki, 229
 Svensson, Ulla, 240
 Swan, S. K., 347
 Swaney, Steven M., 1127
 Swanson, Keith A., 778
 Swedberg, Göte, 761
 Swenson, Christine E., 1869
 Swenson, Jana M., 2311
- Taburet, Anne-Marie, 1777
 Tagliabue, G., 2545
 Taira, Kazushige, 1877
 Takada, Kanji, 810
 Takahata, Masahiro, 384
 Takashima, Ikuro, 901
 Takatsuki, Akira, 980
 Takayama, Satoshi, 1764
 Takeda, Katsuo, 287
 Tal, Ruth, 1037
 Talan, D. A., 1580
 Talarico, Christine, 19
 Talbot, George H., 474
 Tallan, B. M., 554
 Tally, Francis P., 2270
 Tamura, Toshihide, 769
 Tan, J. S., 1580
 Tan, Tina Q., 2401
 Tanaka, Koji, 1945
 Tanaka, Kouichi, 2217
 Tanaka, Makoto, 2173
 Tanaka, Mayumi, 2112
 Tanaka, Nobuo, 2756
 Tanaka, Yasunori, 957
 Tanimura, M., 1043
 Taniyama, Yumi, 1547
 Tankovic, Jacques, 789
 Tarasi, Agapito, 1190
 Tardif, Carole, 2571
 Tardif, Manon, 2727
 Tarpley, W. Gary, 1127
 Tarrand, Jeffrey J., 2584
 Tateda, Kazuhiro, 675
 Taylor, David, 1552
 Taylor, Diane E., 457, 2645
 Taylor, Lester C., 2285
 Teggi, Antonella, 1679
 Teitz, Yael, 2483
 Teixeira, M., 1232
 Telenti, Amalio, 2054
 Tenorio, Carmen, 2427
 Tenover, Fred C., 2311
 Tenovuoto, Jorma, 1158
 ter Kuile, F. O., 1977
 ter Laak, E. A., 317
 Terpenning, Margaret S., 2003
 Testa, Raymond T., 2270
 Thadepalli, Haragopal, 1711
 Thadepalli, Harini D., 1711
 Thal, Lee Ann, 134, 1187, 2474
 Thaller, M. C., 2618
 Thanassi, David G., 1393
 Thauvin-Eliopoulos, C., 1604
- Thauvin-Eliopoulos, Claudie, 507
 Thayer, Walter R., 1645
 Theander, Thor G., 2550
 Then, Rudolf L., 1400
 Thom, Edna, 2144
 Thomas, Richard C., 1127
 Thompson, R. C. A., 328
 Thomson, Kenneth S., 1375
 Thormar, Halldor, 2540
 Thornsberry, Clyde, 1122
 Ticehurst, Julia, 1473
 Tidwell, Richard R., 2668
 Tidwell, R. R., 1713
 Tijnagel, Jolanda, 1525
 Tilles, Jeremiah G., 1593
 Tilling, Janet, 1473
 Ting, Windsor, 2106
 Titus, Donna L., 1576
 Tiwari, M., 2418
 Tod, M., 737, 2674
 Todo, Yozo, 384
 Tokuda, Yoshiko, 2228
 Tolkoff-Rubin, Nina E., 619
 Toltz, Philip, 1610
 Tomasz, Alexander, 342
 Tomažič, J., 1786
 Tomioka, H., 67, 1259
 Tomioka, Haruaki, 722
 Tomonaga, Fumiya, 2042
 Tomono, Kazunori, 2762
 Tong, William, 398
 Torres, Carmen, 2427
 Torres, H., 491
 Tournay, C., 142
 Towle, Michelle, 2193
 Toyosawa, Toshio, 60
 Trautmann, Matthias, 2153
 Trias, Joaquim, 322
 Trieu-Cuot, Patrick, 2593
 Trifillis, A. L., 2496
 Troke, P. F., 1962
 Truffot-Pernot, Chantal, 407
 Trujillano, I., 911
 Tselentis, Yannis, 51
 Tseng, Cheng-Chuang, 1826
 Ts'o, Paul O. P., 429
 Tsuda, Toshihiko, 2412
 Tsuda, Yasuyuki, 2327
 Tsui, S. Y. T., 1001
 Tsuji, Akiyoshi, 60
 Tsuji, Miho, 2228
 Tudela, Encarna, 868
 Turgeon, Fernand, 1174
 Turik, Michael, 2193
 Turner, Ronald B., 297
 Tzeng, Jausheng, 1909
- Uckun, Fatih M., 835
 Ueda, Yasushi, 2217
 Ueno, Kazue, 957
 Ünal, S., 1604
 Ünal, Serhat, 1831
 Urbina, Julio A., 580, 1353
 Ussery, Michael A., 71
 Utsui, Yukio, 2278
 Uzun, Ömrüm, 1831
- Vaara, Martti, 354, 2255
 Valdivia, Eva, 148
 Valero-Guillen, Pedro, 1536
 Valette, M., 2239
 Vallee, E., 633
 Vallois, J. M., 633
- Vance-Bryan, Kyle, 436, 2454
 Vanden Bossche, Hugo, 2101
 van den Broek, P. J., 2318
 Van Den Ende, Jan, 2733
 Van der Auwera, P., 1015, 1860
 Vanderkolk, Julie, 2364
 van der Meer, Jos W. M., 276, 2527
 Van De Velde, Vera, 778
 van Leeuwen, Remko, 1525
 Vantha, Wanta Sok, 1977
 van Winkelhoff, A. J., 1184
 van Woensel, J. B. M., 1977
 Vapiwala, Manisha, 419
 Varela, Manuel F., 1253
 Vaudaux, Pierre, 625
 Vazquez, Jose A., 2474
 Venditti, Mario, 1190
 Venitz, Jürgen, 2139
 Venuti, Elaine, 2736
 Verboom, T., 1184
 Verdier, Francoise, 970
 Vergara, Yolanda, 138
 Verhoef, Jan, 885
 Verschure, M. H., 317
 Videler, Joseph, 1480
 Vieler, Elke, 846
 Vila, Jordi, 138
 Vilde, Jean-Louis, 692, 1690
 Villareal, Kara, 39
 Vimy, Murray J., 825
 Vince, Robert, 1004
 Vincent, S., 2432
 Viola, Renato, 2693
 Visbal, Gonzalo, 580
 Visconti, M., 2545
 Vishvanathan, N., 183
 Visser, Maarten R., 885
 Voeller, Donna, 1227
 Vogels, Maria T. E., 276, 2527
 Von Bandel, Marc, 1873
 Vorachit, M., 2000
 Vrenzos, George, 51
- Wacharotayankun, Rochaporn, 984
 Wainberg, Mark A., 130, 1305, 1390, 2231
 Walcott, Sarah M., 1473
 Waldvogel, Francis A., 625
 Walker, Clay B., 2037
 Walker, Karla J., 1377, 2454
 Walker, Maja, 2087
 Walker, Sheila, 1558
 Wallace, Richard J., Jr., 1850
 Walsh, Thomas J., 1334
 Walter, Eike, 1539
 Walzer, Peter D., 1436
 Wang, Julie, 2139
 Wang, Li, 1781
 Wang, Shaomeng, 1799, 1807
 Wang, Ying, 457
 Ward, S. A., 2337
 Ward, Stephen A., 1318
 Warden, Glenn D., 1890
 Warmock, D. W., 1962
 Warren, John R., 2470
 Warren, Reed P., 2716
 Wasan, Kishor M., 246
 Washington, J. A., 1696
 Washington, John A., II, 1375
- Waskin, Hetty A., 2449
 Wassmundt, Frederick W., 754
 Watanabe, Junko, 2656
 Watanabe, Kiwao, 164
 Watanabe, Kunitomo, 957
 Watanabe, Taiji, 2412
 Waterbury, Julie A., 1576
 Watson, Durward A., 1869
 Watts, J. L., 1122
 Waysbort, A., 1232
 Wear, Douglas J., 2500
 Webb, Douglas, 1270, 1383
 Webb, Vera, 2379
 Weickmann, Joachim, 1614
 Weidekamm, E., 293, 2132
 Weidner, Wolfgang, 846
 Weinstein, Melvin P., 106
 Weinstein, Robert A., 1989
 Weislow, Owen S., 754
 Wennersten, C. B., 1604
 Wennersten, Christine, 2009
 Wennersten, Christine B., 598, 1364
 Were, Joab B. O., 1193
 Westphal, J. F., 1488
 Wexler, Hannah M., 2509
 Wexler, H. M., 2638
 Weyer, Claudia, 1367
 Whaley, R. A., 2493
 Whitby, M., 1924
 White, E. Lucile, 754
 White, John, 1137
 White, Michael, 1436
 Whitman, M. S., 2069
 Wiedemann, B., 224
 Wiener, Janis, 1989
 Wilairat, Prapon, 403
 Wilber, R. B., 1180
 Wilcox, Gary, 1614
 Williams, Denise S., 1447
 Williams, G., 1924
 Willmott, Christopher J. R., 126
 Wilson, Jeanne E., 1720
 Wilson, W. R., 554
 Wingard, John R., 1847
 Winkler, Irvin, 1659
 Winslow, Dean L., 2606
 Wireman, Joy, 825
 Wise, Richard, 637
 Wise, W. Curtis, 393
 Wishnow, R. M., 1580
 Witt, Mallory D., 2030
 Witzig, Richard S., 1997
 Woestenborghs, Robert, 2224
 Wojcik, Stan, 991
 Wolanski, Bohdan S., 1576
 Wolfgang, Jill A., 1576
 Wolfson, John S., 2588
 Wong, Edward S., 1447
 Woodcock, Jocelyn, 637
 Woodford, Neil, 681
 Woods, Jacqueline M., 1473
 Woods-Cook, Kathie, 2087
 Wraber, B., 1786
 Wright, Esther L., 652
 Wright, Susan C., 2534
 Wrighton, Steven A., 265
 Wudl, Fred, 1707
- Xiao, Xinfa, 84
 Xicota, M. Angels, 868

- Yamada, Hidehiko, 2412
Yamada, Hideo, 2327
Yamaguchi, Hideyo, 785, 2228
Yamaguchi, Keizo, 60, 675
Yamaguchi, Totaro, 287
Yamaguchi, Yoshiyuki, 26
Yamamoto, Naoki, 2486
Yamamoto, S., 1043
Yamashiro, Yoshiko, 384
Yamazaki, Masatoshi, 2228
Yamazaki, Toshiyuki, 100
Yancey, R. J., Jr., 1122
Yang, Ying-Zi, 1108
Yang, Youjun, 851
Yano, Takafumi, 287
Yao, Gang-qing, 1420
Yasuda, Hiroshi, 322, 1749
Yazawa, Katsukiyo, 1313
Yeaman, Michael R., 546
Yew, W. W., 1001
Yoder, Steven L., 2563
Yokoo, Mamoru, 363
Yokota, Takeshi, 1749, 2217
Yoneyama, Hiroshi, 2385
Yoshida, Hiroaki, 839
Yoshida, Masao, 2534
Yoshida, Takuji, 793
Yoshihara, Fumie, 2662
Yoshiyama, Yuji, 2042
Young, Glenda, 1850
Young, Robert D., 1102
Yuthavong, Yongyuth, 1108
Zabinski, Richard A., 1377, 2454
Zaccardi, Joe, 1624
Zakut, H., 293
Zannier, Arnold, 1214
Zappala, M., 1497
Zarins, Lidija T., 2003
Zausner, A., 2069
Zenilman, Jonathan M., 2244
Zervos, Marcus J., 134, 1187, 2474
Zeytinoglu, Aysin, 218
Zhanel, George G., 1154
Zhang, Ruiwen, 1771
Zhang, Yansheng, 1850
Zheng, Hui, 2534
Zhong, Jian, 2534
Zhou, Xiang Yang, 1387
Zhou, Zhu, 1816
Zienicke, Helga, 2064
Zieroth, Shelley R., 1154
Zimmerli, Werner, 2622
Zimmerman, Stephen W., 2650
Zinner, Stephen H., 1756
Zon, Gerald, 171
Zscheck, Karen K., 1966

SUBJECT INDEX

VOLUME 37

- A77003
human immunodeficiency virus type 1
preclinical evaluation, 115
toxicity
preclinical evaluation, 115
- aac(6')-II*
characterization, 1896
E. faecium
specificity for, 1896
- aac(3)-VIIa*
E. cloacae
biochemical analysis, 2074
- Abelson murine leukemia virus
thiosemicarbazones
v-abl protein, suppression of, 2483
- Abscesses
ampicillin-sulbactam
comparative evaluation, 610
cefotaxime
comparative evaluation, 610
E. coli
ampicillin-sulbactam, comparative
evaluation, 610
cefotaxime, comparative evaluation, 610
- 2-Acetylpyridine 5-[(dimethylamino)thio-
carbonyl]-thiocarbonohydrazide
cytomegalovirus
potent inhibition of replication, 602
ganciclovir
potentiation of antiviral effects, 602
- 3-N-Acetyltransferase
E. cloacae
aac(3)-VIIa gene, biochemical analysis
of, 2074
- Acetyltransferases
P. aeruginosa
aac(6')-Ib, characterization of, 1456
- Acinetobacter baumannii*
aminoglycoside-modifying enzymes
production of, 138
 β -lactamase production, 138
chloramphenicol acetyltransferase
production of, 138
in vitro susceptibilities, 138
- Acinetobacter haemolyticus*
aac(6')-Ib gene
6'-N-acetyltransferase, 2093
- Acinetobacter* spp.
antimicrobial susceptibility, 750
- Actinobacillus actinomycetemcomitans*
HPQYNQR
in vitro activity, 2710
IIGGR
in vitro activity, 2710
- Acyclic nucleoside phosphonates
bis(pivaloyloxymethyl) prodrugs
metabolism and in vitro antiretroviral
activities, 2247
herpesviruses
(S) and (R) enantiomers, 332
(S) and (R) enantiomers
herpesviruses, 332
retroviruses, 332
retroviruses
(S) and (R) enantiomers, 332
visna virus
inhibition of replication, 2540
- Acyclovir
combinations
348-U87, 975
herpes simplex virus, acyclovir resis-
- tant, 975
ribonucleotide reductase inhibitor, 975
herpes simplex virus resistance
penciclovir, 2241
herpes simplex virus susceptibility
strains from organ transplant recipi-
ents after acyclovir or ganciclovir
prophylaxis, 357
herpes simplex virus type 1
comparative evaluation, 642
salmonellae
in vitro activities, 106
- Aeromonas hydrophila*
 β -lactamase
 β -lactam resistance, contribution to,
1324
carbapenems, high specificity for, 1324
- Aeromonas* spp.
in vitro susceptibilities
tropical isolates from Queensland,
Australia, 905
- Afipia felis*
antibiotic susceptibilities
axenic medium and cells, 1410
- AG-2000
H. pylori
urease activity, inhibition of, 769
- Agar dilution
G. vaginalis
susceptibilities to 25 antimicrobial
agents, 2733
- Albendazole
hydatid disease
treatment of, 1679
- N-n-Alkyl-3,4-dihydroxybenzamide
T. brucei brucei
in vitro and in vivo activities, 1082
- Allopurinol riboside
pharmacokinetics
probenecid, effects of, 1193
- Alpha-1-antitrypsin
doxycycline
protection from human neutrophil col-
lagenase and gelatinase, 592
- Alpha interferon
pharmacokinetics
transplacental passage, two assay
techniques, 1232
- Aluminum hydroxide
levofloxacin
inhibition of absorption of, 2173
- AM-1155
Mycobacterium spp.
in vitro activity, comparative evalua-
tion, 1259
- Ames *Salmonella* TA102 assay
quinolones
bacterial mutagenicity, 213
- Amikacin
A. haemolyticus resistance
aac(6')-Ib gene, characterization of,
2093
combinations
aztreonam, 308
ceftazidime, 308
endocarditis, 308
imipenem, 1931
P. aeruginosa, 308, 1931
E. coli resistance
bleomycin, increase of, 1982
M. fortuitum
- postantibiotic effect, 1001
- M. haemophilum*
in vitro activities, 2323
pharmacokinetics
attachment to collagen for local deliv-
ery in wounds, 1890
patients with septic multiple-organ
failure during intermittent hemo-
filtration, 464
postantibiotic effect
M. fortuitum, 1001
synergy
ethambutol, 1285
M. malmoeense, 1285
- Aminoglycosides
6'-N-acetyltransferase
aac(6')-Ib gene, characterization of,
2093
combinations
inhibitors of glycosylation and fatty
acid and peptide biosynthesis, 652
M. avium, 652
F. oryzzihabitans
in vitro activities against clinical iso-
lates from patients with cancer,
2504
P. aeruginosa resistance
ant(4')-IIa, nucleotide sequence analy-
sis and DNA hybridization stud-
ies, 708
population pharmacokinetics
oncology patients, 1025
resistance gene nomenclature
letter to the editor, 927
T. brucei brucei resistance phenotype
in vivo system to select for blood-
stream-form transfectants, 1167
- 8-Aminoquinolones
P. carinii
in vivo and in vitro studies, 2166
- Amopyroquin
malaria
P. falciparum, 970
P. falciparum
malaria treatment, 970
- Amorolfine
Candida spp.
temperature, effect on activity, 685
- Amoxicillin
B. burgdorferi
in vitro susceptibility, 1444
combinations
clavulanic acid, 14
H. influenzae, β -lactamase producing
and nonproducing, ampicillin re-
sistant, 14
comparative evaluation
chronic bronchitis, 2298
rifloxacin, 2298
otitis media
S. pneumoniae, penicillin resistant,
1599
pharmacokinetics
local gastric and serum concentrations
after different oral applications,
1506
S. mutans
in vitro susceptibility, 1158
synergy
H. pylori, 1184
metronidazole, 1184

- metronidazole, hydroxymetabolite of, 1184
- ampD*
- C. freundii*
- sequences of wild-type and mutant genes, comparison with those in *E. coli*, 224
- E. coli*
- sequences of wild-type and mutant genes, comparison with those in *C. freundii*, 224
- Amphotericin B
- aspergillosis, 2307
- invasive pulmonary, prophylactic inhalations, 1367
- C. albicans*
- comparative evaluation, 729
- disseminated infection in normal and granulocytopenic mice, 729
- interleukin-6, reduction in release, 1958
- tumor necrosis factor alpha, reduction in release, 1958
- C. neoformans*
- in vitro susceptibility, 1383
- recurrent meningitis, isolates from patients with, 1383
- Candida* spp.
- temperature, effect on activity, 685
- comparative evaluation
- fluconazole, 2030
- itraconazole, 2307
- endocarditis
- C. parapsilosis*, 2030
- C. tropicalis*, 2030
- immunological effects on splenocytes from immune-normal and immune-compromised mice, 2716
- in vitro and in vivo studies, 2228
- L. donovani*
- T-cell-deficient mice, 1504
- leishmaniasis, visceral
- T-cell-deficient mice, 1504
- liposomal
- immunological effects on splenocytes from immune-normal and immune-compromised mice, 2716
- liposome composition
- role in distribution of drug in serum lipoproteins, 246
- mono-methyl ester derivative
- neurotoxicity, comparative evaluation, 419
- murine tumor necrosis factor
- augmentation of production, 2228
- neurotoxicity
- mono-methyl ester derivative, comparative evaluation, 419
- rats, comparative evaluation, 419
- P. marneffei*
- response of human immunodeficiency virus-infected patients, 2407
- temperature
- role in distribution of drug in serum lipoproteins, 246
- Ampicillin
- combinations
- ciprofloxacin, 1904
- comparative evaluation, 610
- E. coli* intra-abdominal abscess model, 610
- E. faecalis*, β -lactamase producing, highly gentamicin resistant, 1447
- E. faecium*, 1904
- endocarditis, 507, 1447
- S. aureus*, β -lactamase hyperproducing, 507
- sulbactam, 251, 507, 610, 1447
- susceptibility testing with a predictor panel, 251
- E. faecium* resistance, 1904
- endocarditis, 2069
- H. influenzae*
- distribution in patients with lower respiratory tract infections, effect on, 804
- H. parainfluenzae*
- distribution in patients with lower respiratory tract infections, effect on, 804
- oxidant-scavenging activities
- neutrophil functions, effect on, 950
- Amsacrine
- P. carinii*
- activity in vitro and in a mouse model, 1543
- Anaerobic organisms
- Bay Y3118
- in vitro activity, 2509
- FK037
- in vitro activity, 957
- MDL 62,879, 746
- 9-Anilinoacridines
- Leishmania* spp.
- in vitro activity, 991
- structure-activity relationships, 991
- P. falciparum*
- chloroquine resistant, 403
- mode of action, 403
- structure-activity relationship, 403
- Antibiotic carryover
- quinolones
- antibiotic-removal beads, elimination with, 1377
- Antibodies
- AS-48
- immunocytological studies, 148
- neutralizing
- simian immunodeficiency virus-infected macrophages, 360
- P. aeruginosa* flagella
- therapeutic effects in a murine model, 164
- Antifungal agents
- susceptibility testing
- broth macrodilution, 39
- yeasts, pathogenic, 39
- triazino[5,6-*b*]indoles
- GR99060, 1243
- GR99062, 1243
- ant(4')-IIa*
- P. aeruginosa*
- nucleotide sequence analysis and DNA hybridization studies, 708
- Antipneumocystis agents
- screening assay
- development and characterization, 1674
- Antiviral agents
- combinations
- strategic design and three-dimensional analysis, 540
- hepatitis B virus
- selectivity, high-capacity in vitro assessment, 441
- selectivity
- high-capacity in vitro assessment, 441
- Artemisinin
- iron-dependent free radical generation, 1108
- mechanism of action
- iron dependence, 1108
- AS-48
- antibodies, neutralizing
- immunocytological studies, 148
- Aspergillosis
- amphotericin B
- aerosol, prophylaxis, 1367
- comparative evaluation
- itraconazole-cyclodextrin versus amphotericin B in a rabbit model, 2307
- pulmonary, invasive
- amphotericin B, aerosol, for prophylaxis, 1367
- Aspergillus fumigatus*
- aspergillosis
- itraconazole-cyclodextrin versus amphotericin B in a rabbit model, comparative evaluation, 2307
- D0870
- in vivo and in vitro activities, 2412
- itraconazole
- efficacy in a rat model, 2762
- Atovaquone
- combinations
- clarithromycin, 2371
- minocycline, 2371
- pyrimethamine, 2371
- sulfadiazine, 2371
- T. gondii*
- in vitro and in vivo activities, 2371
- Avermectins
- S. erythraea*
- glycosylation, microbial conversion by, 1737
- 3'-Azido-2',3'-deoxythymidine
- synergy
- carbovir, 144
- human immunodeficiency virus type 1, 144
- 3'-Azido-3'-deoxythymidine
- toxicity
- thymidine kinase activity, correlation with circadian variation in, 1771
- time of administration, effect on, 1771
- 3'-Azido-3'-deoxythymidine
- human immunodeficiency virus type 1
- replication in human fetal brain macrophages, effect on, 1305
- 3'-Azido-3'-deoxythymidine monophosphate
- exonucleolytic repair of AZT-terminated DNA
- inhibition of, 918
- 3'-Azidothymidine
- simian immunodeficiency virus
- macrophages, comparative evaluation, 360
- Azithromycin
- B. burgdorferi*
- in vitro activity, comparative evaluation, 1704
- Brucella* spp.
- in vitro activity, comparative evaluation, 911
- C. pneumoniae*
- in vitro activity, 1746
- C. trachomatis*

- in vitro activity, 1746
 combinations
 pyrimethamine, 1993
T. gondii, 1993
 cross-resistance
 frequency distribution curves, scattergrams, and regression analyses, 2080
 enteric bacterial pathogens
 in vitro activity, 1203
 gram-negative organisms
 outer membrane permeability barrier, 354
 in vitro activities
 frequency distribution curves, scattergrams, and regression analyses, 2080
L. micdadei
 inhibition of intracellular strains, 2261
 lymphocyte response
 in vivo activities, 1786
M. avium
 cross-resistance, 2364
M. avium complex
 rats treated with cyclosporine, 398
M. haemophilum
 in vitro activities, 2323
M. kansasii
 susceptibility testing, 1997
 pharmacokinetics
 pediatric patients, multiple oral doses of suspension, 314
S. aureus
 uptake by human monocytes, 2318
T. gondii
 protein synthesis, inhibition of, 1701
 Aztreonam
C. albicans
 colonization of the human gastrointestinal tract, effect on, 51
 combinations
 amikacin, 308
 endocarditis, 308
P. aeruginosa, 308
 endocarditis
P. aeruginosa, 308
P. aeruginosa
 endocarditis, 308
 yeast colonization of the human gastrointestinal tract, effect on, 51
Bacteroides fragilis
 Bay Y3118
 in vitro activity, 2509
cepA
 cloning and characterization reveal a new subgroup of β -lactamases, 2391
 ciprofloxacin
 T-cell subsets and tumor necrosis factor production in infected mice, effect on, 1711
 clindamycin
 in vivo efficacy, correlation with in vitro susceptibility, 997
 mice, 997
E. coli, polymicrobial infection
 mice, 1531
 quinolones
 in vivo efficacy, correlation with in vitro susceptibility, 997
 mice, 997
 rifloxacin
 T-cell subsets and tumor necrosis factor production in infected mice, effect on, 1711
S. aureus, polymicrobial infection
 mice, 1531
 temafloxacin
 evaluation of activity by an in vitro pharmacodynamic system, 2454
tet(Q)
 nucleotide and deduced amino acid sequences, 2037
Bacteroides gracilis
 Bay Y3118
 in vitro activity, 2509
Bacteroides spp.
 Bay Y3118
 in vitro activity, 2509
 β -lactamase
 cefoxitin resistance, 1028
 novel Ambler class A, 1028
 cefoxitin resistance
 β -lactamase, 1028
Bacteroides thetaiotaomicron
E. coli, polymicrobial infection
 mice, 1531
S. aureus, polymicrobial infection
 mice, 1531
 Bay y 3118
 broth macrodilution assays
 in vitro activity and comparative evaluation, 2348
 Bay y3118
 gram-negative organisms
 anaerobic, 1649
 comparative susceptibilities, 1649
 gram-positive organisms
 anaerobic, 1649
 comparative susceptibilities, 1649
 in vitro activities
 gram-negative organisms, 2017
 gram-positive organisms, 2017
 Benzimidazoles
Giardia spp.
 in vitro activity, 328
 Bis-benzimidazoles
P. carinii
 pneumonia, treatment of, 1713
 Benzoxazinorifamycin
M. avium complex
 radiometric method, determination by, 67
 Benzoxazinorifamycins
 KRM-1648
M. avium, 722
 Benzylpenicillin
Pneumococcus spp.
 postantibiotic effect, 2200
Streptococcus spp.
 postantibiotic effect, 2200
 β -Lactamase inhibitors
 combinations
 β -lactams, 702
S. aureus, borderline methicillin susceptible, 702
S. aureus, methicillin resistant, 702
 β -Lactamases
A. baumannii
 production by, 138
A. hydrophila
 β -lactam resistance, contribution to, 1324
 carbapenems, high specificity for, 1324
B. fragilis
 cloning and characterization of *cepA* reveal new subgroup, 2391
Bacteroides spp.
 cefoxitin resistance, 1028
 novel Ambler class A, 1028
C. coli
 β -lactam susceptibilities, 1174
 carbapenem hydrolyzing
E. cloacae, biochemical properties, 939
 CP-70,429
 stability to, 1547
E. cloacae
 biochemical properties, 939
 cloning of gene into *E. coli*, 939
E. coli
 clavulanate, 2059
 sulbactam, 2059
 tazobactam, 2059
E. faecalis
 mobilization of gene, 1187
 production by, 1966
 fecal activity
 healthy volunteers after cefixime treatment, 1432
 FK-037
 stability to, 566
H. alvei
 ceftazidime resistant, 1375
K. pneumoniae
 β -lactams, broad spectrum, resistance to, 984
 β -lactams, extended spectrum, resistance to, 2020
 MGH-1, 2760
 plasmid encoded, TEM derived, 2020
 plasmid mediated, AmpC type, transferable, 984
 YOU-1, 2760
 YOU-2, 2760
 MGH-1
 gene sequences for, 2760
 minireview
 induction of, molecular basis for, 153
N. farcinica
 characterization, 1850
P. aeruginosa
 carbapenem resistance, role in, 1387
 extended spectrum, characterization of, 962
 OXA-11, extended-spectrum variant of OXA-10, 1637
P. cepacia, 249
 chromosomal penicillinase, member of AmpC family, 667
 plasmid mediated
 β -lactams, broad spectrum, resistance to, 984
E. coli, 1989
K. pneumoniae, 984, 1989
S. aureus
blaI and *blaRI*, regulation by, 1144
 cefazolin, inactivation and efficacy of, 203
 cefmetazole, inactivation and efficacy of, 203
 production by, 1966
Streptococcus spp., group A beta-hemolytic
 production of, role in infection management, 1452
 susceptibility testing

- predictor panel for evaluating methods, 2578
 tazobactam
 kinetic interactions, 851
 TEM-1
 hydrogen bonding by serine 235 for cephalosporinase activity, 2438
 YOU-1
 gene sequences for, 2760
 YOU-2
 gene sequences for, 2760
- β -Lactams**
A. hydrophila resistance
 metallo- β -lactamase, *cphA* encoded, 1324
C. coli susceptibility
 β -lactamase-positive and -negative strains, 1174
 combinations
 β -lactamase inhibitors, 702
 S. aureus, borderline methicillin susceptible, 702
 S. aureus, methicillin resistant, 702
E. faecium resistance
 synergistic combinations, resistance to, 1238
 minireviews
 penicillin-binding protein resistance, 2045
 penicillin-binding protein resistance minireview, 2045
 synergy
 E. faecium resistance, 1238
- Biapenem**
 comparative evaluation
 imipenem, 2009
 gram-negative bacteria, 2009
 gram-positive bacteria, 2009
P. aeruginosa
 phenotypic resistance induced by salicylate, 2743
- Bilobalide**
P. carinii
 in vitro and in vivo activities, 1492
- Bilophila wadsworthia***
 Bay Y3118
 in vitro activity, 2509
 imipenem
 morphological response, 2638
 penicillin-binding protein patterns, 2638
- Bioavailability**
 cefetamet pivoxil
 syrup and tablet formulations to healthy male volunteers, 2706
 (-)-*cis*-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine
 studies with rats, 2285
 clindamycin
 healthy volunteers and AIDS patients, 1137
 fluconazole
 patients with AIDS, 2187
- Biofilms**
S. epidermidis
 diffusion of rifampin, 2522
 diffusion of vancomycin, 2522
- Bioscreen C**
 benzylpenicillin
 postantibiotic effect, 2200
- Bis(pivaloyloxymethyl) prodrugs**
 metabolism and in vitro antiretroviral activities, 2247
- Bis-benzimidazoles**
G. lamblia
 correlation of anti-giardial activity, DNA binding affinity, and giardial topoisomerase II inhibition, 2668
 structure-activity studies, 2668
- Blastomyces dermatitidis***
 D0870
 murine blastomycosis, 1177
- Blastomycosis**
 D0870
 murine, 1177
- Bleomycin**
E. coli
 amikacin and streptomycin resistance, 1982
S. cerevisiae
 cell wall anchorage of mannoproteins, disruption of, 1264
- Boric acid**
Candida spp.
 temperature, effect on activity, 685
- Borrelia burgdorferi***
 azithromycin
 in vitro activity, comparative evaluation, 1704
 clarithromycin
 hamsters, 1329
 in vitro activity, comparative evaluation, 1704
 coumermycin A₁
 growth inhibition and induction of relaxation of supercoiled plasmids, 46
 erythromycin
 in vitro activity, comparative evaluation, 1704
 in vitro susceptibilities, 1444
 vancomycin
 in vitro activity, 1115
- Bronchitis**
 chronic
 rifloxacin and amoxicillin, comparative evaluation, 2298
- Broth macrodilution assay**
 Bay y 3118
 in vitro activity and comparative evaluation, 2348
 yeasts
 susceptibility testing, 39
- Brucella melitensis***
 experimental murine brucellosis
 streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin, 2333
- Brucella* spp.**
 azithromycin
 in vitro activity, comparative evaluation, 911
 clarithromycin
 in vitro activity, comparative evaluation, 911
 dirithromycin
 in vitro activity, comparative evaluation, 911
 doxycycline-rifampin
 comparative evaluation, 1831
 ofloxacin-rifampin
 comparative evaluation, 1831
 rifapentine
 in vitro activity, comparative evaluation, 911
 roxithromycin
- in vitro activity, comparative evaluation, 911
- Butenafine**
C. albicans
 mechanisms of action, 785
 percutaneous permeation, 363
T. mentagrophytes
 guinea pigs, 363
- Camptothecin**
P. carinii
 activity in vitro and in a mouse model, 1543
- Campylobacter coli***
 β -lactamase-positive and -negative strains
 β -lactam susceptibilities, 1174
- Campylobacter jejuni***
 cytokines
 effect of oral recombinant interleukin on mucosal immunity in mice, 2688
 DNA gyrase
 gyrA, cloning and nucleotide sequence, 457
gyrA
 cloning and nucleotide sequence, 457
 quinolone resistance
 DNA gyrase mutations, characterization of, 457
- Tet(O)
 effect of mutational alteration of Asn-128, 2645
 tetracycline resistance
 effect of mutational alteration of Asn-128, 2645
- Campylobacter* spp.**
 azithromycin
 in vitro activity, 1203
- Candida albicans***
 amphotericin B
 comparative evaluation, 729
 disseminated infection in normal and granulocytopenic mice, 729
 tumor necrosis factor alpha, reduction in release, 1958
 aztreonam
 colonization of the human gastrointestinal tract, effect on, 51
 butenafine
 mechanisms of action, 785
 ceftazidime
 colonization of the human gastrointestinal tract, effect on, 51
 ceftriaxone
 colonization of the human gastrointestinal tract, effect on, 51
 cilofungin
 comparative evaluation, 729
 disseminated infection in normal and granulocytopenic mice, 729
- D0870
 in vitro activities, 2126
 in vivo and in vitro activities, 2412
 fluconazole resistance
 patients infected with human immunodeficiency virus type 1, correlation to therapy and symptoms, 2449
 fluconazole susceptibility
 emergence of resistance of Norwegian strains, 2443

- imipenem-cilastatin
 colonization of the human gastrointes-
 tinal tract, effect on, 51
 itraconazole
 placebo-controlled trial, 89
 myeloperoxidase, human recombinant
 candidicidal activity, 142
 picolinic acid
 protective effect on mice, 2422
 Ro 09-1470
 inhibition of P-450 lanosterol C-14
 demethylase, 2662
 ticarcillin-clavulanic acid
 colonization of the human gastrointes-
 tinal tract, effect on, 51
Candida glabrata
 fluconazole resistance, 1962
Candida parapsilosis
 amphotericin B, 2030
 endocarditis, 2030
 fluconazole, 2030
Candida spp.
 amorolfine
 temperature, effect on activity, 685
 amphotericin B
 temperature, effect on activity, 685
 boric acid
 temperature, effect on activity, 685
 flucytosine
 temperature, effect on activity, 685
 platelet microbicidal protein
 fungicidal activity, 546
 susceptibility testing
 current status of the standardization
 process, minireview, 2517
 terbinafine
 temperature, effect on activity, 685
 terconazole
 temperature, effect on activity, 685
Candida tropicalis
 amphotericin B, 2030
 endocarditis, 2030
 fluconazole, 2030
 Candidiasis
 itraconazole
 placebo-controlled trial, 89
 CAPI8
 gram-negative organisms
 in vitro activity, 2534
 gram-positive organisms
 in vitro activity, 2534
Capnocytophaga spp.
 antimicrobial susceptibilities
 letter to the editor, 1206
Capnocytophaga sputigena
 HPQYNQR
 in vitro activity, 2710
 IIGGR
 in vitro activity, 2710
 Carbapenems
 β -lactamase hydrolysis
 E. cloacae, 939
 biapenem
 P. aeruginosa resistance induced by
 salicylate, 2743
 BO-2727
 in vitro activity, 2756
F. oryzihabitans
 in vitro activities against clinical iso-
 lates from patients with cancer,
 2504
 imipenem
 P. aeruginosa resistance induced by
 salicylate, 2743
 LJC 10,627
 neurotoxicity in rats, low levels of,
 199
P. aeruginosa resistance
 cephalosporinase, role in, 1387
 panipenem
 P. aeruginosa resistance induced by
 salicylate, 2743
 Carbenicillin
 epimers
 stereoselective renal tubular secretion
 in human volunteers, 2327
 Carbovir
 cellular metabolism
 effects on, 1004
 metabolism, 1004
 synergy
 3'-azido-2',3'-deoxythymidine, 144
 human immunodeficiency virus type 1,
 144
 Carboxyquinolones
 Q-35
 L. interrogans, 901
 Cecropin
 C terminus, modification of
 broad-spectrum antimicrobial activity,
 essential for, 1614
 Cefaclor
 H. influenzae
 β -lactamase producing and nonproduc-
 ing, ampicillin resistant, 14
 Cefazolin
 abscesses
 β -lactamase-mediated inactivation and
 efficacy, 203
 pharmacokinetics
 protein binding in rats, 1781
 proconvulsant effects
 DBA/2 and Swiss mice, 1497
 S. aureus
 β -lactamase-mediated inactivation and
 efficacy, 203
 seizures
 DBA/2 and Swiss mice, 1497
 Cefepime
 in vitro activity
 multicenter comparison, 1696
 pharmacokinetics
 cystic fibrosis patients, 1414
 Cefetamet pivoxil
 bioavailability
 syrup and tablet formulations to
 healthy male volunteers, 2706
 Cefixime
 β -lactamase activity, fecal
 healthy volunteers after drug treat-
 ment, 1432
 C. difficile shedding
 healthy volunteers after drug treat-
 ment, 1432
 gastrointestinal symptoms
 effect on in healthy volunteers after
 drug treatment, 1432
 H. influenzae
 β -lactamase producing and nonproduc-
 ing, ampicillin resistant, 14
 pharmacokinetics
 biliary excretion in patients with
 T-tube drainage, 1488
 Cefmetazole
 abscesses
 β -lactamase-mediated inactivation and
 efficacy, 203
S. aureus
 β -lactamase-mediated inactivation and
 efficacy, 203
 Cefonicid
 peritonitis, spontaneous bacterial
 comparative evaluation, 1587
 pharmacokinetics
 protein binding in adult and neonatal
 sera, 1343
 protein binding
 adult and neonatal sera, 1343
 Cefoperazone
 combinations
 E. coli, 1927
 K. pneumoniae resistance, 1061
 P. aeruginosa, 1927
 sulbactam, 1061, 1927
 Cefotaxime
 B. burgdorferi
 in vitro susceptibility, 1444
 E. coli
 comparative evaluation, 846
 epididymitis, 846
 postantibiotic effect in pooled cerebro-
 spinal fluid and Mueller-Hinton
 broth, 1154
 epididymitis
 comparative evaluation, 846
 E. coli, 846
 H. influenzae
 β -lactamase producing and nonproduc-
 ing, ampicillin resistant, 14
 pharmacokinetics
 cerebrospinal fluid of patients with
 uninflamed meninges, passage
 into, 1518
 postantibiotic effect
 E. coli, in pooled cerebrospinal fluid
 and Mueller-Hinton broth, 1154
 S. pneumoniae breakpoint
 letter to the editor, 616
 Cefoxitin
 abscesses, intra-abdominal
 comparative evaluation, 610
 Bacteroides resistance
 β -lactamase, 1028
 E. coli
 comparative evaluation, 610
 Cefozopran
 K. pneumoniae
 respiratory tract infection, 100
 P. aeruginosa
 urinary tract infection, 100
 S. aureus
 thigh muscle infection, 100
 Cefpodoxime proxetil
 ex vivo susceptibility
 studies with patients receiving contin-
 uous ambulatory peritoneal dialy-
 sis, 2650
 pharmacokinetics
 studies with patients receiving contin-
 uous ambulatory peritoneal dialy-
 sis, 2650
 Cefprozil
 pharmacokinetics
 tonsillar and adenoidal tissues, pene-
 tration into, 1180
 tonsillopharyngitis, streptococcal
 comparative evaluation, 1620

- Ceftazidime
C. albicans
 colonization of the human gastrointestinal tract, effect on, 51
 combinations
 amikacin, 308
 endocarditis, 308
 P. aeruginosa, 308
E. coli resistance
 β -lactamase, 1989
 endocarditis
 P. aeruginosa, 308
H. alvei resistance
 β -lactamase producing, 1375
 in vitro activity
 multicenter comparison, 1696
K. pneumoniae resistance
 β -lactamase, 1989
P. aeruginosa
 endocarditis, 308
P. cepacia
 comparative evaluation, 123
P. pseudomallei resistance
 biofilm cells, 2000
 pharmacokinetics
 healthy volunteers, 1835
 patients with septic multiple-organ failure during intermittent hemofiltration, 464
 serum bactericidal activities, 1835
 side effects, 1835
 yeast colonization of the human gastrointestinal tract, effect on, 51
 Ceftributen
 H. influenzae
 β -lactamase producing and nonproducing, ampicillin resistant, 14
 Cefprozime
 B. burgdorferi
 in vitro susceptibility, 1444
 Ceftriaxone
 C. albicans
 colonization of the human gastrointestinal tract, effect on, 51
 C. burnetii
 shell vial assay, 491
 combinations
 endocarditis, 1971
 netilmicin, 1971
 concentrations in plasma during liver transplantation, 1873
 gonorrhea, uncomplicated
 single-dose therapy, comparative evaluation, 1670
 in vitro activity
 multicenter comparison, 1696
 peritonitis, spontaneous bacterial
 comparative evaluation, 1587
 pharmacokinetics
 cerebrospinal fluid of patients with uninfamed meninges, passage into, 1518
 elimination, effect of plasmapheresis, 1171
 pregnant women, 54
 protein binding during pregnancy, 54
 S. typhi
 5 days, comparative evaluation, 1572
 synergy
 netilmicin, 207
 streptococcal endocarditis, 207
 tissue penetration during liver transplantation, 1873
 typhoid fever
 5 days, comparative evaluation, 1572
 yeast colonization of the human gastrointestinal tract, effect on, 51
 Cefuroxime
 H. influenzae
 β -lactamase producing and nonproducing, ampicillin resistant, 14
 in vitro activity
 multicenter comparison, 1696
 pharmacokinetics
 protein binding in adult and neonatal sera, 1343
 protein binding
 adult and neonatal sera, 1343
 S. mutans
 in vitro susceptibility, 1158
 Cefuroxime axetil
 pharyngitis
 comparative evaluation, 159
 Streptococcus spp.
 comparative evaluation, 159
 group A, 159
 pharyngitis, 159
 suspension
 comparative evaluation, 159
 group A streptococcal pharyngitis, 159
 Cephalosporin 7 α -hydroxylase
 S. clavuligerus
 cloning and expression in *S. lividans*, 84
 Cephalosporinases
 P. aeruginosa
 carbapenem resistance, role in, 1387
 Cephalosporins
 B. fragilis and *E. coli* infection
 mice, 1531
 B. fragilis and *S. aureus* infection
 mice, 1531
 B. thetaiotaomicron and *E. coli* infection
 mice, 1531
 B. thetaiotaomicron and *S. aureus* infection
 mice, 1531
 cefazopran
 K. pneumoniae, 100
 P. aeruginosa, 100
 respiratory tract infections, 100
 S. aureus, 100
 urinary tract infections, 100
 cefprozime proxetil
 ex vivo susceptibility, 2650
 pharmacokinetics, 2650
 E1077
 in vitro and in vivo activities, 60
 F. oryzae
 in vitro activities against clinical isolates from patients with cancer, 2504
 FK037
 anaerobic organisms, 957
 β -lactamase stability, 566
 in vitro activity, 566
 in vitro and in vivo activities, 301
 polymicrobial infection
 mice, 1531
 3'-quinolone carbamates
 E. coli, mechanism of action, 559
 3'-quinolone esters
 E. coli, mechanism of action, 559
 3'-quinolone tertiary amines
 E. coli, mechanism of action, 559
 Ro 40-6890
 antibiotic activity and host defense mechanisms, 2622
 pharmacodynamic activity in human skin blister fluid, 2622
 S. aureus
 endocarditis, 554
 methicillin susceptible, 554
 Cepheids
 S-1108
 pharmacokinetics, 1043
 safety of and carnitine status of patients, 1043
 CGI 17341
 M. tuberculosis
 in vitro and in vivo activities, 183
 CGP 53437
 antiviral activity
 human immunodeficiency virus type 1 protease, 2087
 Chagas' disease
 ICI 195,739-terbinafine
 murine model, 1353
 ketoconazole-terbinafine
 murine model, 1353
 Chancroid
 agents for treatment of, currently recommended and newer
 H. ducreyi from the United States and Thailand, 1552
 in vitro susceptibilities, 1552
 Chlamydia pneumoniae
 azithromycin
 in vitro activity, 1746
 OPC-17116
 in vitro and in vivo activities, 801
 sparfloxacin
 in vitro and in vivo activities, 801
 tosufloxacin
 in vitro and in vivo activities, 801
 Chlamydia psittaci
 OPC-17116
 in vitro and in vivo activities, 801
 sparfloxacin
 in vitro and in vivo activities, 801
 tosufloxacin
 in vitro and in vivo activities, 801
 Chlamydia spp.
 OPC-17116
 in vitro and in vivo activities, 801
 sparfloxacin
 in vitro and in vivo activities, 801
 tosufloxacin
 in vitro and in vivo activities, 801
 Chlamydia trachomatis
 azithromycin
 in vitro activity, 1746
 CI-960
 salpingitis, 8
 doxycycline
 comparative evaluation, 1373
 genital infections, treatment of, 1373
 genital infections
 doxycycline, comparative evaluation, 1373
 spiramycin, comparative evaluation, 1373
 OPC-17116
 in vitro and in vivo activities, 801
 sparfloxacin
 in vitro and in vivo activities, 801
 spiramycin
 comparative evaluation, 1373
 genital infections, treatment of, 1373

- tosufloxacin
in vitro and in vivo activities, 801
- Chloramphenicol
P. cepacia
comparative evaluation, 123
S. typhi
14 days, comparative evaluation, 1572
typhoid fever
14 days, comparative evaluation, 1572
- Chloramphenicol acetyltransferases
A. baumannii
production by, 138
- Chlorhexidine
S. mutans
in vitro susceptibility, 1158
- Chloroquine
P. falciparum
clonal viability measurements to assess in vitro activity, 1142
- CI-960
C. trachomatis
salpingitis, monkey model, 8
- Cilastatin
combinations
imipenem, 51
yeast colonization of the human gastrointestinal tract, effect on, 51
- Cilofungin
C. albicans
comparative evaluation, 729
disseminated infection in normal and granulocytopenic mice, 729
- Ciprofloxacin
adverse effects
convulsions in mice, 1764
B. burgdorferi
in vitro susceptibility, 1444
combinations
ampicillin, 1904
E. faecium, 1904
novobiocin, 1904
comparative evaluation
DU-6859a, 2747
ofloxacin, 2193
disk elution
M. avium complex susceptibility testing, 1556
M. tuberculosis susceptibility testing, 1556
E. coli
postantibiotic effect in pooled cerebrospinal fluid and Mueller-Hinton broth, 1154
gonorrhea, uncomplicated
single-dose therapy, comparative evaluation, 1670
H. influenzae
adherence changes induced by subinhibitory concentrations, 885
in vitro activities
gram-negative organisms, 2017
gram-positive organisms, 2017
K. pneumoniae
adherence changes induced by subinhibitory concentrations, 885
keratitis
age and therapeutic outcome, 1856
liposome incorporated
treatment of murine salmonellosis, 2293
M. catarrhalis
adherence changes induced by subinhibitory concentrations, 885
M. haemophilum
in vitro activities, 2323
M. pneumoniae
hamsters, 287
N. gonorrhoeae
antibacterial activities, 2244
P. aeruginosa
age and therapeutic outcome, 1856
dose-ranging and fractionation, 1756
in vitro model of infection, 1756
increased susceptibility in the presence of vancomycin, 2506
resistance to unrelated antibiotics, effects on, 1289
P. cepacia
comparative evaluation, 123
pharmacokinetics
effects of cardiopulmonary bypass surgery on disposition, 2106
multiple oral doses to healthy volunteers, 2193
seriously ill patients, 1073
population pharmacokinetics
optimal sampling strategies, 1065
postantibiotic effect
E. coli, in pooled cerebrospinal fluid and Mueller-Hinton broth, 1154
S. aureus
dose-ranging and fractionation, 1756
in vitro model of infection, 1756
resistance to unrelated antibiotics, effects on, 1289
S. pneumoniae
mouse protection model, 234
S. typhimurium resistance
isolates from two patients, 662
serum bactericidal titers
multiple oral doses to healthy volunteers, 2193
synergy
ethambutol, 1285
M. malmoeense, 1285
T-cell subsets and tumor necrosis factor production
mice infected with *B. fragilis*, effect on, 1711
typhoid fever
severe, in children, 1197
vancomycin
increased susceptibility of *P. aeruginosa*, 2506
Citrobacter freundii
ampD
sequences of wild-type and mutant genes, comparison with those of *E. coli*, 224
Clarithromycin
B. burgdorferi
hamsters, 1329
in vitro activity, comparative evaluation, 1704
in vitro susceptibility, 1444
bite wound isolates
aerobic and anaerobic, 1150
Brucella spp.
in vitro activity, comparative evaluation, 911
C. burnetii
in vitro susceptibilities, 2633
combinations
granulocyte colony-stimulating factor, 692
M. avium complex, 692
M. avium, prophylaxis in mice, 1690
minocycline, 1690
RU-4055, 692
cross-resistance
frequency distribution curves, scattergrams, and regression analyses, 2080
gram-negative organisms
outer membrane permeability barrier, 354
in vitro activities
frequency distribution curves, scattergrams, and regression analyses, 2080
Lyme disease
hamsters, 1329
M. avium
cross-resistance, 2364
erratum, 2515
human macrophages, 111
macrophages, inhibition of intracellular growth, 1380
prophylaxis in C57BL/6 mice, 1690
M. avium complex, 692
M. haemophilum
in vitro activities, 2323
M. kansasii
susceptibility testing, 1997
metabolite
B. burgdorferi, susceptibility in vitro, 1444
P. aeruginosa
biofilms, interaction with, 1749
S. pneumoniae resistance
cultures from Providence, R.I., 1742
T. pallidum
hamsters, 864
Clavulanate
combinations
E. coli, 2059
sulbactam, 2059
tazobactam, 2059
E. coli
 β -lactamase, TEM type, resistant, 2059
Clavulanic acid
combinations
amoxicillin, 14
H. influenzae, β -lactamase producing and nonproducing, ampicillin resistant, 14
ticarcillin, 51
yeast colonization of the human gastrointestinal tract, effect on, 51
Clindamycin
B. fragilis
in vivo efficacy, correlation with in vitro susceptibility, 997
mice, 997
bioavailability
healthy volunteers and AIDS patients, 1137
E. coli
in vivo efficacy, correlation with in vitro susceptibility, 997
mice, 997
peptidyl-RNA
dissociation from ribosomes, 2027
pharmacokinetics
bioavailability, 1137
healthy volunteers and AIDS patients, 1137
T. gondii

- infectivity, 2571
 intracellular replication, 2571
 protein synthesis, 2571
- Clofazamine**
M. haemophilum
 in vitro activities, 2323
- Clofazimine**
M. avium-M. intracellulare complex
 in vitro activities, 2584
M. tuberculosis
 in vitro activities, 2584
- Clonal viability measurements**
P. falciparum
 leupeptin, chloroquine, and 5-fluoroorotate, in vitro activity, 1102
- Clostridium difficile***
 cefixime
 effect on shedding in healthy volunteers, 1432
- Clostridium* spp.**
 Bay Y3118
 in vitro activity, 2509
- Co-trimoxazole**
P. cepacia
 comparative evaluation, 123
P. pseudomallei resistance
 biofilm cells, 2000
- Coumermycin A₁**
B. burgdorferi
 growth inhibition and induction of relaxation of supercoiled plasmids, 46
- Coxiella burnetii***
 ceftriaxone
 shell vial assay, 491
 clarithromycin
 in vitro susceptibilities, 2633
- Q fever**
 minireview, 1733
 treatment of, 1733
- Coxsackievirus**
 WIN 54954
 group B diabetogenic strain in mice, 1593
- CP-70,429**
 in vitro antibacterial activity, 1547
 β -lactamase stability, 1547
- CP-99,219**
 gram-positive organisms
 in vitro activity, 366
 in vitro activity, 349
- Cryptococcus neoformans***
 amphotericin B
 in vitro susceptibility, 1383
 recurrent meningitis, isolates from patients with, 1383
- D0870**
 in vitro activities, 2126
 in vivo and in vitro activities, 2412
- fluconazole**
 in vitro susceptibility, 1383
 recurrent meningitis, isolates from patients with, 1383
- itraconazole**
 effects on cytochrome P-450-dependent sterol 14 α -demethylation and reduction of 3-ketosteroids, 2101
- NP-1**
 in vitro activity, 2628
 platelet microbicidal protein
 fungicidal activity, 546
 susceptibility testing
 current status of the standardization process, minireview, 2517
- Cryptosporidium parvum***
 simefungin
 curative and preventive activities, 889
 immunosuppressed rat model, 889
- Cycloguanil**
P. falciparum
 African isolates, 924
- Cyclothialidone**
Eubacterium spp.
 inhibition, 2656
- Cytochrome P-450**
 dirithromycin
 type I binding spectrum, 265
- macrolides**
 type I binding spectrum, 265
- Cytokines**
C. jejuni
 effect of oral recombinant interleukin on mucosal immunity in mice, 2688
 interleukin-8
 nonspecific resistance to infection in neutropenic and normal mice, 276
- Cytomegalovirus**
 1110U81
 ganciclovir, potentiation of antiviral effects, 602
 potent inhibition of replication, 602
 ganciclovir
 decrease in frequency and severity of disease in liver transplant recipients treated with OKT3 monoclonal antibodies, 2490
 sensitivity at diagnosis and during treatment, 1360
 ganciclovir resistance
 point mutation in DNA polymerase gene, 19
 (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine
 interstitial pneumonitis after bone marrow transplantation, 218
 phosphonylmethoxyalkyl derivatives, resistance to
 point mutation in DNA polymerase gene, 19
 phosphorothioate oligonucleotides
 ISIS 2922, in vitro activity of, 1945
- D0870**
A. fumigatus
 in vivo and in vitro activities, 2412
B. dermatitidis
 murine blastomycosis, 1177
 blastomycosis
 murine, 1177
- C. albicans*
 in vitro activities, 2126
 in vivo and in vitro activities, 2412
- C. neoformans*
 in vitro activities, 2126
 in vivo and in vitro activities, 2412
 comparative evaluation
 fluconazole, 2412
 pathogenic yeasts
 in vitro activities, 2126
- Dapsone**
 synergy
 dihydrofolate reductase inhibitors, 1436
P. carinii, 1436
- Ro 11-8958, 1436
- Daptomycin**
 bactericidal activity
 albumin or serum, presence of, controlled pH and calcium, 605
- Decimal assay for additivity**
 synergy and antagonism
 delineation of, 260
- Deglucocetylplatin amides**
E. coli
 uptake, mechanism of, 453
- P. aeruginosa*
 uptake, mechanism of, 453
- Dental amalgam**
 mercury
 bacterial resistance, 825
 bacterial resistance, letter to the editor, 1730
- 3'-Deoxy-2',3'-didehydrothymidine**
 pharmacokinetics
 disposition and metabolism in hepatocytes and nonhuman primates, 1816
- 2'-Deoxy-3'-thiacytidine**
 human immunodeficiency virus type 1
 resistance
 due to amino acid substitution at catalytic site of reverse transcriptase, 2231
- Diarylsulfones**
 human immunodeficiency virus type 1
 mechanism of action, 754
 reverse transcriptase inhibitor, 754
- Didanosine**
 human immunodeficiency virus resistance
pol mutations, multiple resistance, 1480
 salmonellae
 in vitro activities, 106
- 2',3'-Dideoxy-3'-thiacytidine**
 (-) enantiomer
 human immunodeficiency virus, resistance, characterization of, 875
 human immunodeficiency virus resistance
 characterization of, 875
 conferred by the same mutation that confers resistance to ddI and ddC, 1390
 generation of variants, 130
- 2',3'-Dideoxy-5-fluoro-3'-thiacytidine**
 (-) enantiomer
 human immunodeficiency virus, resistance, characterization of, 875
 human immunodeficiency virus resistance
 characterization of, 875
- 2',3'-Dideoxycytidine**
 human immunodeficiency virus resistance
 generation of variants, 130
 salmonellae
 in vitro activities, 106
- 2',3'-Dideoxyinosine**
 salmonellae
 in vitro activities, 106
- 2',3'-Dideoxynucleosides**
 visna virus
 inhibition of replication, 2540
- Dihydrofolate reductase**
T. gondii
 inhibitors, identification of, 1914

- trimethoprim resistance
 integron on a Tn21-like element, 1297
- Dihydrofolate reductase inhibitors
 synergy
 dapson, 1436
P. carinii, 1436
 sulfamethoxazole, 1436
- Dihydrofolate reductases
S. aureus
 characterization of gene for, 1400
 trimethoprim sensitive
S. aureus, characterization of gene for, 1400
- Diltiazem
 netilmicin
 nephrotoxicity in rabbits, induction by, 1790
- Diminazene
 pharmacokinetics
 Boran cattle, noninfected and infected with *T. congolense*, 1050
- Dinitroanilines
L. mexicana
 structure-function analysis, 1909
 trifluralin, 1909
- Dirithromycin
B. burgdorferi
 in vitro susceptibility, 1444
Brucella spp.
 in vitro activity, comparative evaluation, 911
 cytochrome P-450 complex formation
 rat and human livers, 265
 polymorphonuclear leukocytes
 interactions may promote killing of infecting organisms, 2557
- Disk elution
 ciprofloxacin susceptibility testing
M. avium complex, 1556
M. tuberculosis, 1556
- DNA gyrases
E. coli
 quinolones, mechanism of action, 839
 quinolones
E. coli, mechanism of action, 839
- DNA gyrases
C. jejuni
gyrA, cloning and nucleotide sequence, 457
Eubacterium spp.
 cyclothialidine, characterization of, 2656
 fluoroquinolones
 single point mutation in *E. coli* A protein reduces binding, 126
- Doxycycline
 alpha-1-antitrypsin
 protection from human neutrophil collagenase and gelatinase, 592
B. burgdorferi
 in vitro susceptibility, 1444
C. trachomatis
 comparative evaluation, 1373
 genital infections, treatment of, 1373
 combinations
Brucella spp., 1831
 rifampin, 1831
E. coli
 comparative evaluation, 846
 epididymitis, 846
 epididymitis
 comparative evaluation, 846
E. coli, 846
- DR-3354
 comparative evaluation
 accumulation by human polymorphonuclear leukocytes, 1882
- Drosophila melanogaster*
 pyrimido[1,6- α]benzimidazoles
 effects on topoisomerase II and Kc cells, 2599
 Ro 46-7864
 effects on topoisomerase II and Kc cells, 2599
 Ro 47-3359
 effects on topoisomerase II and Kc cells, 2599
- Drug combination testing
 fractional maximal effect method, 523
- DU-6859a
 comparative evaluation
 ciprofloxacin, 2747
 fleroxacin, 2747
 levofloxacin, 2747
 lomefloxacin, 2747
 ofloxacin, 2747
- Duck hepatitis B virus
 suramin
 prevention of infection in vivo, 1539
- DV-7751a
 fluoroquinolones
 in vitro antibacterial activity, 2112
- E1077
 in vitro and in vivo activities, 60
- E-4868
 in vitro and in vivo activities, 868
- Efflux pump inhibitors
 screening assay, 1624
- Encephalitis
 foscarnet
 blood-brain barrier, penetration of, 1010
- Endocarditis
 amphotericin B, 2030
 ampicillin-sulbactam
S. aureus, β -lactamase hyperproduction, 507
 aztreonam, 308
 aztreonam-amikacin, 308
C. parapsilosis, 2030
C. tropicalis, 2030
 ceftazidime, 308
 ceftazidime-amikacin, 308
 ceftriaxone-netilmicin
Streptococcus spp., 1971
 synergy, 207
 cephalosporins
 broad spectrum, 554
E. faecalis, β -lactamase producing, highly gentamicin resistant
 ampicillin-sulbactam, comparative evaluation, 1447
 vancomycin, comparative evaluation, 1447
 fluconazole, 2030
 oxacillin
S. aureus, β -lactamase hyperproduction, 507
S. aureus, methicillin susceptible
 cephalosporins, broad spectrum, 554
Streptococcus spp.
 ceftriaxone-netilmicin synergy, 207
- Endotoxic shock
 magainins
 eicosanoid release by rat peritoneal macrophages, effect on, 393
- Enoxacin
 infection prevention
 adults with acute nonlymphocytic leukemia, 474
 pharmacokinetics
 oral antacids, effect on disposition, 775
 urinary tract infections, recurrent
 cefuroxime axetil, more rapid than, 1558
 rapid symptom alleviation, 1558
- Enterobacter cloacae*
 3-N-acetyltransferase
aac(3)-VIIa gene, biochemical analysis of, 2074
 β -lactamase
 carbapenem hydrolyzing, biochemical properties, 939
- Enterococcus faecalis*
 β -lactamase
 mobilization of gene, 1187
 production, genes involved in regulation, 1966
 β -lactamase producing, highly gentamicin resistant
 ampicillin-sulbactam, comparative evaluation, 1447
 vancomycin, comparative evaluation, 1447
 virulence in a rabbit model conferred by plasmid-associated hemolysin and aggregation substance production, 2474
 highly gentamicin resistant
 molecular characterization of isolates lacking high-level streptomycin resistance, 134
 penicillinase gene
 mobilization of, 1187
 polymerase chain reaction
 heterogeneity of chloramphenicol acetyltransferase genes, 2593
 vancomycin resistance gene
 homology with *vanB*, *vanA*, and *vanC*, 1604
 WIN 57273
 activity against high-level gentamicin-resistant strains, 2470
- Enterococcus faecium*
aac(6')-II
 specificity for, 1896
 ampicillin resistance, 1904
 ampicillin resistant, 2069
 endocarditis, 2069
 gentamicin resistance, 1904
 gentamicin resistant, high level
 isolates from different continents, comparison of, 681
 novobiocin
 in vitro activity against multiresistant strains, 2736
 penicillin resistance
 time-kill studies, 2427
 polymerase chain reaction

- heterogeneity of chloramphenicol acetyltransferase genes, 2593
- streptogramin A acetyltransferase identification of *satA*, 2119
- synergy
- penicillin-gentamicin, 2427
 - vancomycin resistance, 1904
- vancomycin resistance gene
- homology with *vanB*, *vanA*, and *vanC*, 1604
- vancomycin resistant, 2069
- resistance to synergistic β -lactam combinations, 1238
- Enterococcus* spp.
- antimicrobial susceptibilities
 - isolates from hospitalized patients, 1190
 - glycopeptide resistance
 - genetics and mechanisms of, minireview, 1563
 - glycopeptide resistant
 - characterization of isolates from U.S. hospitals, 2311
 - pulsed-field gel electrophoresis, 2311
- Epididymitis
- cefotaxime
 - comparative evaluation, 846
 - doxycycline
 - comparative evaluation, 846
- E. coli*
- cefotaxime, comparative evaluation, 846
 - doxycycline, comparative evaluation, 846
 - ofloxacin, comparative evaluation, 846
 - ofloxacin
 - comparative evaluation, 846
- Epipodophyllotoxins
- P. carinii*
 - activity in vitro and in a mouse model, 1543
- Epstein-Barr virus
- phosphorothioate oligodeoxynucleotides
 - inhibition of replication, 1420
- Equine herpesvirus 1
- phosphonylmethoxyalkyl derivatives
 - murine model for abortion, 2478
- Errata
- M. avium*
 - activities of quinolones, 2766
 - clarithromycin, minocycline, and rifabutin treatments of C57BL/6 mice, 2515
 - quinolones
 - anti-*M. avium* activities, 2766
- Erythromycin
- B. burgdorferi*
 - in vitro activity, comparative evaluation, 1704
 - in vitro susceptibility, 1444
 - cross-resistance
 - frequency distribution curves, scattergrams, and regression analyses, 2080
- H. influenzae*
- distribution in patients with lower respiratory tract infections, effect on, 804
- H. parainfluenzae*
- distribution in patients with lower respiratory tract infections, effect on, 804
 - in vitro activities
 - frequency distribution curves, scattergrams, and regression analyses, 2080
- M. haemophilum*
- in vitro activities, 2323
- P. aeruginosa*
- serum sensitivity, effect of sub-MICs on, 675
- peptidyl-RNA
- accumulation, 2027
- S. mutans*
- in vitro susceptibility, 1158
- S. pneumoniae* resistance
- cultures from Providence, R.I., 1742
- Escherichia coli*
- amikacin resistance
 - bleomycin, increase of, 1982
- ampD*
- sequences of wild-type and mutant genes, comparison with those of *C. freundii*, 224
- ampicillin-sulbactam
- comparative evaluation, 610
- azithromycin
- in vitro activity, 1203
- B. fragilis*, polymicrobial infection
- mice, 1531
- B. thetaiotaomicron*, polymicrobial infection
- mice, 1531
- β -lactamase
- ceftazidime resistance, 1989
- β -lactamase, TEM type, resistant
- clavulanate, 2059
 - sulbactam, 2059
 - tazobactam, 2059
- β -lactamases
- TEM-1, cephalosporinase activity of, 2438
- cefoperazone-sulbactam
- granulocytopenic mice, disseminated infections in, 1927
- cefotaxime
- comparative evaluation, 846
 - postantibiotic effect in cerebrospinal fluid and Mueller-Hinton broth, 1154
- cefoxitin
- comparative evaluation, 610
- ceftazidime resistance
- β -lactamase, 1989
- cephalosporins
- 3'-quinolone esters, carbamates, and tertiary amines, mechanism of action, 559
- ciprofloxacin
- postantibiotic effect in cerebrospinal fluid and Mueller-Hinton broth, 1154
- clindamycin
- in vivo efficacy, correlation with in vitro susceptibility, 997
 - mice, 997
- deglucateicoplanin amide derivatives
- uptake, mechanism of, 453
- DNA gyrase
- quinolones, mechanism of action, 839
- DNA gyrase A protein
- fluoroquinolones, single point mutation reduces binding, 126
- doxycycline
- comparative evaluation, 846
- epididymitis
- cefotaxime, comparative evaluation, 846
 - doxycycline, comparative evaluation, 846
 - ofloxacin, comparative evaluation, 846
 - fluoroquinolone resistant
 - gyrA*, mutations in, 696
 - fluoroquinolone resistant, nalidixic acid susceptible
 - gyrA* point mutation, novel, 1247
 - gentamicin
 - kill kinetics and regrowth patterns after exposure, 914
 - postantibiotic effect in cerebrospinal fluid and Mueller-Hinton broth, 1154
 - isoniazid
 - susceptibilities of *oxyR* regulon mutants, 2251
 - lactoferrin-porin interaction
 - antibacterial activity, effect on, 240
 - mutants
 - supersusceptibility to antibiotics, 2255
 - ofloxacin
 - comparative evaluation, 846
 - pefloxacin
 - one 800-mg versus two 400-mg doses, 737
 - plasmid complementation test
 - quinolone resistance, 2588
 - postantibiotic effect
 - correlation of tobramycin-induced inhibition of protein synthesis, 2678
 - quinolone resistance
 - plasmid complementation test, 2588
 - quinolones
 - DNA gyrase, mechanism of action, 839
 - in vivo efficacy, correlation with in vitro susceptibility, 997
 - mice, 997
 - S. aureus tetK*
 - expression in, 191
 - streptomycin resistance
 - bleomycin, increase of, 1982
 - tobramycin resistance
 - 3'-aminoglycoside phosphotransferase type I, overproduction of, 78
- Ethambutol
- Mycobacterium* spp.
 - glucose metabolism, inhibition of, 1536
 - synergy
 - amikacin, 1285
 - ciprofloxacin, 1285
 - M. malmoense*, 1285
 - rifampin, 1285
- Eubacterium* spp.
- DNA gyrase
 - cyclothialidine, characterization of, 2656
- FDA approvals
- anti-infective agents, biologics, and vaccines approved in 1992, 926
- FK037
- anaerobic organisms
 - in vitro activity, 957
 - B. burgdorferi*
 - in vitro susceptibility, 1444
 - β -lactamase stability, 566
 - in vitro activity, 566

- multicenter comparison, 1696
in vitro and in vivo activities
comparative evaluation, 301
- Flavimonas oryzae*
aminoglycosides
in vitro activities against clinical isolates from patients with cancer, 2504
- carbapenems
in vitro activities against clinical isolates from patients with cancer, 2504
- extended-spectrum cephalosporins
in vitro activities against clinical isolates from patients with cancer, 2504
- monobactams
in vitro activities against clinical isolates from patients with cancer, 2504
- ureidopenicillins
in vitro activities against clinical isolates from patients with cancer, 2504
- Floxacin
breast milk
penetration into, 293
combinations
rifampin, 2132
comparative evaluation
DU-6859a, 2747
in vitro activities
gram-negative organisms, 2017
gram-positive organisms, 2017
pharmacokinetics
breast milk, penetration into, 293
effects in healthy volunteers by
positron emission tomography, ^{18}F labeled, 2144
lactating women, 293
rifampin, influence of, 2132
S. aureus, 2132
- Fluconazole
bioavailability
patients with AIDS, 2187
C. albicans
emergence of resistance of Norwegian strains, 2443
patients infected with human immunodeficiency virus type 1, correlation to therapy and symptoms, 2449
C. glabrata resistance, 1962
C. neoformans
in vitro susceptibility, 1383
recurrent meningitis, isolates from patients with, 1383
comparative evaluation
amphotericin B, 2030
endocarditis
C. parapsilosis, 2030
C. tropicalis, 2030
intracellular activity
human polymorphonuclear leukocytes, 187
P. marneffei
response of human immunodeficiency virus-infected patients, 2407
pharmacokinetics
healthy human subjects, 1270
influence of radiotherapy on penetration into human saliva, 2674
patients with AIDS, 2187
- positron emission tomography, ^{18}F labeled, 1270
uptake in human polymorphonuclear leukocytes, 187
- T. glabrata*
prophylaxis in neutropenic bone marrow transplant patients, 1847
- Flucytosine
Candida spp.
temperature, effect on activity, 685
cis-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine
(-) and (+) enantiomers, 5'-triphosphates
human immunodeficiency virus, 1720
human immunodeficiency virus
(-) and (+) enantiomers, 5' triphosphates, 1720
- 5-Fluorocytosine
P. marneffei
response of human immunodeficiency virus-infected patients, 2407
- 5-Fluoroorotate
P. falciparum
clonal viability measurements to assess in vitro activity, 1102
- Fluoroquinolones
ciprofloxacin
reduced susceptibilities of *S. sonnei* strains, 2486
combinations
inhibitors of glycosylation and fatty acid and peptide biosynthesis, 652
M. avium, 652
CP-99,219
gram-positive organisms, in vitro activity, 366
in vitro activity, 349
DNA gyrase
E. coli A protein, single point mutation reduces binding, 126
DV-7751a
in vitro antibacterial activity, 2112
E-4868
in vitro and in vivo activities, 868
E. coli DNA gyrase A protein
single point mutation reduces binding, 126
E. coli resistance
gyrA, mutations in, 696
E. coli resistance, nalidixic acid susceptible
gyrA, novel point mutation, 1247
gram-positive cocci
bloodstream isolates, 896
in vitro activity, 896
M. pneumoniae, 1826
ofloxacin
reduced susceptibilities of *S. sonnei* strains, 2486
OPC-17116
accumulation by human polymorphonuclear leukocytes, 1882
penetration into bacterial cells
minireview, 1393
Q-35
in vitro and in vivo activities, 1826
reduced phototoxicity in mice irradiated with long-wavelength UV, 2217
S. aureus resistance
efflux mediated, 1086
NorA, multidrug efflux transporter, 128
- sparfloxacin
reduced susceptibilities of *S. sonnei* strains, 2486
- WIN 57273
E. faecalis, 2470
- Flurbiprofen
keratitis
age and therapeutic outcome, 1856
P. aeruginosa
age and therapeutic outcome, 1856
- Foscarnet
human immunodeficiency virus
cerebrospinal fluid of patients with AIDS, penetration of, 1777
human renal proximal tubule cells
nephrotoxicity, 2496
nephrotoxicity
human renal proximal tubule cells, 2496
pharmacokinetics
blood-brain barrier, penetration of, 1010
cerebrospinal fluid of patients with AIDS, penetration of, 1777
- Fosfomycin
B-lymphocyte function
immunomodulatory effect, 270
T cells
immunosuppressive effect, 2684
Fractional maximal effect method
antibiotic combinations
effect, characterization of, 523
nonlinear pharmacodynamics
characterization of, 523
- Fullerenes
human immunodeficiency virus
activity against, 1707
- Fusidic acid
combinations
S. aureus, 2466
vancomycin, 2466
M. kansasii
susceptibility testing, 1997
pharmacokinetics
intravenous, cholestatic patients, 501
- Fusobacterium* spp.
Bay Y3118
in vitro activity, 2509
- G418
T. brucei brucei resistance phenotype
in vivo system to select for bloodstream-form transfectants, 1167
- Gamma interferon
receptors
relation to therapy of typhoid fever, 2418
- Ganciclovir
cytomegalovirus
1110U81, potentiation of antiviral effects, 602
prophylaxis decreases frequency and severity in liver transplant recipients treated with OKT3 monoclonal antibodies, 2490
sensitivity at diagnosis and during treatment, 1360
cytomegalovirus resistance
point mutation in DNA polymerase gene, 19

- Gardnerella vaginalis*
 agar dilution
 susceptibilities to 25 antimicrobial agents, 2733
- Gentamicin
E. coli
 kill kinetics and regrowth patterns after exposure, 914
 postantibiotic effect in pooled cerebrospinal fluid and Mueller-Hinton broth, 1154
E. faecalis resistance, high level
 molecular characterization of isolates lacking high-level streptomycin resistance, 134
E. faecium resistance, 1904
E. faecium resistance, high level
 isolates from different continents, comparison of, 681
 glomerular basement membrane
 alteration of development after administration during gestation, 1510
M. avium complex
 AIDS patients with bacteremia, 1869
 nephrotoxicity
 neonates, drug-treated pregnant Wistar rats, 1510
 polyaspartic acid, protective effects, pharmacologic limits of, 347
P. aeruginosa
 A band and B band lipopolysaccharides, interaction with, 715
 pharmacokinetics
 increased renal uptake in endotoxemic rats receiving thromboxane A₂ therapy, 2727
 population pharmacokinetic models, comparison of, 93
 postantibiotic effect
E. coli, in pooled cerebrospinal fluid and Mueller-Hinton broth, 1154
S. mitis
 chromosomally mediated high-level resistance, 2740
 TLC G-65, 1869
- Giardia lamblia*
 bis-benzimidazoles
 correlation of anti-giardial activity, DNA binding affinity, and giardial topoisomerase II inhibition, 2668
 structure-activity studies, 2668
- Giardia* spp.
 benzimidazoles
 in vitro activity, 328
 tubulin inhibitors
 in vitro activity, 328
- Glucan
 irradiated mice, therapy for after adverse effects from pefloxacin, 1877
- Glucose oxidase
 human immunodeficiency virus type 1 virucidal effects, 26
- Glucose peroxidase
 human immunodeficiency virus type 1 virucidal effects, 26
- Glycopeptides
Enterococcus resistance
 genetics and mechanisms of, minireview, 1563
 gram-positive cocci
 bloodstream isolates, 896
 in vitro activity, 896
- Glycylcyclines
 comparative evaluation
 in vitro and in vivo activities, 2270
 minocycline and tetracycline, 2270
- Gonorrhea
 ceftriaxone
 single-dose therapy for women, comparative evaluation, 1670
 ciprofloxacin
 single-dose therapy for women, comparative evaluation, 1670
- GR99060
 antifungal activity, 1243
- GR99062
 antifungal activity, 1243
- Gram-negative organisms
 anaerobic
 Bay y3118, comparative susceptibilities, 1649
 azithromycin
 outer membrane permeability barrier, 354
 Bay y3118
 comparative susceptibilities, 1649
 biapenem
 in vitro activity, 2009
 CAP18
 in vitro activity, 2534
 clarithromycin
 outer membrane permeability barrier, 354
 CP-70,429
 in vitro activity, 1547
 imipenem
 in vitro activity, 2009
 outer membrane permeability barrier
 azithromycin, clarithromycin, and roxithromycin, 354
 roxithromycin
 outer membrane permeability barrier, 354
- Gram-positive organisms
 aerobic
 MDL 62,879, 746
 anaerobic
 Bay y3118, comparative susceptibilities, 1649
 Bay y3118
 comparative susceptibilities, 1649
 biapenem
 in vitro activity, 2009
 bloodstream isolates
 fluoroquinolones, 896
 glycopeptides, 896
 ramoplanin, 896
 CAP18
 in vitro activity, 2534
 CP-70,429
 in vitro activity, 1547
 CP-99,219
 in vitro activity, 366
 fluoroquinolones
 in vitro activity, 896
 glycopeptides
 in vitro activity, 896
 imipenem
 in vitro activity, 2009
 MDL 62,879
 aerobic, 746
 PD 138312
 in vitro activities, 2563
 PD 140248
 in vitro activities, 2563
- ramoplanin
 in vitro activity, 896
 RP59500
 in vitro activity, 598
 vancomycin resistant
 ramoplanin, 1364
 RP59500, 598
- Granulocyte colony-stimulating factor
 combinations
 clarithromycin, 692
M. avium complex, 692
M. avium complex, 692
- Granulocyte-macrophage colony-stimulating factor
 pharmacokinetics
 zidovudine, administration with, 512
- Griseofulvin
 comparative evaluation
 itraconazole, 2064
 tinea unguium, 2064
- 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid
 influenza viruses
 growth inhibition, 1473
 sialidase, inhibition of, 1473
- gyrA*
E. coli
 fluoroquinolone resistance, 696
 mutations in, 696
E. coli, fluoroquinolone resistant, nalidixic acid susceptible
 point mutation, novel, 1247
- Haemophilus ducreyi*
 chancroid, currently recommended and newer agents for
 in vitro susceptibilities, 1552
 isolates from the United States and Thailand, 1552
 parenteral and oral antimicrobial agents
 in vitro activities, 1986
- Haemophilus influenzae*
 ampicillin
 distribution in patients with lower respiratory tract infections, effect on, 804
 β -lactamase producing and nonproducing, ampicillin resistant
 amoxicillin-clavulanic acid, susceptibility to, 14
 cefaclor, susceptibility to, 14
 cefixime, susceptibility to, 14
 cefotaxime, susceptibility to, 14
 ceftibuten, susceptibility to, 14
 cefuroxime, susceptibility to, 14
 ciprofloxacin
 adherence changes induced by subinhibitory concentrations, 885
 ecology in sputum and saliva, 804
 erythromycin
 distribution in patients with lower respiratory tract infections, effect on, 804
 macrolides
 subinhibitory concentrations, influence on human neutrophil chemiluminescence, 1015
 sparfloxacin
 adherence changes induced by subinhibitory concentrations, 885
 trimethoprim
 adherence changes induced by subin-

- inhibitory concentrations, 885
Haemophilus parainfluenzae
 ampicillin
 distribution in patients with lower respiratory tract infections, effect on, 804
 ecology in sputum and saliva, 804
 erythromycin
 distribution in patients with lower respiratory tract infections, effect on, 804
Hafnia alvei
 cefazidime resistant
 β -lactamase producing, 1375
 Halofantrine
 P. falciparum, 1955
 efficacy in semi-immune patients in Cameroon, 1955
 P. falciparum resistance, 2337
Helicobacter pylori
 AG-2000
 urease activity, inhibition of, 769
 lansoprazole
 urease activity, inhibition of, 769
 metronidazole and its hydroxymetabolite synergy, 1184
 metronidazole's hydroxymetabolite-tetracycline-HCl synergy, 1184
 metronidazole's hydroxymetabolite-amoxicillin synergy, 1184
 metronidazole-tetracycline-HCl synergy, 1184
 metronidazole-amoxicillin synergy, 1184
 omeprazole
 urease activity, inhibition of, 769
 Hepatitis B virus
 antiviral agents
 assessment in vitro, high capacity, 441
 duck
 suramin, prevention of infection in vivo, 1539
 Hepatitis C virus
 alpha interferon treatment
 HCV RNA levels in patients with chronic infections, 595
 RNA levels
 patients with chronic infections receiving interferon treatment, 595
 Herpes simplex virus
 acyclovir and foscarnet resistant
 pencyclovir, 2241
 acyclovir resistant
 348-U87-acyclovir, 975
 ribonucleotide reductase inhibitor-acyclovir, 975
 acyclovir susceptibility
 strains from organ transplant recipients after acyclovir or ganciclovir prophylaxis, 357
 acyclovir-5-fluorodeoxyuridine-2-acetylpyridine thiosemicarbazone
 three-dimensional analysis of, 540
 pencyclovir
 in vitro activities, 2241
 Herpes simplex virus type 1
 acyclovir
 comparative evaluation, 642
 pencyclovir
 comparative evaluation, 642
 Herpesviruses
 acyclic nucleoside phosphonates
 (S) and (R) enantiomers, 332
 (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine, 332
 High-performance liquid chromatography
 carbenicillin epimers
 analysis in biological fluids, 2327
 Human immunodeficiency virus
 antiretroviral agents
 resistance to, minireview, 1207
 (-)-2',3'-dideoxy-5-fluoro-3'-thiacytidine
 characterization of, 875
 (-)-2',3'-dideoxy-3'-thiacytidine
 characterization of, 875
 foscarnet
 cerebrospinal fluid of patients with AIDS, penetration of, 1777
 fullerene, derivatized C₆₀
 activity of, 1707
 protease inhibitors
 allophenylnorstatine containing, in vitro activities, 810
 XM323
 in vitro activity, 2606
 Human immunodeficiency virus type 1
 3TC resistance
 conferred by same mutation that confers resistance to ddI and ddC, 1390
 A77003
 preclinical evaluation, 115
 protease inhibitor, 115
 anti-CD4-pokeweed antiviral protein immunconjugate
 in vitro activity, 835
 3'-azido-3'-deoxythymidine
 replication in human fetal brain macrophages, effect on, 1305
 C. albicans
 fluconazole resistance, 2449
 carbovir
 cellular metabolism, effects on, 1004
 metabolism, 1004
 carbovir-3'-azido-2',3'-deoxythymidine
 synergy, 144
 CGP 53437
 protease, inhibition of, 2087
 chimeric enzymes, inhibition of
 nucleoside inhibitors, 1037
 2'-deoxy-3'-thiacytidine resistance
 due to amino acid substitution at catalytic site of reverse transcriptase, 2231
 diarylsulfones
 mechanism of action, 754
 reverse transcriptase inhibitor, 754
 2',3'-dideoxy-3'-thiacytidine resistance
 generation of variants, 130
 2',3'-dideoxycytidine resistance
 generation of variants, 130
 drug susceptibility
 peripheral blood mononuclear cell culture assay, 1095
 fluconazole
 C. albicans resistance, 2449
 FTC
 5'-triphosphates of (-) and (+) enantiomers, 1720
 glucose oxidase and peroxidase
 virucidal effects, 26
 peripheral blood mononuclear cell culture assay
 drug susceptibility, determination of, 1095
 protease inhibitors
 A77003, 115
 reverse transcriptase inhibition
 nucleoside inhibitors, 1037
 reverse transcriptase inhibitor
 isolates resistant to related inhibitors, activity against, 947
 reverse transcriptase inhibitor resistance
 mutant enzyme and viral variant assessment, 1576
 reverse transcriptase inhibitors
 FTC, 5'-triphosphates of (-) and (+) enantiomers, 1720
 infectious amplification from lymphocytes and modulation, 2206
 S-2720, activity of, 1659
 S-2720
 inhibition of reverse transcriptase and viral replication, 1659
 thiazolo-iso-indolinones
 resistance, 2612
 U-90152
 replication, inhibition of, 1127
 zidovudine and didanosine resistant
 pol mutations, 1480
 zidovudine sensitivity
 discontinuation of zidovudine treatment, effects on, 1525
 Human immunodeficiency virus type 2
 chimeric enzymes, inhibition of
 nucleoside inhibitors, 1037
 Human renal proximal tubule cells
 nephrotoxicity
 in vitro studies, 2496
 Hydatid disease
 albendazole
 treatment of, 1679
 mebendazole
 treatment of, 1679
 (-)-9-[4-Hydroxy-2-(hydroxymethyl)butyl]guanine
 simian varicella virus
 African green monkeys, 1370
 (S)-1-(3-Hydroxy-2-phosphonyl-methoxypropyl)cytosine
 cytomegalovirus
 interstitial pneumonitis after bone marrow transplantation, 218
 Hydroxyitraconazole
 bioassay and chromatography, effect on, 2224
 itraconazole, metabolism of, 2224
 ICI 195,739
 combinations
 Chagas' disease, murine, 1353
 T. cruzi, 1353
 terbinafine, 1353
 Imipenem
 B. wadsworthii
 morphological response, 2638
 penicillin-binding protein patterns, 2638
 combinations
 amikacin, 1931
 cilastatin, 51
 P. aeruginosa, 1931
 yeast colonization of the human gastrointestinal tract, effect on, 51
 P. aeruginosa

- phenotypic resistance induced by salicylate, 2743
- pharmacodynamics
- P. aeruginosa*, 1931
- postantibiotic effect
- repeated exposures, 1723
- R. equi* resistance
- penicillin-binding proteins, potential role in, 1406
- Imipenem resistance
- P. aeruginosa*
- mechanism of efficient elimination of protein D2, 2385
- Immune globulin
- respiratory syncytial virus
- prophylaxis for high-risk infants, evaluation of, 1655
- Influenza virus
- rimantadine
- susceptibilities of subtypes A/H1N1 and A/H3N2, 2239
- Influenza viruses
- 4-guanidino-2,4-dideoxy-2,3-dehydro-*N*-acetylneuraminic acid
- growth inhibition, 1473
- sialidase, inhibition of, 1473
- Intercellular adhesion molecule 1
- E. coli*, expression in
- functional studies, 1278
- soluble
- function studies of, 1278
- Interleukin-6
- amphotericin B, 1958
- C. albicans*, 1958
- receptors
- relation to therapy of typhoid fever, 2418
- Interleukin-8
- nonspecific resistance to infection
- neutropenic and normal mice, 276
- Intestinal microflora
- anaerobic
- resistance patterns, 1665
- Isepamicin
- pharmacokinetics
- nephrotoxicity, influence on in rats, 2042
- ISIS 2922
- cytomegalovirus
- in vitro activity, 1945
- Isoniazid
- E. coli*
- susceptibilities of *oxyR* regulon mutants, 2251
- S. typhimurium*
- susceptibilities of *oxyR* regulon mutants, 2251
- Isoprinosine
- P. carinii*
- dihydropteroate synthetase inhibition, 1227
- Itraconazole
- A. fumigatus*
- efficacy in a rat model, 2762
- alveolar macrophages, uptake by, 903
- aspergillosis, 2307
- bioassay and chromatography, discrepancies in
- hydroxyitraconazole, metabolism to, 2224
- C. albicans*
- placebo-controlled trial, 89
- C. neoformans*
- effects on cytochrome P-450-dependent sterol 14 α -demethylation and reduction of 3-ketosteroids, 2101
- candidiasis, acute vaginal
- placebo-controlled trial, 89
- comparative evaluation
- amphotericin B, 2307
- griseofulvin, 2064
- interpatient variations in concentration, 2224
- P. marneffei*
- response of human immunodeficiency virus-infected patients, 2407
- pharmacokinetics
- food interaction, 778
- steady state, 778
- tinea unguis, 2064
- Ivermectins
- S. erythraea*
- glycosylation, microbial conversion by, 1737
- Keratitis
- ciprofloxacin
- age and therapeutic outcome, 1856
- flurbiprofen
- age and therapeutic outcome, 1856
- P. aeruginosa*
- age and therapeutic outcome, 1856
- prednisolone
- age and therapeutic outcome, 1856
- Ketoconazole
- combinations
- Chagas' disease, murine, 1353
- T. cruzi*, 1353
- terbinafine, 1353
- mevinolin
- T. cruzi*, potentiation of antiproliferative effects, 580
- P. marneffei*
- response of human immunodeficiency virus-infected patients, 2407
- Klebsiella pneumoniae*
- β -lactamase
- β -lactams, broad spectrum, resistance to, 984
- β -lactams, extended spectrum, resistance to, 2020
- ceftazidime resistance, 1989
- plasmid encoded, TEM derived, 2020
- plasmid mediated, AmpC type, transferable, 984
- cefoperazone-sulbactam resistance
- coexistence of two different resistance mechanisms, 1061
- cefazopran
- respiratory tract infection, 100
- ceftazidime resistance
- β -lactamase, 1989
- ciprofloxacin
- adherence changes induced by subinhibitory concentrations, 885
- interleukin-1-induced nonspecific resistance
- role of acute-phase proteins in studies with mice, 2527
- sparfloxacin
- adherence changes induced by subinhibitory concentrations, 885
- trimethoprim
- adherence changes induced by subinhibitory concentrations, 885
- KNI-227
- human immunodeficiency virus
- protease inhibitor, allophenylnorstatine containing, 810
- KNI-272
- human immunodeficiency virus
- protease inhibitor, allophenylnorstatine containing, 810
- KRM-1648
- M. avium*, 722
- L-696,229
- analogs
- human immunodeficiency virus isolates resistant to related inhibitors, 947
- human immunodeficiency virus
- isolates resistant to related inhibitors, activity against, 947
- Lactoferrin
- porin binding
- E. coli* antibacterial activity, relationship with, 240
- S. typhimurium* antibacterial activity, relationship with, 240
- Lansoprazole
- H. pylori*
- urease activity, inhibition of, 769
- Legionella micdadei*
- azithromycin
- inhibition of intracellular strains, 2261
- intracellular
- azithromycin inhibition, 2261
- Legionella* spp.
- RP 74501-RP 74502
- in vitro activity, 908
- Leishmania amazonensis*
- quinoline alkaloids
- 2 substituted, 859
- Leishmania donovani*
- amphotericin B
- T-cell-deficient mice, 1504
- leishmaniasis
- trans*-aconitic acid in combined chemotherapy, 2459
- licochalcone A
- inhibition of growth, 2550
- pentamidine
- T-cell-deficient mice, 1504
- trans*-aconitic acid
- role in combined chemotherapy for experimentally infected hamsters, 2459
- Leishmania major*
- licochalcone A
- inhibition of growth, 2550
- Leishmania mexicana*
- dinitroanilines
- structure-function analysis, 1909
- trifluralin, 1909
- Leishmania panamensis*
- sodium stibogluconate
- in vitro activities of fractions, 1842
- Leishmania* spp.
- 9-anilinoacridines
- in vitro activity, 991
- structure-activity relationships, 991
- quinoline alkaloids
- 2 substituted, 859
- Leishmania venezuelensis*
- quinoline alkaloids
- 2 substituted, 859

- Leishmaniasis
 cutaneous
 quinolone alkaloids, 2 substitut. j., 859
 quinoline alkaloids
 2 substituted, 859
 visceral
 amphotericin B, T-cell-deficient mice, 1504
 pentamidine, T-cell-deficient mice, 1504
- Leptospira interrogans*
 Q-35
 five serogroups, 901
- Letters to the editor
 aminoglycoside resistance genes
 nomenclature, 927
- Capnocytophaga* spp.
 antimicrobial susceptibilities, 1206
- cefotaxime
 S. pneumoniae breakpoint, 616
- dental amalgam
 multiple antibiotic resistance, 1730
- Nocardia* spp.
 susceptibility testing, 2514
- S. pneumoniae*
 cefotaxime breakpoint, 616
- susceptibility data
 multidimensional analysis, 929
- Leukemia
 enoxacin
 infection prevention in adults with
 nonlymphocytic leukemia, 474
- Leupeptin
 P. falciparum
 clonal viability measurements to as-
 sess in vitro activity, 1102
- Levofloxacin
 adverse effects
 convulsions in mice, 1764
 aluminum hydroxide
 inhibition of absorption by, 2173
 comparative evaluation
 accumulation by human polymor-
 phic leukocytes, 1882
 DU-6859a, 2747
 synergy
 oxacillin, 339
 S. aureus, quinolone resistant, 339
- Licochalcone A
 L. donovani
 inhibition of growth, 2550
 L. major
 inhibition of growth, 2550
- Lincomycin
 peptidyl-RNA
 accumulation, 2027
 dissociation from ribosomes, 2027
- Lipophilic agents
 penetration into bacterial cells
 minireview, 1393
- Liposomes
 ciprofloxacin, liposome incorporated
 treatment of murine salmonellosis,
 2293
- LJC 10,627
 toxicity
 central nervous systems of rats, low
 levels of, 199
- Lomefloxacin
 comparative evaluation
 DU-6859a, 2747
 pharmacodynamics
 concentration in plasma-time profile,
 relation to survival, 483
 neutropenic rat model of *Pseudomo-
 nas* sepsis, 483
 urinary tract infections
 3-day treatment, 574
 acute uncomplicated, 574
 comparative evaluation, 574
- Luciferase
 M. tuberculosis
 antimicrobial activity against, method
 for screening for, 1348
- Lyme disease
 clarithromycin
 hamsters, 1329
- Macrolides
 combinations
 inhibitors of glycosylation and fatty
 acid and peptide biosynthesis, 652
 M. avium, 652
 cytochrome P-450 complex formation
 rat and human livers, 265
 dirithromycin
 interactions with polymorphonuclear
 leukocytes, 2557
 H. influenzae
 subinhibitory concentrations, influence
 on human neutrophil chemilumi-
 nescence, 1015
 P. acidilactici resistance
 genetic basis for, 789
 P. aeruginosa
 serum sensitivity, effect of sub-MICs
 on, 675
- Magainins
 eicosanoid release
 rat peritoneal macrophages, effect on,
 393
- Magnesium-aluminum hydroxide
 rifaximin
 effects on absorption, 2212
- Malaria
 amproyloquin
 intramuscular, 970
 halofantrine
 efficacy in semi-immune patients in
 Cameroon, 1955
 mefloquine
 P. falciparum, 1977
 P. falciparum, 1955
 amproyloquin, 970
 mefloquine, 1977
- Mastitis
 bovine
 pirimycin, activity and disk diffusion
 breakpoints, 1122
 pirimycin
 activity against bovine pathogens,
 1122
 disk diffusion breakpoints, 1122
- MDL 62,879
 anaerobic bacteria, 746
 gram-positive organisms
 aerobic, 746
 in vitro activity, 741
- Mebendazole
 hydatid disease
 treatment of, 1679
- mec*
 Staphylococcus spp., methicillin resis-
 tant
 distribution of regulator genes in, 1219
- Mefloquine
 malaria
 comparison of two regimens, 1977
 P. falciparum
 comparative evaluation of two regi-
 mens, 1977
- Meningitis
 pneumococcal, penicillin and cephalo-
 sporin resistant
 treatment regimens, evaluation of,
 1630
 recurrent cryptococcal
 susceptibility of *C. neoformans* iso-
 lates to amphotericin B and flu-
 conazole, 1383
- Mercury
 bacterial resistance
 letter to the editor, 1730
 mercury from dental fillings provokes
 increased occurrence, 825
- Meropenem
 P. cepacia
 comparative evaluation, 123
 pharmacokinetics
 patients with various degrees of renal
 function, 229
- Metabolic disposition
 (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-
 1,3-oxathiolan-5-yl] cytosine
 studies with rats, 2285
- Methicillin
 S. aureus resistance
 abnormal peptidoglycan, 342
 β -lactam- β -lactamase inhibitor combi-
 nations, 702
 β -lactams, 702
 penicillin-binding protein 2A, role in
 cell wall synthesis, 342
 S. aureus resistance and susceptibility
 sequential acquisition of norfloxacin
 and ofloxacin resistance in iso-
 lates, 2278
 Staphylococcus resistance
 mec regulator genes, distribution of,
 1219
- Metronidazole
 synergy
 amoxicillin, 1184
 H. pylori, 1184
 hydroxymetabolite of metronidazole,
 1184
 tetracycline-HCl, 1184
- Mevinolin
 T. cruzi
 ketoconazole and terbinafine, potentia-
 tion of antiproliferative effects,
 580
- Miconazole
 P. marneffei
 response of human immunodeficiency
 virus-infected patients, 2407
- Microdilution checkerboard method
 synergy measurement
 reproducibility, 613
- Minireviews
 β -lactamases
 induction of, molecular basis for, 153
 β -lactams
 penicillin-binding protein resistance,
 2045
 C. neoformans
 susceptibility testing, status of the
 standardization process, 2517

- Candida* spp.
susceptibility testing, status of the standardization process, 2517
- Enterococcus* spp.
glycopeptide resistance, genetics and mechanisms of, 1563
- glycopeptides
Enterococcus resistance, genetics and mechanisms of, 1563
- human immunodeficiency virus
antiretroviral agents, resistance to, 1207
- lipophilic agents with multiple protonation sites
penetration into bacterial cells, 1393
- new antibiotics
discovery and development, problem of resistance, 377
- nosocomial pneumonia
critically ill patients, prevention of, 931
- organ transplant recipients
antimicrobial strategies, 619
- penicillin-binding proteins
 β -lactam resistance, 2045
- Q fever
treatment of, 1733
- rifampin
nonstaphylococcal, nonmycobacterial disease, 1
- Minocycline
combinations
clarithromycin, 1690
M. avium, prophylaxis in mice, 1690
rifabutin, 1690
M. avium
erratum, 2515
- Monobactams
F. oryzihabitans
in vitro activities against clinical isolates from patients with cancer, 2504
- Moraxella catarrhalis*
ciprofloxacin
adherence changes induced by subinhibitory concentrations, 885
- sparfloxacin
adherence changes induced by subinhibitory concentrations, 885
- trimethoprim
adherence changes induced by subinhibitory concentrations, 885
- Mupirocin
S. aureus resistance, high level
isoleucyl-tRNA synthetases, evidence for two distinct, 32
- Mupirocin resistance
S. aureus
detection and characterization, 2003
- Mureidomycins
bacterial translocase reaction in peptidoglycan synthesis, inhibition of, 980
- Murine leukemia virus
protease inhibitors
antiretroviral activity, 71
- Mutagenicity
quinolones
Ames *Salmonella* TA102 assay, 213
- Mycobacterium avium*
activities of quinolones
erratum, 2766
- aminoglycosides
combination with inhibitors of glycosylation and fatty acid and peptide biosynthesis, 652
- azithromycin resistance
clarithromycin, 2364
cross-resistance, 2364
- clarithromycin
erratum, 2515
human macrophages, 111
macrophages, inhibition of intracellular growth, 1380
prophylaxis in C57BL/6 mice, 1690
- clarithromycin resistance
azithromycin, 2364
cross-resistance, 2364
- clarithromycin-minocycline
prophylaxis in C57BL/6 mice, 1690
- fluoroquinolones
combination with inhibitors of glycosylation and fatty acid and peptide biosynthesis, 652
- KRM-1648, 722
- macrolides
combination with inhibitors of glycosylation and fatty acid and peptide biosynthesis, 652
- minocycline
erratum, 2515
- quinolones
in vitro activities, 1799
structure-activity relationship studies, 1807
- rifabutin
erratum, 2515
prophylaxis in C57BL/6 mice, 1690
- rifabutin-minocycline
prophylaxis in C57BL/6 mice, 1690
- Mycobacterium avium* complex
azithromycin
rats treated with cyclosporine, 398
benzoxazinorifamycin
radiometric method, determination by, 67
- clarithromycin, 692
- gentamicin
AIDS patients with bacteremia, 1869
TLC G-65, 1869
- granulocyte colony-stimulating factor, 692
- granulocyte colony-stimulating factor-clarithromycin, 692
- rifabutin
rats treated with cyclosporine, 398
- rifapentine
rats treated with cyclosporine, 398
- RU-40555, 692
- RU-40555-clarithromycin, 692
- Mycobacterium avium*-*M. intracellulare* complex
clofazimine
in vitro activities, 2584
- resorcinomycin
in vitro activities, 2584
- Mycobacterium fortuitum*
amikacin
postantibiotic effect, 1001
- ofloxacin
postantibiotic effect, 1001
- Mycobacterium haemophilum*
amikacin
in vitro activities, 2323
- azithromycin
in vitro activities, 2323
- ciprofloxacin
in vitro activities, 2323
- clarithromycin
in vitro activities, 2323
- clofazimine
in vitro activities, 2323
- erythromycin
in vitro activities, 2323
- ofloxacin
in vitro activities, 2323
- rifabutin
in vitro activities, 2323
- rifampin
in vitro activities, 2323
- sparfloxacin
in vitro activities, 2323
- Mycobacterium kansasii*
susceptibility testing
azithromycin, 1997
clarithromycin, 1997
fusidic acid, 1997
ofloxacin, 1997
sparfloxacin, 1997
- Mycobacterium leprae*
rifampin resistance
molecular basis, 414
- Mycobacterium mageritense*
ethambutol
ciprofloxacin, amikacin, rifampin, synergy with, 1285
- susceptibility to antibacterial drugs and drug combinations, 1285
- Mycobacterium paratuberculosis*
rifabutin
systemic infection in mice, 1645
- Mycobacterium* spp.
AM-1155
in vitro activity, comparative evaluation, 1259
- ethambutol
glucose metabolism, inhibition of, 1536
- roxithromycin
in vitro activity, 1560
pH, effect on radiometric MICs, 1560
- Mycobacterium tuberculosis*
antimicrobial activity
method for screening for, 1348
- CGI 17341
in vitro and in vivo activities, 183
- clofazimine
in vitro activities, 2584
- luciferase expressing
antimicrobial activity against, method for screening for, 1348
- multidrug resistant
studies with mice, 2344
- polymerase chain reaction
detection, 2054
- resorcinomycin
in vitro activities, 2584
- rifampin resistant
detection, 2054
- single-strand conformation polymorphism analysis
detection, 2054
- sparfloxacin, 407
- Mycoplasma bovis*
antimicrobial susceptibilities, 317
- Mycoplasma dispar*
antimicrobial susceptibilities, 317

- Mycoplasma fermentans*
susceptibility testing
in vitro strains from AIDS patients, 2500
in vitro strains from non-AIDS patients with acute respiratory disease, 2500
tissue culture, 2500
- Mycoplasma hominis*
OPC 17116
susceptibility in vitro, 1726
- Mycoplasma pneumoniae*
ciprofloxacin
hamsters, 287
ofloxacin
hamsters, 287
OPC 17116
susceptibility in vitro, 1726
Q-35
in vitro and in vivo activities, 1826
temafloxacin
hamsters, 287
- Myeloperoxidase
C. albicans
human recombinant, candidicidal activity, 142
human recombinant
C. albicans, candidicidal activity, 142
- Neisseria gonorrhoeae*
ciprofloxacin
antibacterial activities, 2244
ofloxacin
antibacterial activities, 2244
in vitro susceptibilities, 2007
OPC-17116
antibacterial activities, 2244
- Neisseria meningitidis*
ofloxacin
single doses to eradicate tonsillopharyngeal carriage in Norway, 2024
penicillin susceptible, moderately
isolation in Argentina, 1728
- Nephrotoxicity
gentamicin
neonates, drug-treated pregnant Wistar rats, 1510
- Netilmicin
combinations
ceftriaxone, 1971
endocarditis, 1971
diltiazem
nephrotoxicity in rabbits, effects on, 1790
synergy
ceftriaxone, 207
streptococcal endocarditis, 207
- Nevirapine
pharmacokinetics
single-rising-dose study in humans, 178
- Nitrofurazone
urinary tract infections
catheter associated, 2033
- Nitroimidazoles
CGI 17341
M. tuberculosis, 183
M. tuberculosis
CGI 17341, 183
- NM394
antibacterial activity, 793
- Nocardia brasiliensis*
rifampin
inactivation of, 1313
- Nocardia farcinica*
 β -lactamases
characterization, 1850
- Nocardia* spp.
antimicrobial susceptibilities in vitro, 882
susceptibility testing
letter to the editor, 2514
- Norfloxacin
urinary tract infections
3-day treatment, 574
acute uncomplicated, 574
comparative evaluation, 574
- Northern (RNA) blot analysis
C. albicans
picolinic acid, protective effect on mice, 2422
- Novobiocin
combinations
ciprofloxacin, 1904
E. faecium, 1904
rifampin, 1334
S. aureus, methicillin resistant, eradication of, 1334
E. faecium
in vitro activity against multiresistant strains, 2736
- NP-1
C. neoformans
fungicidal properties, 2628
in vitro activity, 2628
- Ofloxacin
B. burgdorferi
in vitro susceptibility, 1444
combinations
Brucella spp., 1831
rifampin, 1214, 1831
Staphylococcus-infected orthopedic implants, 1214
comparative evaluation
accumulation by human polymorphonuclear leukocytes, 1882
ciprofloxacin, 2193
DU-6859a, 2747
E. coli
comparative evaluation, 846
epididymitis, 846
epididymitis
comparative evaluation, 846
E. coli, 846
in vitro activities
gram-negative organisms, 2017
gram-positive organisms, 2017
M. fortuitum
postantibiotic effect, 1001
M. haemophilum
in vitro activities, 2323
M. kansasii
susceptibility testing, 1997
M. pneumoniae
hamsters, 287
N. gonorrhoeae
antibacterial activities, 2244
in vitro susceptibilities, 2007
N. meningitidis
single doses to eradicate tonsillopharyngeal carriage in Norway, 2024
pharmacokinetics
bioequivalence after multiple doses to healthy volunteers, 1468
multiple oral doses to healthy volunteers, 2193
postantibiotic effect
M. fortuitum, 1001
serum bactericidal titers
multiple oral doses to healthy volunteers, 2193
- Omeprazole
H. pylori
urease activity, inhibition of, 769
- OPC 17116
M. hominis
susceptibility in vitro, 1726
M. pneumoniae
susceptibility in vitro, 1726
U. urealyticum
susceptibility in vitro, 1726
- OPC-17116
C. pneumoniae
in vitro and in vivo activities, 801
C. psittaci
in vitro and in vivo activities, 801
C. trachomatis
in vitro and in vivo activities, 801
comparative evaluation
accumulation by human polymorphonuclear leukocytes, 1882
N. gonorrhoeae
antibacterial activities, 2244
- Ophthalmitis
sparfloxacin
rabbit model, efficacy in, 633
- Oral flora
mercury resistant
mercury from dental fillings provokes increased occurrence, 825
- Oral microflora
anaerobic
resistance patterns, 1665
- Organ transplant patients
antimicrobial strategies
minireview, 619
- Ornidazole
concentrations in plasma during liver transplantation, 1873
tissue penetration during liver transplantation, 1873
- Orthopedic implants
Staphylococcus infections
rifampin-ofloxacin, 1214
- Otitis media
S. pneumoniae, penicillin resistant
amoxicillin, increased dosages of, 1599
- Oxacillin
endocarditis
S. aureus, β -lactamase hyperproducing, 507
S. aureus
 β -lactamase hyperproducing, 507
synergy
levofloxacin, 339
S. aureus, quinolone resistant, 339
- Oxidase inhibitors
P. berghei
drug susceptibility, enhancement of, 1318
P. falciparum
drug susceptibility, enhancement of, 1318

- Panipenem
P. aeruginosa, 322
 diffusion through outer membrane, role of OprD protein, 322
 phenotypic resistance induced by salicylate, 2743
- Papillomavirus
 E2 mRNA
 phosphorothioate oligonucleotides, potential treatment for genital warts, 171
 phosphorothioate oligonucleotides E2 mRNA, potential treatment for genital warts, 171
- Pasteurella multocida*
 Tet H
 active efflux of tetracycline, 2699
- PBP 2a
S. aureus
bla and *blaR1*, regulation by, 1144
- PD 127391
P. cepacia
 comparative evaluation, 123
- PD 131628
P. cepacia
 comparative evaluation, 123
- PD 138312
 gram-positive organisms
 in vitro activities, 2563
- PD 140248
 gram-positive organisms
 in vitro activities, 2563
- Pediococcus acidilactici*
 macrolide resistance
 genetic basis for, 789
- Pediococcus* spp.
 antimicrobial susceptibilities, 789
- Pefloxacin
 bactericidal activities
 one 800-mg versus two 400-mg doses, 737
 irradiated mice, adverse effects on and glucan therapy for, 1877
 pharmacokinetics
 one 800-mg versus two 400-mg doses, 737
- Penciclovir
 herpes simplex virus type 1
 comparative evaluation, 642
- Pencyclovir
 herpes simplex virus
 acyclovir and foscarnet resistant, 2241
 in vitro activities, 2241
 herpes simplex virus resistance
 pencyclovir, 2241
- Penems
 CP-70,429
 β -lactamase stability and in vitro activity, 1547
- Penicillin
E. faecium resistance
 time-kill studies, 2427
 haptenation
 serum proteins, facilitation of, 1463
N. meningitidis, moderately susceptible isolation in Argentina, 1728
S. mutans
 in vitro susceptibility, 1158
 synergy
 gentamicin, 2427
- Penicillin V
 tonsillopharyngitis, streptococcal
 comparative evaluation, 1620
- Penicillin-binding proteins
B. wadsworthia
 inhibition by imipenem, 2638
 β -lactam resistance
 minireview, 2045
 expression of a novel membrane protein and increased expression of penicillin-binding protein 2 complex, 2432
 minireviews
 β -lactam resistance, 2045
- R. equi*
 imipenem resistance, potential role in, 1406
- S. aureus*
bla and *blaR1*, regulation by, 1144
 cell wall synthesis, role in, 342
- S. pneumoniae*
 2B and 2X, genetic diversity of, 1938
- Penicillium marneffei*
 human immunodeficiency virus
 response of patients to antifungal therapy, 2407
- Pentamidine
L. donovani
 T-cell-deficient mice, 1504
 leishmaniasis, visceral
 T-cell-deficient mice, 1504
- Peptide antibiotics
 AS-48
 neutralizing antibodies, immunocytological studies, 148
 MDL 62,879
 in vitro activity, 741
- Peptidoglycan synthesis inhibitors
 mureidomycins
 bacterial translocase reaction, inhibition of, 980
- Peptostreptococcus* spp.
 Bay Y3118
 in vitro activity, 2509
- Peripheral blood mononuclear cell culture assay
 human immunodeficiency virus
 drug susceptibility, determination of, 1095
- Peritonitis
 bacterial, spontaneous
 ceftriaxone versus cefonicid, 1587
- cefonicid
 comparative evaluation, 1587
- ceftriaxone
 comparative evaluation, 1587
- Pharmacokinetics
 3'-deoxy-2',3'-didehydrothymidine
 disposition and metabolism in hepatocytes and nonhuman primates, 1816
 allopurinol riboside
 probenecid, effects of, 1193
 alpha interferon
 transplacental passage, two assay techniques, 1232
- amikacin
 attachment to collagen for local delivery in wounds, 1890
 patients with septic multiple-organ failure during intermittent hemofiltration, 464
- amoxicillin
 local gastric and serum concentrations after different oral applications, 1506
- azithromycin
 pediatric patients, multiple oral doses of suspension, 314
- carbenicillin epimers
 stereoselective renal tubular secretion, 2327
- cefazolin
 protein binding in rats, 1781
- cefepime
 cystic fibrosis patients, 1414
- cefixime
 biliary excretion in patients with T-tube drainage, 1488
- cefonicid
 protein binding in adult and neonatal sera, 1343
- cefotaxime
 cerebrospinal fluid of patients with uninfamed meninges, passage into, 1518
- cefpodoxime proxetil
 studies with patients receiving continuous ambulatory peritoneal dialysis, 2650
- cefprozil
 tonsillar and adenoidal tissues, penetration into, 1180
- ceftazidime
 patients with septic multiple-organ failure during intermittent hemofiltration, 464
 serum bactericidal activities, 1835
 side effects, 1835
- ceftriaxone
 cerebrospinal fluid of patients with uninfamed meninges, passage into, 1518
 elimination, effect of plasmapheresis, 1171
 liver transplantation, 1873
 pregnant women, 54
 protein binding during pregnancy, 54
- cefuroxime
 protein binding in adult and neonatal sera, 1343
- ciprofloxacin
 effects of cardiopulmonary bypass surgery on disposition, 2106
 healthy volunteers, multiple oral doses, 2193
 seriously ill patients, 1073
 (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine
 studies with rats, 2285
- clindamycin
 bioavailability, 1137
 healthy volunteers and AIDS patients, 1137
- diminazine
 Boran cattle, noninfected and infected with *T. congolense*, 1050
- enoxacin
 oral antacids, effect on disposition, 775
- floxacin
 breast milk, penetration into, 293
 effects in healthy volunteers by positron emission tomography, ¹⁸F labeled, 2144
 lactating women, 293
 rifampin, influence of, 2132
- fluconazole
 healthy human subjects, 1270

- influence of radiotherapy on penetration into human saliva, 2674
 patients with AIDS, 2187
 positron emission tomography, ^{18}F labeled, 1270
 uptake in human polymorphonuclear leukocytes, 187
- foscarnet
 blood-brain barrier, penetration of, 1010
- fusidic acid
 intravenous, cholestatic patients, 501
- gentamicin
 increased renal uptake in endotoxemic rats receiving thromboxane A_2 therapy, 2727
 population pharmacokinetic models, comparison of, 93
 patients with AIDS and severe AIDS-related complex, 512
- isepamicin
 nephrotoxicity, influence on in rats, 2042
- itraconazole
 alveolar macrophages, uptake by, 903
 food interaction, 778
 steady state, 778
- lomefloxacin
 concentration in plasma-time profile, relation to survival, 483
 neutropenic rat model of *Pseudomonas* sepsis, 483
- meropenem
 patients with various degrees of renal function, 229
- nevirapine
 single-rising-dose study in humans, 178
- nonparametric expectation maximization
 oncology patients receiving aminoglycoside therapy, 1025
- ofloxacin
 bioequivalence after multiple doses to healthy volunteers, 1468
 healthy volunteers, multiple oral doses, 2193
- ornidazole
 liver transplantation, 1873
- pefloxacin
 one 800-mg versus two 400-mg doses, 737
- piperacillin
 healthy volunteers, 1860
- piperacillin-tazobactam
 healthy volunteers, 1860
- population
 ciprofloxacin, optimal sampling strategies, 1065
 nonparametric approach, 1025
- ribavirin
 children with human immunodeficiency virus infection, 532
- rifampin
 fleroxacin, influence on, 2132
 zidovudine, interaction with, 1426
- rufoxacin
 biliary excretion in humans, 2545
 patients with impaired renal function, 637
- S-1108
 safety of and carnitine status of patients, 1043
- S. aureus*
 fleroxacin-rifampin, 2132
 SCE-2787
 serum bactericidal activities, 1835
 side effects, 1835
- sparfloxacin
 ocular penetration in rabbits with ophthalmitis, 633
- stavudine
 cynomolgus monkeys, 1160
- teicoplanin
 evaluation of a fluorescence polarization immunoassay, 1924
 prophylaxis in monolateral and bilateral total knee replacement procedures, 2693
- ticarcillin-clavulanic acid
 healthy volunteers, 1860
- trimethoprim-sulfamethoxazole
 12/60 mg/kg/day, multiple dose, 448
 healthy volunteers, 448
- vancomycin
 obesity, effect on, 436
 pulmonary lining fluid, penetration into, 281
 serum protein-binding characteristics, 1132
- zidovudine
 effects of standard breakfast in patients with AIDS, 2153
 prodrugs, enhanced levels in brain tissue, 818
 rifampin, interaction with, 1426
 zidovudine-granulocyte-macrophage colony-stimulating factor
 patients with AIDS and severe AIDS-related complex, 512
- Pharyngitis
 cefuroxime axetil suspension
 comparative evaluation, 159
Streptococcus spp., group A
 cefuroxime axetil suspension, comparative evaluation, 159
 (R)-9-(2-Phosphonomethoxypropyl)-2,6-diaminopurine
 herpesviruses, 332
 retroviruses, 332
- Phosphorylmethoxyalkyl derivatives
 cytomegalovirus resistance
 point mutation in DNA polymerase gene, 19
- Phosphorothioate oligodeoxynucleotides
 Epstein-Barr virus
 inhibition of replication, 1420
- Picolinic acid
C. albicans
 protective effect on mice, 2422
- Picornavirus
 capsid binders
 detection with soluble intercellular adhesion molecule 1, 1693
- Piperacillin
 combinations
 comparative evaluation, 1580
 skin and skin structure infections, 1580
 tazobactam, 1580, 2578
 pharmacokinetics
 healthy volunteers, 1860
- Piperacillin-tazobactam
 pharmacokinetics
 healthy volunteers, 1860
- Pirlimycin
 bovine mastitis, isolates from
 activity of, 1122
 disk diffusion breakpoints, 1122
- Plasmids
 R751
 multidrug resistance to antiseptics and disinfectants, 761
 resistance
S. aureus, 2003
- Plasmodium berghei*
 oxidase inhibitors
 drug susceptibility, enhancement of, 1318
- Plasmodium falciparum*
 5-fluoroorotate
 clonal viability measurements to assess in vitro activity, 1102
- ampropyroquin
 malaria treatment, 970
- chloroquine
 clonal viability measurements to assess in vitro activity, 1102
- chloroquine resistant
 9-anilinoacridines, 403
- clonal viability measurements
 leupeptin, chloroquine, and 5-fluoroorotate, in vitro activity, 1102
- cross-resistance patterns, 2337
- cycloguanil
 African isolates, 924
- halofantrine resistance, 2337
- leupeptin
 clonal viability measurements to assess in vitro activity, 1102
- malaria
 ampropyroquin, 970
 halofantrine, 1955
 mefloquine, 1977
- mefloquine
 malaria treatment, 1977
- oxidase inhibitors
 drug susceptibility, enhancement of, 1318
- Platelet microbicidal protein
C. neoformans
 fungicidal activity, 546
- Candida* spp.
 fungicidal activity, 546
- Pneumocystis carinii*
 8-aminoquinolones
 in vivo and in vitro studies, 2166
- amsacrine
 activity in vitro and in a mouse model, 1543
- bis-benzimidazoles
 pneumonia, treatment of, 1713
- biguanide folate antagonist
 PS-15, immunosuppressed rat model, 1417
- bilobalide
 in vitro and in vivo activities, 1492
- camptothecin
 activity in vitro and in a mouse model, 1543
- dihydrofolate reductase inhibitors and dapsone
 synergy, 1436
- dihydrofolate reductase inhibitors and sulfamethoxazole
 synergy, 1436
- epipodophyllotoxins
 activity in vitro and in a mouse model,

- 1543
isoprinosine
dihydropteroate synthetase inhibition, 1227
pneumonia
bis-benzimidazoles, cationically substituted, activity of, 1713
PS-15
folate antagonism, 1417
immunosuppressed rat model, 1417
quinolones
activity in vitro and in a mouse model, 1543
Ro 11-8958-dapsone
synergy, 1436
Ro 11-8958-sulfamethoxazole
synergy, 1436
topoisomerase inhibitors
activity in vitro and in a mouse model, 1543
Pneumonia
cytomegalovirus
ganciclovir sensitivity at diagnosis and during treatment, 1360
nosocomial
critically ill patients, prevention of, 931
minireview, 931
Pneumonitis
cytomegalovirus
(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine, 218
Poloxamers
T. gondii, 2265
toxoplasmosis, 2265
Poly(I):poly(C₁₂U)
biologic effects
healthy volunteers, 429
Polyspartic acid
gentamicin
nephrotoxicity, protective effects, pharmacologic limits of, 347
nephrotoxicity
gentamicin, protective effects, pharmacologic limits of, 347
Polymerase chain reaction
E. faecalis
heterogeneity of chloramphenicol acetyltransferase genes, 2593
E. faecium
heterogeneity of chloramphenicol acetyltransferase genes, 2593
M. tuberculosis
rifampin resistant, 2054
S. pneumoniae
heterogeneity of chloramphenicol acetyltransferase genes, 2593
Polymorphonuclear leukocytes
dirithromycin
interactions may promote killing of infecting organisms, 2557
suramin
suppression of bactericidal activity, 495
Porphyromonas spp.
Bay Y3118
in vitro activity, 2509
Positron emission tomography
floxacin
pharmacokinetics, ¹⁸F labeled, 2144
pharmacokinetics
floxacin, ¹⁸F labeled, 2144
fluconazole, ¹⁸F labeled, 1270
Postantibiotic effect
benzylpenicillin
Bioscreen C, 2200
Streptococcus and *Pneumococcus* spp., 2200
E. coli
correlation of tobramycin-induced inhibition of protein synthesis, 2678
imipenem
repeated exposure to, 1723
temafloxacin
repeated exposure to, 1723
tobramycin
hyperoxia, prolongation by, role of reactive oxygen species, 120
P. aeruginosa, 120
repeated exposure to, 1723
Prednisolone
keratitis
age and therapeutic outcome, 1856
P. aeruginosa
age and therapeutic outcome, 1856
Prevotella spp.
Bay Y3118
in vitro activity, 2509
Pristinamycin resistance
S. aureus
isolates responsible for outbreak in Parisian hospital, 2159
Probenecid
allopurinol riboside
pharmacokinetics, effects on, 1193
Protease inhibitors
human immunodeficiency virus
in vitro activity of XM323, 2606
murine leukemia virus
antiretroviral activity, 71
simian immunodeficiency virus
antiretroviral activity, 71
PS-15
P. carinii
folate antagonism, 1417
immunosuppressed rat model, 1417
Pseudomonas aeruginosa
6'-N-acetyltransferase
aac(6')-Ib, characterization of, 1456
antiflagella monoclonal antibodies
therapeutic effects in a murine model, 164
ant(4')-IIa
nucleotide sequence analysis and DNA hybridization studies, 708
aztreonam, 308
aztreonam-amikacin, 308
 β -lactamase
extended spectrum, characterization of, 962
OXA-11, extended-spectrum variant of OXA-10, 1637
biapenem
phenotypic resistance induced by salicylate, 2743
biofilms
clarithromycin, interaction with, 1749
inhibition of formation on prosthetic devices by proteolytic enzymes, 2618
BO-2727
in vitro activity, 2756
carbapenem resistance
cephalosporinase, role in, 1387
cefoperazone-sulbactam
granulocytopenic mice, disseminated infections in, 1927
ceftazopran
urinary tract infection, 100
ceftazidime, 308
ceftazidime-amikacin, 308
ciprofloxacin
age and therapeutic outcome, 1856
dose-ranging and fractionation, 1756
in vitro model of infection, 1756
increased susceptibility in the presence of vancomycin, 2506
resistance to unrelated antibiotics, effects on, 1289
clarithromycin
biofilms, interaction with, 1749
deglycoteicoplanin amide derivatives
uptake, mechanism of, 453
erythromycin
sub-MICs, effect on serum sensitivity, 675
flurbiprofen
age and therapeutic outcome, 1856
gentamicin
A band and B band lipopolysaccharides, interaction with, 715
imipenem
phenotypic resistance induced by salicylate, 2743
imipenem resistance
mechanism of efficient elimination of protein D2, 2385
imipenem-amikacin
in vitro pharmacodynamic effects, 1931
interleukin-1-induced nonspecific resistance
role of acute-phase proteins in studies with mice, 2527
keratitis
age and therapeutic outcome, 1856
macrolides
sub-MICs, effect on serum sensitivity, 675
panipenem, 322
diffusion through outer membrane, role of OprD protein, 322
phenotypic resistance induced by salicylate, 2743
postantibiotic effect
tobramycin, prolongation by hyperoxia, role of reactive oxygen species, 120
prednisolone
age and therapeutic outcome, 1856
tobramycin
postantibiotic effect, prolongation by hyperoxia, role of reactive oxygen species, 120
vancomycin
increased susceptibility to ciprofloxacin, 2506
Pseudomonas cepacia
 β -lactamase
strain 249 chromosomal penicillinase, member of AmpC family, 667
ceftazidime
comparative evaluation, 123
chloramphenicol
comparative evaluation, 123
ciprofloxacin
comparative evaluation, 123
co-trimoxazole
comparative evaluation, 123

- meropenem
comparative evaluation, 123
PD 127391
comparative evaluation, 123
PD 131628
comparative evaluation, 123
Pseudomonas pseudomallei
ceftazidime resistance
biofilm cells, 2000
co-trimoxazole
biofilm cells, 2000
Pulsed-field gel electrophoresis
enterococci
characterization of glycopeptide-resistant isolates from U.S. hospitals, 2311
Pyrimethamine
combinations
azithromycin, 1993
T. gondii, 1993
creatinine secretion, renal inhibition of, 1056
Pyrimido[1,6- α]benzimidazoles
D. melanogaster
effects on topoisomerase II and Kc cells, 2599
Q-35
L. interrogans
five serogroups, 901
M. pneumoniae
in vitro and in vivo activities, 1826
mice irradiated with long-wavelength UV
reduced phototoxicity, 2217
Q fever
C. burnetii
minireview, 1733
treatment of
minireview, 1733
Quinapyramine
T. congolense, resistant clone
derivation and characterization, 1163
Quinoline alkaloids
2 substituted
L. amazonensis, 859
L. venezuelensis, 859
leishmaniasis, cutaneous, 859
L. amazonensis, 859
L. venezuelensis, 859
leishmaniasis, 859
Quinolones
1-8 bridged
topoisomerase II, stereospecificity for the C-11 methyl group, 646
AM-1155
antimycobacterial activities, comparative evaluation, 1259
Ames *Salmonella* TA102 assay
bacterial mutagenicity, 213
antibiotic carryover
antibiotic-removal beads, elimination with, 1377
anti-*M. avium* activities
erratum, 2766
B. fragilis
in vivo efficacy, correlation with in vitro susceptibility, 997
mice, 997
Bay y 3118
broth macrodilution assays, 2348
C. jejuni resistance
DNA gyrase mutations, characterization of, 457
cefazolin-induced seizures
DBA/2 mice, potentiation of, 1497
CI-960
C. trachomatis salpingitis, 8
combinations
Brucella spp., 1831
comparative evaluation, 1831
CP-115,953
activities against mammalian systems, comparative evaluation, 2179
DNA gyrases
E. coli, mechanism of action, 839
E. coli
DNA gyrase, mechanism of action, 839
in vivo efficacy, correlation with in vitro susceptibility, 997
mice, 997
E. coli resistance
plasmid complementation test, 2588
M. avium
in vitro activities, 1799
structure-activity relationship studies, 1807
M. pneumoniae
hamsters, 287
NM394
antibacterial activity, 793
OPC 17116
M. hominis, *M. pneumoniae*, and *U. urealyticum*, 1726
P. carinii
activity in vitro and in a mouse model, 1543
PD 138312
in vitro activities, 2563
PD 140248
in vitro activities, 2563
proconvulsant effects
DBA/2 mice, 1497
T-3761
in vitro and in vivo activities, 384
topoisomerase II
stereospecificity for the C-11 methyl group, 646
topoisomerase II and cultured cells, activities against, 2179
R751
integron
multidrug resistance to antiseptics and disinfectants, 761
Ramoplanin
gram-positive organisms
bloodstream isolates, 896
in vitro activity, 896
vancomycin resistant, 1364
"Red man syndrome"
vancomycin
skin tests to healthy volunteers, 2139
Renal function
creatinine secretion
pyrimethamine, inhibition of, 1056
Resorcinomycin
M. avium-*M. intracellulare* complex
in vitro activities, 2584
M. tuberculosis
in vitro activities, 2584
Respiratory pathogens
ciprofloxacin
adherence changes induced by subinhibitory concentrations, 885
sparfloxacin
adherence changes induced by subinhibitory concentrations, 885
trimethoprim
adherence changes induced by subinhibitory concentrations, 885
Respiratory syncytial virus
immune globulin
prophylaxis for high-risk infants, evaluation of, 1655
Respiratory tract infections
cefazopran, 100
K. pneumoniae
cefazopran, 100
Retroviruses
acyclic nucleoside phosphonates
(S) and (R) enantiomers, 332
(R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine, 332
Reverse transcriptase inhibitors
diarylsulfones
human immunodeficiency virus, 754
FTC
human immunodeficiency virus, 1720
human immunodeficiency virus
diarylsulfones, mechanism of action, 754
FTC, 5'-triphosphates of (-) and (+) enantiomers, 1720
L-696,229, activity against isolates resistant to related inhibitors, 947
nonnucleoside inhibitors, 1037
S-2720, 1659
human immunodeficiency virus resistance
mutant enzyme and viral variant assessment, 1576
human immunodeficiency virus type 1
infectious amplification from lymphocytes and modulation, 2206
L-696,229
human immunodeficiency virus isolates resistant to related inhibitors, 947
S-2720
human immunodeficiency virus, 1659
thiazolo-iso-indolinones
human immunodeficiency virus type 1 resistance, 2612
U-90152
human immunodeficiency virus, 1127
Rhinovirus
WIN 54954
prophylaxis, efficacy of, 297
Rhodococcus equi
penicillin-binding proteins
imipenem resistance, potential role in, 1406
Ribavirin
pharmacokinetics
children with human immunodeficiency virus infection, 532
safety and tolerance
children with human immunodeficiency virus infection, 532
Rickettsia spp.
spotted fever group
in vitro susceptibilities to clarithromycin, 2633

- Rifabutin
combinations
 M. avium, prophylaxis in mice, 1690
 minocycline, 1690
M. avium
 erratum, 2515
 prophylaxis in C57BL/6 mice, 1690
M. avium complex
 rats treated with cyclosporine, 398
M. haemophilum
 in vitro activities, 2323
M. paratuberculosis
 systemic infection in mice, 1645
- Rifampin
combinations
 Brucella spp., 1831
 doxycycline, 1831
 floxacin, 2132
 novobiocin, 1334
 ofloxacin, 1214, 1831
 S. aureus, methicillin resistant, eradication of, 1334
 Staphylococcus-infected orthopedic implants, 1214
M. haemophilum
 in vitro activities, 2323
M. leprae resistance
 molecular basis, 414
minireview
 nonstaphylococcal, nonmycobacterial disease, 1
N. brasiliensis
 inactivation of drug by glycosylation, 1313
nonstaphylococcal, nonmycobacterial disease
 minireview, 1
pharmacokinetics
 floxacin, influence on, 2132
 S. aureus, 2132
 zidovudine, interaction with, 1426
S. epidermidis
 diffusion through a biofilm, 2522
staphylococcal bacteremia
 use with neonates, 2401
synergy
 ethambutol, 1285
 M. malmoense, 1285
zidovudine
 pharmacokinetic interaction with, 1426
- Rifapentine
 Brucella spp.
 in vitro activity, comparative evaluation, 911
 M. avium complex
 rats treated with cyclosporine, 398
- Rimantadine
 influenza virus
 susceptibilities of subtypes A/H1N1 and A/H3N2, 2239
- Ro 11-8958
 synergy
 dapson, 1436
 P. carinii, 1436
 sulfamethoxazole, 1436
- Ro 40-6890
 antimicrobial susceptibility, 893
 disk diffusion susceptibility, 893
S. aureus
 antibiotic activity and host defense mechanisms, 2622
 pharmacodynamic activity in human skin blister fluid, 2622
- Ro 41-3399
 metabolite
 antimicrobial susceptibility, 893
 disk diffusion susceptibility, 893
- Roxithromycin
 Brucella spp.
 in vitro activity, comparative evaluation, 911
 gram-negative organisms
 outer membrane permeability barrier, 354
 Mycobacterium spp.
 in vitro activity, 1560
 pH, effect on radiometric MICs, 1560
- RP 74501-RP 74502
 Legionella spp.
 in vitro activity, 908
- RP59500
 gram-positive organisms
 vancomycin resistant, 598
- RU-40555
 combinations
 clarithromycin, 692
 M. avium complex, 692
 M. avium complex, 692
- Rufloxacin
 comparative evaluation
 amoxicillin, 2298
 chronic bronchitis, 2298
 magnesium-aluminum hydroxide
 effects on absorption, 2212
 pharmacokinetics
 biliary excretion in humans, 2545
 patients with impaired renal function, 637
 T-cell subsets and tumor necrosis factor production
 mice infected with *B. fragilis*, effect on, 1711
- S-1108
 pharmacokinetics, 1043
 safety of and carnitine status of patients, 1043
- S-2720
 human immunodeficiency virus
 inhibition of reverse transcriptase and viral replication, 1659
- Saccharomyces cerevisiae*
 bleomycin
 cell wall anchorage of mannoproteins, disruption of, 1264
- Ro 09-1470
 inhibition of P-450 lanosterol C-14 demethylase, 2662
- Saccharopolyspora erythraea*
 avermectins and ivermectins, glycosylation, microbial conversion by, 1737
- Salmonella typhi*
 ceftriaxone
 5 days, comparative evaluation, 1572
 chloramphenicol
 14 days, comparative evaluation, 1572
- Salmonella typhimurium*
 ciprofloxacin resistance
 isolates from two patients, 662
 isoniazid
 susceptibilities of *oxyR* regulon mutants, 2251
 lactoferrin-porin interaction
 antibacterial activity, effect on, 240
 mutants
 supersusceptibility to antibiotics, 2255
- Salmonellae
 acyclovir, 106
 antimicrobial resistance
 Spanish hospital, 1200
 azithromycin
 in vitro activity, 1203
 2',3'-dideoxycytidine, 106
 2',3'-dideoxyinosine, 106
 zidovudine, 106
- Salmonellosis
 murine
 ciprofloxacin, 2293
- Salpingitis
 CI-960
 monkey model, 8
- SCE-2787
 pharmacokinetics
 healthy volunteers, 1835
 serum bactericidal activities, 1835
 side effects, 1835
- Screening assays
 anti-*P. carinii* agents
 development and characterization, 1674
- Shell vial assay
 C. burnetii susceptibility
 shell vial assay, 491
- Shigella sonnei*
 dysentery
 fluoroquinolones, 2486
 fluoroquinolones
 reduced susceptibilities of strains from patients with dysentery, 2486
- Shigella* spp.
 azithromycin
 in vitro activity, 1203
- Simian immunodeficiency virus
 antibodies, neutralizing
 macrophages, comparative evaluation, 360
 3'-azidothymidine
 macrophages, comparative evaluation, 360
 protease inhibitors
 antiretroviral activity, 71
- Simian varicella virus
 (-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine
 African green monkeys, 1370
- Sinefungin
 Cryptosporidium parvum
 curative and preventive activities, 889
 immunosuppressed rat model, 889
- Skin infections
 piperacillin-tazobactam
 comparative evaluation, 1580
 ticarcillin-clavulanate
 comparative evaluation, 1580
- Sodium stibogluconate
 L. panamensis
 in vitro activities of fractions, 1842
- Soluble intercellular adhesion molecule 1
 picornavirus capsid binders
 detection of, 1693
- Sparfloxacin
 bite wound isolates
 aerobic and anaerobic, 1150
 C. pneumoniae
 in vitro and in vivo activities, 801
 C. psittaci
 in vitro and in vivo activities, 801
 C. trachomatis

- in vitro and in vivo activities, 801
- H. influenzae*
- adherence changes induced by subinhibitory concentrations, 885
- K. pneumoniae*
- adherence changes induced by subinhibitory concentrations, 885
- M. catarrhalis*
- adherence changes induced by subinhibitory concentrations, 885
- M. haemophilum*
- in vitro activities, 2323
- M. kansasii*
- susceptibility testing, 1997
- M. tuberculosis*, 407
- ophthalmitis
- rabbits with, efficacy in, 633
- pharmacokinetics
- ocular penetration in rabbits with ophthalmitis, 633
- Spiramycin
- C. trachomatis*
 - comparative evaluation, 1373
 - genital infections, treatment of, 1373
- Staphylococcus aureus*
- abscesses
 - cefazolin, β -lactamase-mediated inactivation and efficacy, 203
 - cefmetazole, β -lactamase-mediated inactivation and efficacy, 203
- adherence
- teicoplanin, effect of subinhibitory concentrations on, 921
 - vancomycin, effect of subinhibitory concentrations on, 921
- ampicillin-sulbactam
- β -lactamase-hyperproducing strain, 507
- antimicrobial susceptibility
- fibronectin-coated surfaces, isolates on, 625
- azithromycin
- uptake by human monocytes, 2318
- B. fragilis*, polymicrobial infection mice, 1531
- B. thetaiotaomicron*, polymicrobial infection mice, 1531
- bacteremia
- use of intravenous rifampin with neonates, 2401
- β -lactamase
- production, genes involved in regulation, 1966
- β -lactamases
- blaI* and *blaRI*, regulation of, 1144
- blaI* and *blaRI*
- β -lactamase and PBP 2a regulation, 1144
- cefazolin
- β -lactamase-mediated inactivation and efficacy, 203
- cefmetazole
- β -lactamase-mediated inactivation and efficacy, 203
- cefprozopran, 100
- cephalosporins
- broad spectrum, 554
- ciprofloxacin
- dose-ranging and fractionation, 1756
 - in vitro model of infection, 1756
 - resistance to unrelated antibiotics, effects on, 1289
- dihydrofolate reductase, trimethoprim sensitive
- characterization of gene for, 1400
 - enhanced intracellular antibacterial activity, 2318
- fibronectin-coated surfaces, isolates on antimicrobial susceptibility, 625
- floxacin-rifampin
- pharmacokinetics, 2132
- fluoroquinolone resistance
- efflux mediated, 1086
 - NorA, multidrug efflux transporter, 128
- levofloxacin-oxacillin
- synergy, 339
- methicillin resistant
- β -lactam- β -lactamase inhibitor combinations, 702
 - β -lactams, 702
 - blaI* and *blaRI* regulate β -lactamase and PBP 2a production, 1144
 - ciprofloxacin, resistance to unrelated antibiotics, effects on, 1289
 - endocarditis, 2466
 - fusidic acid, alone or in combination with vancomycin, 2466
 - penicillin-binding protein 2A, role in cell wall synthesis, 342
 - rifampin-novobiocin, 1334
- methicillin resistant and susceptible sequential acquisition of norfloxacin and ofloxacin resistance, 2278
- methicillin susceptible
- cephalosporins, broad spectrum, 554
- methicillin susceptible, borderline
- β -lactam- β -lactamase inhibitor combinations, 702
 - β -lactams, 702
- mupirocin resistance
- detection and characterization, 2003
- mupirocin resistance, high level
- isoleucyl-tRNA synthetases, evidence for two distinct, 32
- NorA
- Bmr, comparison of substrate specificities, 128
 - multidrug efflux transporter, 128
- oxacillin
- β -lactamase-hyperproducing strain, 507
- pefloxacin
- one 800-mg versus two 400-mg doses, 737
- povidone iodine
- irrigation, 2754
- pristinamycin resistance
- isolates responsible for outbreak in Parisian hospital, 2159
- quinolone resistant
- levofloxacin-oxacillin synergy, 339
- rifampin
- use with neonates, 2401
- Ro 40-6890
- antibiotic activity and host defense mechanisms, 2622
 - pharmacodynamic activity in human skin blister fluid, 2622
- teicoplanin
- adherence, effect of subinhibitory concentrations on, 921
 - teicoplanin resistance
 - expression of a novel membrane protein and increased expression of penicillin-binding protein 2 complex, 2432
- tetK*
- E. coli*, expression in, 191
- TetK, TetA(B), and TetA(C)
- substrate specificities, comparison of, 191
- vancomycin
- adherence, effect of subinhibitory concentrations on, 921
- Staphylococcus epidermidis*
- adherence
 - teicoplanin, effect of subinhibitory concentrations on, 921
 - vancomycin, effect of subinhibitory concentrations on, 921
- biofilms
- diffusion of rifampin, 2522
 - diffusion of vancomycin, 2522
 - inhibition of formation on prosthetic devices by proteolytic enzymes, 2618
- teicoplanin
- adherence, effect of subinhibitory concentrations on, 921
- vancomycin
- adherence, effect of subinhibitory concentrations on, 921
- Staphylococcus* spp.
- adherence
 - teicoplanin, effect of subinhibitory concentrations on, 921
 - vancomycin, effect of subinhibitory concentrations on, 921
- mec* regulator genes
- distribution in methicillin-resistant strains, 1219
- methicillin resistant
- mec* regulator genes, distribution of, 1219
- orthopedic implant infections
- rifampin-ofloxacin, 1214
 - rifampin-ofloxacin
 - infected orthopedic implants, 1214
- teicoplanin
- adherence, effect of subinhibitory concentrations on, 921
- vancomycin
- adherence, effect of subinhibitory concentrations on, 921
- Stavudine
- pharmacokinetics
 - cynomolgus monkeys, 1160
- Streptococcus mitis*
- gentamicin
 - chromosomally mediated high-level resistance, 2740
- Streptococcus mutans*
- amoxicillin
 - in vitro susceptibility, 1158 - cefuroxime
 - in vitro susceptibility, 1158 - chlorhexidine
 - in vitro susceptibility, 1158 - erythromycin
 - in vitro susceptibility, 1158 - penicillin
 - in vitro susceptibility, 1158 - tetracycline
 - in vitro susceptibility, 1158 - trimethoprim-sulfamethoxazole
 - in vitro susceptibility, 1158

- Streptococcus pneumoniae*
 cefotaxime breakpoint
 letter to the editor, 616
 ciprofloxacin
 mouse protection model, 234
 clarithromycin resistance
 cultures from Providence, R.I., 1742
 erythromycin resistance
 cultures from Providence, R.I., 1742
 meningitis
 penicillin and cephalosporin resistant,
 evaluation of treatment regimens,
 1630
 penicillin and cephalosporin resistant
 meningitis, evaluation of treatment
 regimens, 1630
 penicillin resistant
 otitis media, treatment with amoxicil-
 lin, 1599
 penicillin-binding proteins 2B and 2X,
 genetic diversity of, 1938
 polymerase chain reaction
 heterogeneity of chloramphenicol ace-
 tyltransferase genes, 2593
- Streptococcus pyogenes*
 poloxamer 188
 effects of scrubbing, 2754
- Streptococcus* spp.
 ceftriaxone-netilmicin
 endocarditis, 207
 synergy, 207
 endocarditis
 ceftriaxone-netilmicin, 1971
 ceftriaxone-netilmicin synergy, 207
 group A
 antibiotic susceptibilities, hospital iso-
 lates, 1717
 cefuroxime axetil suspension, compar-
 ative evaluation, 159
 group A, beta-hemolytic
 bacterial interference, role in infection
 management, 1452
 β -lactamase production, role in infec-
 tion management, 1452
 tonsillopharyngitis
 cefprozil versus penicillin V, 1620
 viridans group
 activities of potential therapeutic and
 prophylactic antibiotics against
 blood culture isolates, 2493
 neutropenic patients receiving cipro-
 floxacin, 2493
- Streptogramin A* acetyltransferases
E. faecium
 identification of *satA*, 2119
- Streptogramins*
 RP 74501-RP 74502
Legionella spp., 908
 RP59500
 gram-positive organisms, vancomycin
 resistant, 598
- Streptomyces clavuligerus*
 cephalosporin 7 α -hydroxylase
 cloning and expression in *S. lividans*,
 84
- Streptomyces* spp.
 chromosomal DNA
 role in multiple antibiotic resistance,
 2379
 multiple antibiotic resistance
 chromosomal DNA in antibiotic prep-
 arations, 2379
- Streptomycin
 combinations
B. melitensis, 2333
 ciprofloxacin, doxycycline, and ri-
 fampin, 2333
E. coli resistance
 bleomycin, increase of, 1982
- Sulfactam
 combinations
 ampicillin, 251, 507, 610, 1447
 cefoperazone, 1927
 clavulanate, 2059
 comparative evaluation, 610
E. coli, 1927, 2059
E. coli intra-abdominal abscess model,
 610
E. faecalis, β -lactamase producing,
 highly gentamicin resistant, 1447
 endocarditis, 507, 1447
P. aeruginosa, 1927
S. aureus, β -lactamase hyperproduc-
 ing, 507
 susceptibility testing with a predictor
 panel, 251
 tazobactam, 2059
E. coli
 β -lactamase, TEM type, resistant,
 2059
 oxidant-scavenging activities
 neutrophil functions, effect on, 950
- Sulfamethoxazole
 synergy
 dihydrofolate reductase inhibitors,
 1436
P. carinii, 1436
 Ro 11-8958, 1436
- Suramin
 duck hepatitis B virus
 prevention of infection in vivo, 1539
 polymorphonuclear leukocyte bacteri-
 cidal activity
 suppression of, 495
- Susceptibility testing
 agar dilution
G. vaginalis, 2733
 amoxicillin
 blood culture isolates of viridans
 group streptococci from neutro-
 penic patients receiving ciproflox-
 acin, 2493
 ampicillin-sulfactam
 predictor panel, 251
 azlocillin
 blood culture isolates of viridans
 group streptococci from neutro-
 penic patients receiving ciproflox-
 acin, 2493
 broth microdilution
 multicenter evaluation, 39
 yeasts, 39
C. neoformans
 current status of the standardization
 process, minireview, 2517
Candida spp.
 current status of the standardization
 process, minireview, 2517
 clarithromycin
 blood culture isolates of viridans
 group streptococci from neutro-
 penic patients receiving ciproflox-
 acin, 2493
 co-amoxiclav
 blood culture isolates of viridans
 group streptococci from neutro-
 penic patients receiving ciproflox-
 acin, 2493
- dye uptake assay
 in vitro activity of clarithromycin
 against spotted fever group rick-
 ettsiae, 2633
- erythromycin
 blood culture isolates of viridans
 group streptococci from neutro-
 penic patients receiving ciproflox-
 acin, 2493
- G. vaginalis*
 agar dilution, 2733
- M. fermentans*
 in vitro strains from AIDS patients,
 2500
 in vitro strains from non-AIDS pa-
 tients with acute respiratory dis-
 ease, 2500
 tissue culture, 2500
- M. kansasii*
 azithromycin, 1997
 clarithromycin, 1997
 fusidic acid, 1997
 ofloxacin, 1997
 sparfloxacin, 1997
- Nocardia* spp.
 letter to the editor, 2514
- piperacillin-tazobactam
 predictor panel for evaluating meth-
 ods, 2578
- plaque assay
 in vitro activity of clarithromycin
 against spotted fever group rick-
 ettsiae, 2633
- roxithromycin
Mycobacterium spp., effect of pH on
 MICs, 1560
- yeasts
 broth macrodilution, 39
 multicenter evaluation, 39
- Synergy
 3'-azido-2',3'-deoxythymidine
 carbovir, 144
 human immunodeficiency virus type 1,
 144
 carbovir
 3'-azido-2',3'-deoxythymidine, 144
 human immunodeficiency virus type 1,
 144
 decimal assay for additivity, 260
E. faecium
 penicillin-gentamicin, 2427
 ethambutol-amikacin
M. malmoense, 1285
 ethambutol-ciprofloxacin
M. malmoense, 1285
 ethambutol-rifampin
M. malmoense, 1285
 levofloxacin-oxacillin
S. aureus, quinolone resistant, 339
M. malmoense
 ethambutol-amikacin, 1285
 ethambutol-ciprofloxacin, 1285
 ethambutol-rifampin, 1285
 microdilution checkerboard method
 measurement of, reproducibility of
 results, 613
 penicillin-gentamicin
E. faecium, 2427

- T-3761
in vitro and in vivo activities, 384
- Tazobactam
β-lactamases
kinetic interactions, 851
combinations
clavulanate, 2059
E. coli, 2059
piperacillin, 2578
sulbactam, 2059
E. coli
β-lactamase, TEM type, resistant, 2059
- Teicoplanin
adherence
Staphylococcus spp., effect of subinhibitory concentrations on, 921
bactericidal activity
albumin or serum, presence of, controlled pH and calcium, 605
pharmacokinetics
evaluation of a fluorescence polarization immunoassay, 1924
prophylaxis in monolateral and bilateral total knee replacement procedures, 2693
S. aureus resistance
expression of a novel membrane protein and increased expression of penicillin-binding protein 2 complex, 2432
Staphylococcus spp.
adherence, effect of subinhibitory concentrations on, 921
- Temafloxacin
B. fragilis
evaluation of activity by an in vitro pharmacodynamic system, 2454
bite wound isolates
aerobic and anaerobic, 1150
M. pneumoniae
hamsters, 287
postantibiotic effect
repeated exposures, 1723
- Terbinafine
Candida spp.
temperature, effect on activity, 685
combinations
Chagas' disease, murine, 1353
ICI 195,739, 1353
ketoconazole, 1353
T. cruzi, 1353
mevinolin
T. cruzi, potentiation of antiproliferative effects, 580
- Terconazole
Candida spp.
temperature, effect on activity, 685
- tet*(Q)
B. fragilis
nucleotide and deduced amino acid sequences, 2037
- TetA(D)
nucleotide and deduced protein sequences, 1253
relationship to other antimicrobial transport proteins, 1253
- TetK
S. aureus
E. coli, expression in, 191
substrate specificities, comparison with those of TetA(B) and TetA(C), 191
- Tetracycline
C. jejuni resistance
effect of mutational alteration of Asn-128, 2645
resistance determinants
TetA(D), nucleotide and deduced protein sequences, 1253
S. mutans
in vitro susceptibility, 1158
Tet(O)
effect of mutational alteration of Asn-128, 2645
TetA(D)
nucleotide and deduced protein sequences, 1253
relationship to other antimicrobial transport proteins, 1253
- Tetracycline-HCl
synergy
H. pylori, 1184
metronidazole, 1184
metronidazole, hydroxymetabolite of, 1184
- Tetracyclines
glycylcyclines
comparative evaluation, 2270
penetration into bacterial cells
minireview, 1393
screening assay, 1624
- Thiazolo-iso-indolinones
human immunodeficiency virus type 1 resistance, 2612
- Thiosemicarbazones
Abelson murine leukemia virus *v-abl* protein, suppression of, 2483
- Ticarcillin
combinations
clavulanate, 1580
clavulanic acid, 51
comparative evaluation, 1580
skin and skin structure infections, 1580
yeast colonization of the human gastrointestinal tract, effect on, 51
- Ticarcillin-clavulanic acid
C. albicans
colonization of the human gastrointestinal tract, effect on, 51
pharmacokinetics
healthy volunteers, 1860
yeast colonization of the human gastrointestinal tract, effect on, 51
- Time-kill curves
mathematical model for comparison of, 1685
- Time-kill studies
turbidimetric assay
viable bacterial densities, quantitation of, 371
- Tinea unguium
griseofulvin
ultramicrosize, 2064
itraconazole, 2064
- Tobramycin
E. coli resistance
3'-aminoglycoside phosphotransferase type I, overproduction of, 78
postantibiotic effect
hyperoxia, prolongation by, role of reactive oxygen species, 120
P. aeruginosa, 120
repeated exposures, 1723
- Tonsillopharyngitis
cefprozil
comparative evaluation, 1620
penicillin V
comparative evaluation, 1620
streptococcal
cefprozil versus penicillin V, 1620
- Topoisomerase inhibitors
P. carinii
activity in vitro and in a mouse model, 1543
- Topoisomerases
quinolones
1-8 bridged, stereospecificity for the C-11 methyl group, 646
activities against mammalian systems, comparative evaluation, 2179
- Torulopsis glabrata*
fluconazole
prophylaxis in neutropenic bone marrow transplant patients, 1847
- Tosufloxacin
C. pneumoniae
in vitro and in vivo activities, 801
C. psittaci
in vitro and in vivo activities, 801
C. trachomatis
in vitro and in vivo activities, 801
- Toxicity
A77003
preclinical evaluation, 115
amphotericin B
mono-methyl ester derivative, 419
neurotoxicity, comparative evaluation, 419
3'-azido-3'-deoxythymidine
time of administration, effect on, 1771
gentamicin
polyaspartic acid, protective effects, pharmacologic limits of, 347
human renal proximal tubule cells
use in studying foscarnet-induced nephrotoxicity in vitro, 2496
- LJC 10,627
central nervous systems of rats, low levels of, 199
nephrotoxicity
isepamicin, 2042
neurotoxicity
amphotericin B, 419
amphotericin B mono-methyl ester derivative, 419
- Taxoplasma gondii*
anticoccidial agents
susceptibility and resistance, 2358
atovaquone-clarithromycin
in vitro and in vivo activities, 2371
atovaquone-minocycline
in vitro and in vivo activities, 2371
atovaquone-pyrimethamine
in vitro and in vivo activities, 2371
atovaquone-sulfadiazine
in vitro and in vivo activities, 2371
azithromycin
combinations, in vitro activities of, 1993
protein synthesis, inhibition of, 1701
clindamycin
infectivity, 2571
intracellular replication, 2571
protein synthesis, 2571
dihydrofolate reductase
inhibitors, identification of, 1914

- poloxamers
 toxoplasmosis, 2265
 pyrimethamine
 combinations, in vitro activities of, 1993
 toxoplasmosis
 poloxamers, 2265
 Toxoplasmosis
 poloxamers, 2265
 T. gondii, 2265
Treponema pallidum
 clarithromycin
 hamsters, 864
 Triazino[5,6-*b*]indoles
 GR99060
 antifungal properties, 1243
 GR99062
 antifungal properties, 1243
 Triazoles
 D0870
 blastomycosis, murine, 1177
 pathogenic yeasts, 2126
Trichophyton mentagrophytes
 butenafine
 guinea pigs, 363
 Trimethoprim
 dihydrofolate reductase cassette
 integron on a Tn21-like element, 1297
 H. influenzae
 adherence changes induced by subinhibitory concentrations, 885
 K. pneumoniae
 adherence changes induced by subinhibitory concentrations, 885
 M. catarrhalis
 adherence changes induced by subinhibitory concentrations, 885
 resistance
 dihydrofolate reductase cassette inserted on an integron on a Tn21-like element, 1297
 Trimethoprim-sulfamethoxazole
 pharmacokinetics
 12/60 mg/kg/day, multiple dose, 448
 healthy volunteers, 448
 S. mutans
 in vitro susceptibility, 1158
Trichomonas foetus
 zinc
 electron microscopic study, 2722
Trypanosoma brucei brucei
 N-*n*-alkyl-3,4-dihydroxybenzamide
 in vitro and in vivo activities, 1082
 G418 resistance phenotype
 in vivo system to select for bloodstream-form transfectants, 1167
Trypanosoma congolense
 Boran cattle
 diminazine pharmacokinetics, effect of infection on, 1050
 quinapyramine resistant
 derivation and characterization, 1163
Trypanosoma cruzi
 N,N'-bis(benzyl)-substituted polyamine analogs
 inhibition of host cell invasion and intracellular replication, 2235
 ICI 195,739-terbinafine
 murine model, 1353
 ketoconazole-terbinafine
 murine model, 1353
Trypanosoma (Schizotrypanum) cruzi
 mevinolin
 ketoconazole and terbinafine, potentiation of antiproliferative effects, 580
 Tuberculosis
 multidrug resistant
 studies with mice, 2344
 Tumor necrosis factor
 murine models
 amphotericin B, 2228
 receptors
 relation to therapy of typhoid fever, 2418
 Tumor necrosis factor alpha
 amphotericin B, 1958
 C. albicans, 1958
 Turbidimetric assays
 viable bacterial densities, quantitation of *E. coli*, 371
 Typhoid fever
 ceftriaxone
 5 days, comparative evaluation, 1572
 chloramphenicol
 14 days, comparative evaluation, 1572
 ciprofloxacin
 severe, in children, 1197
 interleukin-6, gamma interferon, and tumor necrosis factor receptors
 relation to outcome of antimicrobial therapy, 2418
 severe
 ciprofloxacin, 1197
 U-90152
 human immunodeficiency virus type 1 replication, inhibition of, 1127
Ureaplasma diversum
 antimicrobial susceptibilities, 317
Ureaplasma urealyticum
 OPC 17116
 susceptibility in vitro, 1726
 Ureidopenicillins
 F. oryzzihabitus
 in vitro activities against clinical isolates from patients with cancer, 2504
 Urinary tract infections
 acute uncomplicated
 lomefloxacin, 3 days, comparative evaluation, 574
 norfloxacin, 3 days, comparative evaluation, 574
 cefoxopran, 100
 enoxacin
 cefuroxime axetil, more rapid than, 1558
 rapid symptom alleviation, 1558
 lomefloxacin
 3 days, comparative evaluation, 574
 nitrofurazone
 catheter associated, 2033
 norfloxacin
 3 days, comparative evaluation, 574
 P. aeruginosa
 cefoxopran, 100
 recurrent
 enoxacin, rapid symptom alleviation, 1558
 rapid symptom alleviation, 1558
 Vancomycin
 adherence
 Staphylococcus spp., effect of subinhibitory concentrations on, 921
 B. burgdorferi
 in vitro activity, 1115
 E. faecalis
 β-lactamase producing, highly gentamicin resistant, 1447
 endocarditis, 1447
 E. faecalis resistance gene
 homology with *vanB*, *vanA*, and *vanC*, 1604
 E. faecium resistance, 1904
 endocarditis, 2069
 E. faecium resistance gene
 homology with *vanB*, *vanA*, and *vanC*, 1604
 gram-positive organism resistance
 ramoplanin, 1364
 gram-positive organisms, resistance
 RP59500, 598
 pharmacokinetics
 obesity, effect on, 436
 pulmonary lining fluid, penetration into, 281
 serum protein-binding characteristics, 1132
 pulmonary lining fluid
 penetration into, 281
 "red man syndrome"
 skin tests to healthy volunteers, 2139
 S. epidermidis
 diffusion through a biofilm, 2522
 Staphylococcus spp.
 adherence, effect of subinhibitory concentrations on, 921
 Visna virus
 acyclic nucleoside phosphonate analogs
 inhibition of replication, 2540
 2',3'-dideoxynucleosides
 inhibition of replication, 2540
 WIN 54954
 coxsackievirus
 group B diabetogenic strain in mice, 1593
 rhinovirus
 prophylaxis, efficacy of, 297
 WIN 57273
 E. faecalis
 activity against high-level gentamicin-resistant strains, 2470
 Yeasts
 D0870
 in vitro activities, 2126
 susceptibility testing
 broth macrodilution, 39
 multicenter evaluation, 39
 Zalcitabine
 salmonellae
 in vitro activities, 106
 Zidovudine
 embryos, implantation of
 prevention of, 1610
 human immunodeficiency virus resistance
 pol mutations, multiple resistance, 1480
 human immunodeficiency virus type 1
 sensitivity
 discontinuation of zidovudine treatment, effects on, 1525
 pharmacokinetics

effects of standard breakfast in patients with AIDS, 2153
granulocyte-macrophage colony-stimulating factor, administration with, 512
prodrugs, enhanced levels in brain tissue, 818

sue, 818
rifampin, interaction with, 1426
prodrugs
pharmacokinetics, enhanced levels in brain tissue, 818
rifampin

pharmacokinetic interaction with, 1426
salmonellae
in vitro activities, 106
Zinc
T. foetus
electron microscopic study, 2722



**Statement of Ownership,
Management and
Circulation**
(Required by 39 U.S.C. 3685)

1A. Title of Publication		1B. PUBLICATION NO.		2. Date of Filing	
Antimicrobial Agents and Chemotherapy		0 0 6 6 4 8 0 4		10-12-93	
3. Frequency of Issue		3A. No. of Issues Published Annually		3B. Annual Subscription Price	
Monthly		12		\$49 mbr, \$250 nonmbr	
4. Complete Mailing Address of Known Office of Publication (Street, City, County, State and ZIP+4 Code) (Not printers)					
American Society for Microbiology 1325 Massachusetts Ave., N.W., Washington, D.C. 20005-4171					
5. Complete Mailing Address of the Headquarters of General Business Offices of the Publisher (Not printer)					
(Same as above)					
6. Full Names and Complete Mailing Address of Publisher, Editor, and Managing Editor (This item MUST NOT be blank)					
Publisher (Name and Complete Mailing Address)					
(Same as above)					
Editor (Name and Complete Mailing Address)					
Robert C. Moellering, Jr. (Address same as above)					
Managing Editor (Name and Complete Mailing Address)					
Linda M. Illig (Address same as above)					
7. Owner (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated.) (Item must be completed.)					
Full Name		Complete Mailing Address			
American Society for Microbiology		1325 Massachusetts Ave., N.W. Washington, D.C. 20005-4171			
8. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages or Other Securities (If there are none, so state)					
Full Name		Complete Mailing Address			
None					
9. For Completion by Nonprofit Organizations Authorized to Mail at Special Rates (DMM Section 424.12 only) The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (Check one)					
(1) <input checked="" type="checkbox"/> Has Not Changed During Preceding 12 Months		(2) <input type="checkbox"/> Has Changed During Preceding 12 Months		(If changed, publisher must submit explanation of change with this statement.)	
10. Extent and Nature of Circulation (See instructions on reverse side)		Average No. Copies Each Issue During Preceding 12 Months		Actual No. Copies of Single Issue Published Nearest to Filing Date	
A. Total No. Copies (Net Press Run)		8,775		8,800	
B. Paid and/or Requested Circulation					
1. Sales through dealers and carriers, street vendors and counter sales					
2. Mail Subscription (Paid and/or requested)		7,171		7,751	
C. Total Paid and/or Requested Circulation (Sum of 10B1 and 10B2)		7,171		7,751	
D. Free Distribution by Mail, Carrier or Other Means Samples, Complimentary, and Other Free Copies		110		110	
E. Total Distribution (Sum of C and D)		7,281		7,861	
F. Copies Not Distributed					
1. Office use, left over, unaccounted, spoiled after printing		1,494		939	
2. Return from News Agents					
G. TOTAL (Sum of E, F1 and 2—should equal net press run shown in A)		8,775		8,800	
11. I certify that the statements made by me above are correct and complete		Signature and Title of Editor, Publisher, Business Manager, or Owner			
		Linda M. Illig Director, Journals			

